<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7244039</PMID><DateCompleted><Year>1981</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2739</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>1981</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatrie, Neurologie, und medizinische Psychologie</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol (Leipz)</ISOAbbreviation></Journal><ArticleTitle>[The origin of cycloid psychoses].</ArticleTitle><Pagination><MedlinePgn>145-57</MedlinePgn></Pagination><Abstract><AbstractText>Hereditary affliction with psychosis is not a marked phenomenon in cycloid psychoses, it is, however, found that parents may promote the outbreak of the disease by their abnormal behaviour. Of greater importance are causes which--unlike other forms of endogenic psychosis--develop their effect in infancy. Inharmonious constellations among brothers and sisters have been found to be essential. It has been proved that in the physiological and psychic development of man the mutual influence of children plays an important role. Paying more attention to the influence exerted by the parents, especially the mother, this law has been overlooked until now. The constellations of brothers and sisters, which are of course an everyday phenomenon, are not effective in themselves, but will only become effective when they coincide in a specific manner with temperaments that in their nature show a certain relationship with psychoses. On the other hand, physical influences do exist in a form that is found in no other type of the so-called endogenous psychoses. As regards their quite peculiar genesis, the demarkation of the cycloid psychoses from the unsystematic forms of schizophrenia, which are mainly hereditary, is indispensable. In the term "schizo-affective psychoses" of the WHO the two forms are unfortunately mixed up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leonhard</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Genese der zykloiden Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol (Leipz)</MedlineTA><NlmUniqueID>0376467</NlmUniqueID><ISSNLinking>0033-2739</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="N">Parent-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="N">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7244039</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30328224</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>20 Suppl 2</Volume><PubDate><Year>2018</Year><Month>11</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Modelling mood disorders: An ACE solution?</ArticleTitle><Pagination><MedlinePgn>4-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12700</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The treatment of mood disorders remains sub-optimal. A major reason for this is our lack of understanding of the underlying pathophysiology of depression and bipolar disorder. A core problem is the lack of specificity of our current diagnoses. This paper discusses the history of this problem and posits a solution in the form of a more sophisticated model.</AbstractText><AbstractText Label="METHOD">The authors review the notable historical works that laid the foundations of mood disorder nosology; discuss the more recent influences that shaped modern diagnoses; and examine the evidence that mood disorders are characterised by multidimensional and longitudinal symptom profiles.</AbstractText><AbstractText Label="RESULTS">The ACE model considers mood disorders as a combination of symptoms across three domains: Activity, Cognition, and Emotion; that vary over time. This multidimensional and longitudinal perspective is consistent with the prevalence of complex clinical presentations, such as mixed states, and highlights the importance of recurrence in mood disorders.</AbstractText><AbstractText Label="CONCLUSIONS">The ACE model encourages researchers to characterise patients from a number of equally important perspectives and, by doing so, add specificity to the treatment of mood disorders.</AbstractText><CopyrightInformation>© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-4524-9091</Identifier><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Psychiatry, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School Northern, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9425-7119</Identifier><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Psychiatry, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School Northern, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Amber</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9001-4585</Identifier><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Psychiatry, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School Northern, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Grace</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3598-9712</Identifier><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Psychiatry, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School Northern, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Discipline of Psychiatry, Sydney Medical School, Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulder</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago - Christchurch, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Sophisticated Mood Appraisal &amp; Refinement of Treatment (SMART) Group.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago - Christchurch, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2019 Sep;21(6):562-563</RefSource><PMID Version="1">31169947</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2019 Aug;21(5):392-393</RefSource><PMID Version="1">31188518</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2020 Sep;22(6):629-630</RefSource><PMID Version="1">32297423</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2020 Sep;22(6):631-632</RefSource><PMID Version="1">32558090</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="Y">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">major depressive disorder</Keyword><Keyword MajorTopicYN="Y">mixed states</Keyword><Keyword MajorTopicYN="Y">modelling</Keyword><Keyword MajorTopicYN="Y">mood disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30328224</ArticleId><ArticleId IdType="doi">10.1111/bdi.12700</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9426881</PMID><DateCompleted><Year>1998</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>12</Issue><PubDate><Year>1997</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Expanded trinucleotide CAG repeats in families with bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>1115-22</MedlinePgn></Pagination><Abstract><AbstractText>Clinical anticipation has been reported in bipolar affective disorder (BPAD). The hypothesis that expanded trinucleotide repeats are related to anticipation and transmission pattern in families with bipolar affective disorder is tested in this study. Eighty-seven two-generation pairs of patients recruited from 29 bipolar families were analyzed. The repeat expansion detection method was used to detect CAG repeat expansions between successive generations. Significant changes in age at onset and episode frequency in successive generations were observed. Mean trinucleotide CAG repeat length between parental and offspring generation significantly increased when the phenotype increased in severity, i.e., changed from major depression, single episode or unipolar recurrent depression to BPAD. A parent-of-origin effect was also observed with a significant increase in median length CAG between G1 and G2 with maternal inheritance. This increase was observed notably in female offspring. Our findings indicate for the first time that expansion of CAG repeat length could explain the clinical observation of anticipation in families with BPAD. These results provide further support for expanded trinucleotide repeat sequences as risk factors in major affective disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Clinics of Brussels, Erasme Hospital, Free University of Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindbald</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Souery</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mahieu</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nylander</LastName><ForeName>P O</ForeName><Initials>PO</Initials></Author><Author ValidYN="Y"><LastName>De Bruyn</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zander</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Engström</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Adolfsson</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schalling</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lipp</LastName><ForeName>O</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018911" MajorTopicYN="N">Trinucleotide Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9426881</ArticleId><ArticleId IdType="pii">S0006322397003958</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(97)00395-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21546839</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review.</ArticleTitle><Pagination><MedlinePgn>336-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCO.0b013e328347341d</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The higher prevalence of psychiatric disorders in multiple sclerosis (MS) compared with the general population is well documented, with depression being the leading disorder. Apart from depression, other psychiatric disorders and symptoms such as bipolar disorder, pseudobulbar affect, euphoria sclerotica, anxiety and personality changes are also reported to be overpresented in MS patients. Psychiatric disorders in MS lead to significant disruption in patients' family, work and social life, affecting patients' quality of life in general. Moreover, they are reported to be associated with poorer adherence to MS medication. The literature concerning bipolar disorder and affect disorders in MS is rather scarce. The purpose of this article is to provide a critical review on the latter subject.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">This review focuses upon the recent findings with regard to the epidemiology and the comorbidity rates of bipolar and affect disorders in MS, questions raised about the potential underlying mechanisms that could explain such a high comorbidity, diagnostic issues and the recent developments in the treatment of those psychiatric disorders in MS.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Despite the fact that the higher prevalence of psychiatric disorders in MS is well established, such disorders still remain underdiagnosed and undertreated. A shift in the clinical suspicion towards the psychiatric morbidity in MS patients and the optimal treatment of those disorders is fundamental.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iacovides</LastName><ForeName>Apostolos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA General Hospital, Thessaloniki, Greece. apiacov@med.auth.gr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreoulakis</LastName><ForeName>Elias</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005059" MajorTopicYN="N">Euphoria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21546839</ArticleId><ArticleId IdType="doi">10.1097/YCO.0b013e328347341d</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10686973</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>29</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0755-4982</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Manic-depressive disorders in adolescence. Lithium treatment].</ArticleTitle><Pagination><MedlinePgn>167-70</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">FIRST INTENTION PREVENTION: Lithium is the first intention preventive treatment for bipolar disorders. It the most effective choice in this indication and provides the most benefit for the patient, particularly the young patient still in the process of maturation.</AbstractText><AbstractText Label="SURVEILLANCE" NlmCategory="UNASSIGNED">Serum lithium must be monitored regularly. It is important for the clinician to be aware of different factors which can modify serum levels, including disease states or iatrogenic effects related to co-prescriptions. PATIENT INFORMATION: Long-term compliance and surveillance, and thus treatment efficacy, depend greatly on the quality of the information provided to the patient and his/her family.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clervoy</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinique de psychiatrie, HIA du Val-de-Grâce, Paris. Patrick.Clervoy@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcos</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Troubles maniaco-dépressifs à l'adolescence. Le traitement lithié.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000296" MajorTopicYN="Y">Adolescent Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007049" MajorTopicYN="N">Iatrogenic Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10686973</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18384245</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Onset of depressive episodes is faster in patients with bipolar versus unipolar depressive disorder: evidence from a retrospective comparative study.</ArticleTitle><Pagination><MedlinePgn>1075-80</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Depressive episodes can have a very fast onset (&lt; 1 hour) or start very slowly (&gt; 1 month). This interesting aspect, pointing to different neurophysiological pathomechanisms, has not been systematically evaluated so far. The aim of this study was to describe speed of onset of depressive episodes in a consecutive sample of patients with at least 1 depressive episode and to investigate potential differences between patients with major depression versus bipolar affective disorders concerning this variable.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We examined 158 consecutive adult patients with major depression (N = 108) and bipolar disorder (N = 50) diagnosed according to criteria of the International Statistical Classification of Diseases, 10th revision, by applying the structured Onset-of-Depression Inventory. Patients with acute critical life events preceding the onset were excluded from final analyses. Data were collected between December 2001 and January 2007.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was a significant positive association between speed of onset of the present depressive episode and that of the preceding depressive episode (rho = 0.66, p &lt; .001). Patients with bipolar disorder developed full-blown depressive episodes significantly faster than patients with major depression (p &lt; .001): Whereas depressive episodes began within 1 week in 58% of patients with bipolar disorder, this was the case in only 7.4% of patients with major depression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Intraindividually, the speed of onset of depression is similar across different episodes. In the absence of acute critical life events, fast onset of depressive episodes (within 1 week) is common in bipolar disorder but rare in major depression. This aspect might be useful to identify depressive episodes occurring within a bipolar affective illness and might characterize a subgroup of patients with a distinct neurobiology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hegerl</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Leipzig, Johannisallee 20, D-04317 Leipzig, Germany. Ulrich.Hegerl@medizin.uni-leipzig.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottner</LastName><ForeName>Anja-Christine</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Holtschmidt-Täschner</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Born</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Seemüller</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Scheunemann</LastName><ForeName>Winfried</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Schütze</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Henkel</LastName><ForeName>Verena</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Mergl</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18384245</ArticleId><ArticleId IdType="pii">ej07m03725</ArticleId><ArticleId IdType="doi">10.4088/jcp.v69n0705</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9288440</PMID><DateCompleted><Year>1997</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>42 Suppl 2</Volume><PubDate><Year>1997</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Treatment of mania, mixed state, and rapid cycling.</ArticleTitle><Pagination><MedlinePgn>79S-86S</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To summarize the quality of evidence for the efficacy of different biological treatments in mania, mixed state, and rapid cycling and to propose guidelines for treatment of these conditions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Articles published on treatment of acute mania, mixed states, and rapid cycling were reviewed and rated for quality of evidence using Periodic Health Examination guidelines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lithium and divalproex sodium are effective in classical pure mania, whereas divalproex sodium and carbamazepine are likely more effective in mixed states. Divalproex sodium is likely more efficacious than carbamazepine and lithium when the mania is part of a rapid-cycling course. Typical neuroleptics are efficacious in acute mania, particularly in the presence of marked psychotic symptoms. Atypical neuroleptics can be useful in refractory mania. Some benzodiazepines do have antimanic effects, but they are increasingly being shown to have usefulness as adjuncts to mood stabilizers or neuroleptics rather than as primary antimanic agents. Electroconvulsive therapy (ECT) is an efficacious and broad-spectrum treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mania can present with or without mood-congruent or mood-incongruent psychotic features and as part of a rapid-cycling or nonrapid-cycling course. Mixed state is a common presentation in an acutely manic patient. The accurate assessment of these issues can serve as a guide in determining treatment options and choices.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kusumakar</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia. vkusumakar@usa.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Haslam</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>S V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Matte</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Silverstone</LastName><ForeName>P H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>94</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9288440</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3167370</PMID><DateCompleted><Year>1988</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>152</Volume><PubDate><Year>1988</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Resistant bipolar affective disorder treated by stereotactic subcaudate tractotomy.</ArticleTitle><Pagination><MedlinePgn>354-8</MedlinePgn></Pagination><Abstract><AbstractText>The results of stereotactic subcaudate tractotomy in nine patients with resistant bipolar affective disorder are presented in the form of a single case study with a summary of the other eight cases. Follow-up studies at 2-4 years showed substantial improvement in five patients and amelioration of symptoms in a further four patients, with a tendency for a greater improvement in the manic than in the depressive episodes. These preliminary results suggest that there is a place for this operation in the management of severe bipolar affective disorders which are not responding to any other treatment, although decisive recovery occurs less often than with unipolar depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poynton</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>United Medical School, Guy's Hospital, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bridges</LastName><ForeName>P K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011612" MajorTopicYN="N">Psychosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3167370</ArticleId><ArticleId IdType="pii">S0007125000218813</ArticleId><ArticleId IdType="doi">10.1192/bjp.152.3.354</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5142760</PMID><DateCompleted><Year>1972</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-5686</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>1971</Year></PubDate></JournalIssue><Title>Confinia psychiatrica. Borderland of psychiatry. Grenzgebiete der Psychiatrie. Les Confins de la psychiatrie</Title><ISOAbbreviation>Confin Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Aspects of pictorial creation in manic-depressive psychosis.</ArticleTitle><Pagination><MedlinePgn>133-42</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Enăchescu</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Confin Psychiatr</MedlineTA><NlmUniqueID>0207314</NlmUniqueID><ISSNLinking>0010-5686</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001154" MajorTopicYN="Y">Art</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="N">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009788" MajorTopicYN="N">Occupational Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1971</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1971</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1971</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5142760</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5248244</PMID><DateCompleted><Year>1969</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1591</ISSN><JournalIssue CitedMedium="Print"><Volume>203</Volume><PubDate><Year>1968</Year></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica. Supplementum</Title><ISOAbbreviation>Acta Psychiatr Scand Suppl</ISOAbbreviation></Journal><ArticleTitle>Genetic transmission of depressive psychoses.</ArticleTitle><Pagination><MedlinePgn>45-52</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perris</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Psychiatr Scand Suppl</MedlineTA><NlmUniqueID>0370365</NlmUniqueID><ISSNLinking>0065-1591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005808" MajorTopicYN="N">Genes, Recessive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1968</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1968</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1968</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5248244</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1968.tb01957.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21304123</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2012</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Season>Winter</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tourette's syndrome and type 2 bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>E26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.23.1.E26</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Luís</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Damásio</LastName><ForeName>Joana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Magalhães</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Joaquim</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005879" MajorTopicYN="N">Tourette Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21304123</ArticleId><ArticleId IdType="pii">23/1/E26</ArticleId><ArticleId IdType="doi">10.1176/jnp.23.1.jnpe26</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15571786</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>82 Suppl 1</Volume><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A prospective follow-up study of pediatric bipolar disorder in boys with attention-deficit/hyperactivity disorder.</ArticleTitle><Pagination><MedlinePgn>S17-23</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine patterns of persistence and remission in pediatric bipolar disorder attending to syndromatic, symptomatic, functional and affective definitions of remission of bipolar symptomatology in a longitudinal sample of ADHD children with comorbid bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ADHD boys (128) were followed over 1- and 4-year follow-up assessments with structured diagnostic interviews to assess the persistence of psychiatric comorbidity. The course and duration of bipolar disorder was estimated by calculating the time from age at onset and the age at remission reported at either the 1- or 4-year follow-up assessments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-two (17%, Prevalent Cases) subjects met criteria for bipolar disorder at the baseline assessment. The average age of these subjects was 10.5+/-3.0 (range: 6 to 17 years) at baseline and 14.4+/-3.1 years of age at follow-up. The rate of remission was heavily dependent on the definition used. The rate of functional remission was the lowest and the rate of syndromatic remission was the highest. Regardless of the definition used, however, the disorder was chronic and lasted many years.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">These data should be considered preliminary due to the sample size and the absence of mood symptom rating scales.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">That less than 20% of subjects attained functional remission or euthymia over the entire time period evaluated provides further evidence that pediatric bipolar disorder is a chronic mood disorder with a poor prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>WACC 725, Massachusetts General Hospital, Pediatric Psychopharmacology Unit, MGH, 55 Fruit Street, Boston, MA 02114, USA. jbiederman@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mick</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>Stephen V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Van Patten</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Burback</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01MH065523</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08MH001503</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HD036317</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15571786</ArticleId><ArticleId IdType="pii">S0165-0327(04)00194-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.05.012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17162825</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>The neuropsychology of mood disorders.</ArticleTitle><Pagination><MedlinePgn>458-63</MedlinePgn></Pagination><Abstract><AbstractText>Cognitive dysfunction is central to our understanding of mood disorders in terms of patient experiences, Diagnostic and Statistical Manual of Mental Disorders criteria, and psychological models. In this article, we highlight key findings from studies that have used neuropsychological tests and functional neuroimaging techniques to explore cognitive dysfunction in patients with depression and mania. In particular, we focus on affective processing bias, abnormal response to negative feedback, and decision making. Results are discussed in the context of current conceptualizations of dysfunctional neural circuitry, and in relation to important clinical research implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chamberlain</LastName><ForeName>Samuel R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK. src33@cam.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahakian</LastName><ForeName>Barbara J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0001354</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>019407</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008606" MajorTopicYN="N">Mental Processes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>72</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17162825</ArticleId><ArticleId IdType="doi">10.1007/s11920-006-0051-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2004 Jun 15;55(12):1163-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15184035</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2004 May;22(1):409-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15110034</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Clin Neuropsychiatry. 2002 Oct;7(4):243-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12382207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 1995 Aug;7(8):653-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8704740</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Sep 1;50(5):358-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11543739</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 May;31(4):679-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11352370</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Jul;27(4):931-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9234470</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1985 Sep 27;229(4720):1397-400</Citation><ArticleIdList><ArticleId IdType="pubmed">4035356</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1993 Jan;162:118-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8425125</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2005 May;29(3):399-419</Citation><ArticleIdList><ArticleId IdType="pubmed">15820546</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Jun;30(6):1138-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15689962</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion J Clin Psychiatry. 2001 Aug;3(4):151-155</Citation><ArticleIdList><ArticleId IdType="pubmed">15014598</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2002 Oct;27(7):843-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12183219</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Dec 1;48(11):1045-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11094137</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 1998 Oct 1;2(10):379-88</Citation><ArticleIdList><ArticleId IdType="pubmed">21227253</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1995 Aug;30(5):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7482006</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1994 Jun 13;648(1):157-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7922518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1993 Mar;13(3):914-23</Citation><ArticleIdList><ArticleId IdType="pubmed">8441016</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimaging Clin N Am. 2003 Nov;13(4):805-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15024963</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 May;49(5):384-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1586274</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2000 Jun;14(2):139-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10890308</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 1997 Jun;46(1-2):290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9191104</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1998 Jan 1;18(1):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9412519</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Feb 15;130(2):131-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15033183</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2001 Dec;124(Pt 12):2550-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11701607</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1999 Sep;175:246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10645326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Oct 15;19(20):9029-38</Citation><ArticleIdList><ArticleId IdType="pubmed">10516320</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2004 Dec;6(6):451-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15538994</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychother Pract Res. 1997 Fall;6(4):276-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9292441</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9221971</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2001 Nov 21;286(19):2391</Citation><ArticleIdList><ArticleId IdType="pubmed">11712923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognition. 1994 Apr-Jun;50(1-3):7-15</Citation><ArticleIdList><ArticleId IdType="pubmed">8039375</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1986 Nov;16(4):789-94</Citation><ArticleIdList><ArticleId IdType="pubmed">3823296</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jul;59(7):597-604</Citation><ArticleIdList><ArticleId IdType="pubmed">12090812</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 1972;23:407-12</Citation><ArticleIdList><ArticleId IdType="pubmed">4566487</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2002 Mar;180:227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11872515</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1988 Aug;18(3):689-95</Citation><ArticleIdList><ArticleId IdType="pubmed">3186869</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Apr;167(1):112-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12605289</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Sep;30(5):1025-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12027040</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2003 Aug;33(6):959-67</Citation><ArticleIdList><ArticleId IdType="pubmed">12946080</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Aug 15;50(4):271-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11522262</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1997 Mar 3;8(4):1057-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9141092</ArticleId></ArticleIdList></Reference><Reference><Citation>Percept Mot Skills. 1980 Oct;51(2):541-2</Citation><ArticleIdList><ArticleId IdType="pubmed">7443375</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2003 May;33(4):601-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12785462</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1999 Nov;29(6):1307-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10616937</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2000;126:413-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11105660</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1979 Jun;88(3):242-7</Citation><ArticleIdList><ArticleId IdType="pubmed">500951</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2003 Apr;33(3):455-67</Citation><ArticleIdList><ArticleId IdType="pubmed">12701666</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Jan;61(1):34-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14706942</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1994 Jun;52(3):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7991720</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1994 Feb 15;266(3):255-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8174608</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Jul 15;42(2):85-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9209724</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jan 1;55(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14706419</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1996 Nov;34(11):1085-95</Citation><ArticleIdList><ArticleId IdType="pubmed">8904746</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Feb;159(2):302-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11823275</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 1986;9:357-81</Citation><ArticleIdList><ArticleId IdType="pubmed">3085570</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):165-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9989549</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2001 Oct;10(10):1789-96</Citation><ArticleIdList><ArticleId IdType="pubmed">11772285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Apr 24;386(6627):824-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9126739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 1991 Feb;72(2):256-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1991797</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1999 Apr;20(4):322-39</Citation><ArticleIdList><ArticleId IdType="pubmed">10088133</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Jul 1;19(13):5473-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10377356</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2000 Jun 5;11(8):1739-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10852235</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 1995;5 Suppl:77-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8775763</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1993 Sep;163:338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8401963</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2001 Jan;16(1):89-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12404603</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Cogn. 2004 Jun;55(1):41-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15134842</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20374154</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1369-1627</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>International review of psychiatry (Abingdon, England)</Title><ISOAbbreviation>Int Rev Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Valproate and neuroprotective effects for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>410-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540260902962206</ELocationID><Abstract><AbstractText>Valproate is an anticonvulsant drug but also a mood stabilizer commonly used to treat bipolar disorder. It has a structure of short-chain fatty acid and is becoming a first line treatment for bipolar disorder. The effect mechanism of the vaproate has not been completely established but it has been suggested that alterations in gene expression may be involved in chronic treatment. On the other hand, a growing body of evidence emphasizes that valproate has neuroprotective and neurotrophic actions. Neuroimaging studies that examine neurochemistry in the living brain provide further support for the hypothesis that bipolar disorder is related to changes in neuronal viability and function. In cellular view of point, it was showed that valproate protected rat cerebral cortical and cerebellar granule cells from glutamate-related excitotoxicity, and apoptotic death of the endoplasmic reticulum in C6 glioma cells and PC 12 cells. At the genetic level, growing data suggest that the long-term treatment of mood disorders may involve the regulation of signalling pathways and gene expression in critical neuronal circuits. It has been shown that lithium and valproate produce some changes in basal and stimulated DNA binding to activator protein 1 (AP-1) transcription factors, considering that strategic changes in gene expression in critical neuronal circuits may be important in the treatment of a variety of psychiatric disorders. So, a growing body of evidence establishes its neuroprotective and neurotrophic actions in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atmaca</LastName><ForeName>Murad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Firat University, School of Medicine, Department of Psychiatry, Elazig, Turkey. matmaca_p@yahoo.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Rev Psychiatry</MedlineTA><NlmUniqueID>8918131</NlmUniqueID><ISSNLinking>0954-0261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018808" MajorTopicYN="N">Transcription Factor AP-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20374154</ArticleId><ArticleId IdType="doi">10.1080/09540260902962206</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23857742</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-5872</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists</Title><ISOAbbreviation>Asia Pac Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Is it useful to use the Korean version of the mood disorder questionnaire for assessing bipolar spectrum disorder among Korean college students?</ArticleTitle><Pagination><MedlinePgn>170-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/appy.12026</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The purpose of this study was to assess the usefulness of the Korean version of the Mood Disorder Questionnaire (K-MDQ) as a screening tool for the identification of bipolar spectrum disorder (BSD) among Korean college students.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample of 1,020 college students was stratified to reflect geographical differences among the students. The K-MDQ and an epidemiological survey were administered between November 2006 and February 2007. To validate the K-MDQ as a screening tool for BSD, the Korean version of the Bipolar Spectrum Diagnostic Scale (K-BSDS) and the Structured Clinical Interview for DSM-IV (SCID) were also administered.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rates satisfying MDQ criterion 1, and all three MDQ criteria, were 55.5% and 2.3%, respectively. According to the K-BSDS, 59.9% of the sample met the criteria for BSD using a threshold of 10, while no statistical differences were observed among subgroups. When we examined the diagnostic agreement between K-MDQ and K-BSDS, 79.5% of students who met MDQ criterion 1 were also positive on the BSDS. Sixteen (21.6%) of the 74 students who participated in the SCID interview were diagnosed with BSD.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Although the K-MDQ is a useful tool to assess BSD among inpatients and outpatients, it does not appear useful as a screening tool to detect BSD among college students.</AbstractText><CopyrightInformation>Copyright © 2013 Wiley Publishing Asia Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Seung Oh</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Gwangju Mirae Hospital, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Moon Doo</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jung Goo</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jeong-Seok</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Won</LastName><ForeName>Seung-Hee</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Young Sup</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Seok</LastName><ForeName>Jeong-Ho</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Won</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Se Joo</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Kyung Joon</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Jon</LastName><ForeName>Duk-In</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Young Chul</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Bahk</LastName><ForeName>Won Myong</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Bo-Hyun</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Asia Pac Psychiatry</MedlineTA><NlmUniqueID>101506757</NlmUniqueID><ISSNLinking>1758-5864</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013334" MajorTopicYN="N">Students</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014495" MajorTopicYN="N">Universities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Korean</Keyword><Keyword MajorTopicYN="N">Korean version of the Mood Disorder Questionnaire</Keyword><Keyword MajorTopicYN="N">bipolar spectrum disorder</Keyword><Keyword MajorTopicYN="N">college student</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">screening</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>02</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23857742</ArticleId><ArticleId IdType="doi">10.1111/appy.12026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8254153</PMID><DateCompleted><Year>1994</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0268-1315</ISSN><JournalIssue CitedMedium="Print"><Volume>8 Suppl 1</Volume><PubDate><Year>1993</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International clinical psychopharmacology</Title><ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Subaffective personality disorders.</ArticleTitle><Pagination><MedlinePgn>39-46</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sass</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Psychiatrische Klinik der Medizinischen, Fakultät der RWTH Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herpertz</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Steinmeyer</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Clin Psychopharmacol</MedlineTA><NlmUniqueID>8609061</NlmUniqueID><ISSNLinking>0268-1315</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009440" MajorTopicYN="N">Neurasthenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8254153</ArticleId><ArticleId IdType="doi">10.1097/00004850-199309001-00006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23790741</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The effects of mindfulness-based cognitive therapy in patients with bipolar disorder: a controlled functional MRI investigation.</ArticleTitle><Pagination><MedlinePgn>1152-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.05.074</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00453-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Preliminary research findings have shown that mindfulness-based cognitive therapy improves anxiety and depressive symptoms in bipolar disorder. In this study, we further investigated the effects of MBCT in bipolar disorder, in a controlled fMRI study.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Twenty three patients with bipolar disorder underwent neuropsychological testing and functional MRI. Sixteen of these patients were tested before and after an eight-week MBCT intervention, and seven were wait listed for training and tested at the same intervals. The results were compared with 10 healthy controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Prior to MBCT, bipolar patients reported significantly higher levels of anxiety and symptoms of stress, scored significantly lower on a test of working memory, and showed significant BOLD signal decrease in the medial PFC during a mindfulness task, compared to healthy controls. Following MBCT, there were significant improvements in the bipolar treatment group, in measures of mindfulness, anxiety and emotion regulation, and in tests of working memory, spatial memory and verbal fluency compared to the bipolar wait list group. BOLD signal increases were noted in the medial PFC and posterior parietal lobe, in a repeat mindfulness task. A region of interest analysis revealed strong correlation between signal changes in medial PFC and increases in mindfulness.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The small control group is a limitation in the study.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that MBCT improves mindfulness and emotion regulation and reduces anxiety in bipolar disorder, corresponding to increased activations in the medial PFC, a region associated with cognitive flexibility and previously proposed as a key area of pathophysiology in the disorder.</AbstractText><CopyrightInformation>© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ives-Deliperi</LastName><ForeName>Victoria L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Human Biology, University of Cape Town, Western Cape 7800, South Africa. vives@mweb.co.za</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howells</LastName><ForeName>Fleur</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Dan J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Meintjes</LastName><ForeName>Ernesta M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019122" MajorTopicYN="N">Meditation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064866" MajorTopicYN="Y">Mindfulness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">MBCT</Keyword><Keyword MajorTopicYN="N">Mindfulness</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23790741</ArticleId><ArticleId IdType="pii">S0165-0327(13)00453-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.05.074</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1605062</PMID><DateCompleted><Year>1992</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>5</Issue><PubDate><Year>1992</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Manic-depressive psychosis in children younger than 15 years: a register-based investigation of 39 cases in Denmark.</ArticleTitle><Pagination><MedlinePgn>401-6</MedlinePgn></Pagination><Abstract><AbstractText>Using a nationwide psychiatric case register covering a background population of 5.1 million inhabitants, 39 children (23 boys, 16 girls) were identified who got the diagnosis of manic-depressive psychosis between 1970 and 1986 before the age of 15. The frequency of manic-depressive psychosis in this child psychiatric population was 1.2%. The mean age for first-time admission with this diagnosis was 12.7 years. There was no sex difference. Twenty-six of the children got the diagnosis of manic-depressive psychosis during their first admission. Survival analysis was used to describe the prognosis and the diagnostic development of the group. As a whole, the group had a poor prognosis with many readmissions. The most common differential diagnoses were other types of psychosis in boys and oppositional and emotional disorders in girls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>P H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Aarhus Child Psychiatric Hospital, Risskov, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Møller</LastName><ForeName>L L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Dehlholm</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Brask</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1605062</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1992.tb10327.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34112182</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Inflammatory signaling mechanisms in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-021-00742-6</ELocationID><Abstract><AbstractText>Bipolar disorder is a decidedly heterogeneous and multifactorial disease, with a high individual and societal burden. While not all patients display overt markers of elevated inflammation, significant evidence suggests that aberrant immune signaling contributes to all stages of the disease, and likely explains the elevated rates of comorbid inflammatory illnesses seen in this population. While individual systems have been intensely studied and targeted, a relative paucity of attention has been given to the interconnecting role of inflammatory signals therein. This review presents an updated overview of some of the most prominent pathophysiologic mechanisms in bipolar disorder, from mitochondrial, endoplasmic reticular, and calcium homeostasis, to purinergic, kynurenic, and hormonal/neurotransmitter signaling, showing inflammation to act as a powerful nexus between these systems. Several areas with a high degree of mechanistic convergence within this paradigm are highlighted to present promising future targets for therapeutic development and screening.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth), 1941 East Road, Houston, TX, 77054, USA. gregory.h.jones@uth.tmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vecera</LastName><ForeName>Courtney M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth), 1941 East Road, Houston, TX, 77054, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinjari</LastName><ForeName>Omar F</ForeName><Initials>OF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth), 1941 East Road, Houston, TX, 77054, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado-Vieira</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth), 1941 East Road, Houston, TX, 77054, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BDNF</Keyword><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Glutamate</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Mitochondria</Keyword><Keyword MajorTopicYN="N">NLRP3</Keyword><Keyword MajorTopicYN="N">P2X7</Keyword><Keyword MajorTopicYN="N">Purine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>11</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34112182</ArticleId><ArticleId IdType="doi">10.1186/s12929-021-00742-6</ArticleId><ArticleId IdType="pii">10.1186/s12929-021-00742-6</ArticleId><ArticleId IdType="pmc">PMC8194019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2012 Sep;12(9):663-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22903149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunother Cancer. 2015 Dec 15;3:51</Citation><ArticleIdList><ArticleId IdType="pubmed">26674411</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2019 Mar 01;10:66</Citation><ArticleIdList><ArticleId IdType="pubmed">30881316</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2020 May;45(6):990-997</Citation><ArticleIdList><ArticleId IdType="pubmed">32092760</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2019 Oct;24(10):1523-1532</Citation><ArticleIdList><ArticleId IdType="pubmed">29988087</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2020 Sep 29;14:554548</Citation><ArticleIdList><ArticleId IdType="pubmed">33132844</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Jan;70(1):31-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22945416</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Heart Circ Physiol. 2013 Dec;305(12):H1830-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24142413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2017 Jun;55:62-74</Citation><ArticleIdList><ArticleId IdType="pubmed">28089906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 May;10(3):349-59</Citation><ArticleIdList><ArticleId IdType="pubmed">18402623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Jan;23(1):94-106</Citation><ArticleIdList><ArticleId IdType="pubmed">28948971</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2004 Jun;184:496-502</Citation><ArticleIdList><ArticleId IdType="pubmed">15172943</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2004 Jan;29(1):99-106</Citation><ArticleIdList><ArticleId IdType="pubmed">14575732</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):929-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16814263</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2002 Apr;58(4):297-304</Citation><ArticleIdList><ArticleId IdType="pubmed">12027524</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2013 Jun;19(6):403-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23574634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2010 Jun;120(6):1809-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20501951</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):370-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17064834</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2018 May;151:234-244</Citation><ArticleIdList><ArticleId IdType="pubmed">29288626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2019 May;21(3):235-243</Citation><ArticleIdList><ArticleId IdType="pubmed">30375143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Jan;25(1):131-147</Citation><ArticleIdList><ArticleId IdType="pubmed">30980044</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2021 Mar 15;11(1):167</Citation><ArticleIdList><ArticleId IdType="pubmed">33723220</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25912533</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cell Rev Rep. 2019 Aug;15(4):497-505</Citation><ArticleIdList><ArticleId IdType="pubmed">31020518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Aug-Sep;13(5-6):454-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22017215</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2014 Aug;40:219-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24703991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2009 May;75(5):1021-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19188338</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2021 Jan 20;24(1):8-21</Citation><ArticleIdList><ArticleId IdType="pubmed">33252694</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Nov 5;527(7576):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26524527</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 Feb 25;4:e365</Citation><ArticleIdList><ArticleId IdType="pubmed">24569695</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2017 Jul;42(8):1698-1705</Citation><ArticleIdList><ArticleId IdType="pubmed">28195577</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 2012 Jul;66(7):630-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22337473</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2016 Mar;39(1):125-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26876323</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2019 Apr;274:395-399</Citation><ArticleIdList><ArticleId IdType="pubmed">30852433</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2018 Jan 24;8(1):27</Citation><ArticleIdList><ArticleId IdType="pubmed">29362444</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2020 Jul 29;23(7):434-439</Citation><ArticleIdList><ArticleId IdType="pubmed">32573722</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2013 Jul;228(1):157-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23455595</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Aug;134(2):91-103</Citation><ArticleIdList><ArticleId IdType="pubmed">27097559</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Feb;20(2):162-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25403839</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2017 Jan;42(1):193-215</Citation><ArticleIdList><ArticleId IdType="pubmed">27629368</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2013 Jan;26(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23196997</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Sci. 2015 Jan;127(1):6-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25704012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2010 Sep;11(9):642-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20717121</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2018 May 1;83(9):718-719</Citation><ArticleIdList><ArticleId IdType="pubmed">29628041</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Neurobiol. 2019 Aug;39(6):729-750</Citation><ArticleIdList><ArticleId IdType="pubmed">31089834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2017 Jul;121:114-121</Citation><ArticleIdList><ArticleId IdType="pubmed">28465217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pineal Res. 2005 Jan;38(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15617531</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2008 Nov;327(2):316-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18708586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Aug 9;7(1):7677</Citation><ArticleIdList><ArticleId IdType="pubmed">28794421</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Genomics. 2006 Feb 14;24(3):191-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16352696</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2019 Oct;236(10):2909-2921</Citation><ArticleIdList><ArticleId IdType="pubmed">30756134</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2018 Sep 20;12:314</Citation><ArticleIdList><ArticleId IdType="pubmed">30294261</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Jun;147(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23602339</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2003 Jan;18(1):53-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12490776</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt A):23-27</Citation><ArticleIdList><ArticleId IdType="pubmed">28392482</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jun;30(4):617-29</Citation><ArticleIdList><ArticleId IdType="pubmed">16580767</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2016 Sep 20;12:2373-2380</Citation><ArticleIdList><ArticleId IdType="pubmed">27703355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediators Inflamm. 2018 Mar 26;2018:7019398</Citation><ArticleIdList><ArticleId IdType="pubmed">29769837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2020 Feb;22(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">31398273</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 2003 Jul;33(4):421-33</Citation><ArticleIdList><ArticleId IdType="pubmed">14574141</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):819-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20206224</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2018 Nov;269:207-211</Citation><ArticleIdList><ArticleId IdType="pubmed">30153598</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2015 Jul;40(4):250-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25768030</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2014 Jan 1;75(1):31-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23582268</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2019 Aug;60:97-107</Citation><ArticleIdList><ArticleId IdType="pubmed">30808582</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2018 Apr 10;419:8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">29339210</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2007 Jun 21;421(1):33-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17548157</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2019 Nov 1;236:116790</Citation><ArticleIdList><ArticleId IdType="pubmed">31626791</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Sci. 2018 Oct 4;25(1):71</Citation><ArticleIdList><ArticleId IdType="pubmed">30285728</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2013 Apr 08;4:85</Citation><ArticleIdList><ArticleId IdType="pubmed">23580000</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2018;24(22):2549-2555</Citation><ArticleIdList><ArticleId IdType="pubmed">30073921</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2018 Apr;30(2):70-78</Citation><ArticleIdList><ArticleId IdType="pubmed">28399943</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:117-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biosci. 2020 Mar 5;10:28</Citation><ArticleIdList><ArticleId IdType="pubmed">32166013</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2019 Jan 24;9:767</Citation><ArticleIdList><ArticleId IdType="pubmed">30733690</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2016 Jul 1;80(1):12-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26831917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2012 Oct 15;189(8):3795-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22984081</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2016 Sep;68:694-713</Citation><ArticleIdList><ArticleId IdType="pubmed">27377693</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Sci. 2015 Jan;127(1):2-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25704011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2017 Sep;31(9):1137-1148</Citation><ArticleIdList><ArticleId IdType="pubmed">28858537</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Aug;69(8):1237-45</Citation><ArticleIdList><ArticleId IdType="pubmed">18681754</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharmacol Sin. 2016 Jul;37(7):865-72</Citation><ArticleIdList><ArticleId IdType="pubmed">27018176</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 Jul 1;43(4):881-890</Citation><ArticleIdList><ArticleId IdType="pubmed">28049760</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2018 Oct;73:717-724</Citation><ArticleIdList><ArticleId IdType="pubmed">30102967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Nov;16(7):741-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24862833</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Neurosci. 2020 Jul 31;13:124</Citation><ArticleIdList><ArticleId IdType="pubmed">32848594</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2015 Jan;232(1):245-50</Citation><ArticleIdList><ArticleId IdType="pubmed">24961563</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2016 Nov 29;10:612</Citation><ArticleIdList><ArticleId IdType="pubmed">27965560</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2016;22(8):987-1012</Citation><ArticleIdList><ArticleId IdType="pubmed">26654772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2018 Sep;35(10):1335-1353</Citation><ArticleIdList><ArticleId IdType="pubmed">29939763</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2017 Apr 28;292(17):6869-6881</Citation><ArticleIdList><ArticleId IdType="pubmed">28302726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2019 Dec 4;:</Citation><ArticleIdList><ArticleId IdType="pubmed">31801967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Feb;17(1):39-49</Citation><ArticleIdList><ArticleId IdType="pubmed">25039314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May;147(1-3):441-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23141631</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2018 Oct;33(10):1355-1360</Citation><ArticleIdList><ArticleId IdType="pubmed">30022520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Feb 17;7:42755</Citation><ArticleIdList><ArticleId IdType="pubmed">28209997</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2014 Sep;39(9):1621-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24482021</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2018 Nov 27;9:614</Citation><ArticleIdList><ArticleId IdType="pubmed">30538645</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2011 Mar;36(2):114-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21138659</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Aug 15;218(1-2):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24794031</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2018 Aug;30(4):363-375</Citation><ArticleIdList><ArticleId IdType="pubmed">30102081</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Aug 30;228(3):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26160203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2019 Nov 15;:</Citation><ArticleIdList><ArticleId IdType="pubmed">31732715</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Apr;145(1-3):36-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23403415</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2017 Jan;210(1):10-15</Citation><ArticleIdList><ArticleId IdType="pubmed">27856422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2019 Jul;79:244-255</Citation><ArticleIdList><ArticleId IdType="pubmed">30790702</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2013 Jan;100:15-29</Citation><ArticleIdList><ArticleId IdType="pubmed">23044468</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1984;11(4):219-23</Citation><ArticleIdList><ArticleId IdType="pubmed">6436729</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2018 Sep;213(3):514-525</Citation><ArticleIdList><ArticleId IdType="pubmed">30113291</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2017 Jan;42(1):368-369</Citation><ArticleIdList><ArticleId IdType="pubmed">27909322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 2018 Nov;103:115-124</Citation><ArticleIdList><ArticleId IdType="pubmed">30248487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2017 Feb;37(1):40-45</Citation><ArticleIdList><ArticleId IdType="pubmed">27902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2011;29:707-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21219188</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2015 Mar;32(3):167-73</Citation><ArticleIdList><ArticleId IdType="pubmed">25620378</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2017 Jul;81:144-150</Citation><ArticleIdList><ArticleId IdType="pubmed">28482311</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2012 Mar 23;36(3):401-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22342844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2019 Feb;177:12-19</Citation><ArticleIdList><ArticleId IdType="pubmed">30586559</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine. 2011 Nov;56(2):458-65</Citation><ArticleIdList><ArticleId IdType="pubmed">21795061</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2018 Feb 28;9(3):329</Citation><ArticleIdList><ArticleId IdType="pubmed">29491386</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2012 Mar 22;3:25</Citation><ArticleIdList><ArticleId IdType="pubmed">22461775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 6;460(7256):748-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2005 Feb 9;1034(1-2):11-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15713255</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2017 Jun 20;11:316</Citation><ArticleIdList><ArticleId IdType="pubmed">28676747</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2019 Oct;81:484-494</Citation><ArticleIdList><ArticleId IdType="pubmed">31279682</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2013 Aug;38(9):1607-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23857540</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2018 Aug 31;16(3):235-245</Citation><ArticleIdList><ArticleId IdType="pubmed">30121990</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2020 Jun 1;150(6):1354-1359</Citation><ArticleIdList><ArticleId IdType="pubmed">31825066</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2019 Jan;99:183-190</Citation><ArticleIdList><ArticleId IdType="pubmed">30248494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1654-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23663951</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2019 Apr;33(4):815-825</Citation><ArticleIdList><ArticleId IdType="pubmed">30846866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2017 Jan;84:113-118</Citation><ArticleIdList><ArticleId IdType="pubmed">27718369</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2015 Nov 25;58(22):8762-82</Citation><ArticleIdList><ArticleId IdType="pubmed">26207924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Apr;25(4):873-882</Citation><ArticleIdList><ArticleId IdType="pubmed">29934548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Mar 5;274(10):6039-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10037682</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 Nov 2;131(3):596-610</Citation><ArticleIdList><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2016 Jan;64(1):76-89</Citation><ArticleIdList><ArticleId IdType="pubmed">26295445</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Mar 15;211:99-106</Citation><ArticleIdList><ArticleId IdType="pubmed">28107669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 Jan;22(1):127-133</Citation><ArticleIdList><ArticleId IdType="pubmed">27046644</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Dec;206:300-304</Citation><ArticleIdList><ArticleId IdType="pubmed">27656788</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2016 Aug;44:22-41</Citation><ArticleIdList><ArticleId IdType="pubmed">27318131</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2017 Mar 21;7(3):e1065</Citation><ArticleIdList><ArticleId IdType="pubmed">28323284</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2014 Jun;28(6):571-81</Citation><ArticleIdList><ArticleId IdType="pubmed">24715548</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Behav Neurosci. 2018;36:107-135</Citation><ArticleIdList><ArticleId IdType="pubmed">28831734</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2016 Jan;72:43-50</Citation><ArticleIdList><ArticleId IdType="pubmed">26540403</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2701-2706</Citation><ArticleIdList><ArticleId IdType="pubmed">30692251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 Jul 1;43(4):764-777</Citation><ArticleIdList><ArticleId IdType="pubmed">28187219</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ther. 2015 Nov-Dec;22(6):477-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25383489</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Feb;121(1-2):161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19524303</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2018 May 1;83(9):720-721</Citation><ArticleIdList><ArticleId IdType="pubmed">29050637</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2011 Oct;21(5):479-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22040193</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):561-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19224657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2001 Nov;26(5):411-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11762208</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2017 Mar;34(3):713-724</Citation><ArticleIdList><ArticleId IdType="pubmed">28144920</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2010 Aug;177(2):575-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20566748</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Oct 30;5:15962</Citation><ArticleIdList><ArticleId IdType="pubmed">26514444</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2013 Apr;30(4):297-306</Citation><ArticleIdList><ArticleId IdType="pubmed">23468190</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Oct 02;8(10):e75426</Citation><ArticleIdList><ArticleId IdType="pubmed">24098382</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2020 Oct;34(10):1125-1133</Citation><ArticleIdList><ArticleId IdType="pubmed">32648790</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed J. 2020 Apr;43(2):134-142</Citation><ArticleIdList><ArticleId IdType="pubmed">32386841</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2016 Nov;58:11-17</Citation><ArticleIdList><ArticleId IdType="pubmed">27181178</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2020 Nov 24;11:578396</Citation><ArticleIdList><ArticleId IdType="pubmed">33381032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 20;143(1-3):148-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22749155</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Jan 10;8:1957</Citation><ArticleIdList><ArticleId IdType="pubmed">29379504</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2019 Feb;24(2):606-615</Citation><ArticleIdList><ArticleId IdType="pubmed">30447328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2021 Jun;168:105586</Citation><ArticleIdList><ArticleId IdType="pubmed">33812005</ArticleId></ArticleIdList></Reference><Reference><Citation>Commun Integr Biol. 2011 Jan;4(1):14-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21509169</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2015 Feb 1;77(3):e19-e20</Citation><ArticleIdList><ArticleId IdType="pubmed">25104172</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2015 Feb;29(2):97-115</Citation><ArticleIdList><ArticleId IdType="pubmed">25586400</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Mar;62:78-83</Citation><ArticleIdList><ArticleId IdType="pubmed">25691093</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Mol Diagn. 2017 Feb;17(2):107-108</Citation><ArticleIdList><ArticleId IdType="pubmed">27935358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Apr;23(4):801-811</Citation><ArticleIdList><ArticleId IdType="pubmed">29532791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cells. 2020 Feb 28;9(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">32121312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Mar;18(2):89-101</Citation><ArticleIdList><ArticleId IdType="pubmed">26990051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Jan 1;170:95-103</Citation><ArticleIdList><ArticleId IdType="pubmed">25237732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;19(4):1331-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20061611</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Mol Med. 2015;15(3):206-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25817855</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxid Med Cell Longev. 2019 Oct 7;2019:3462530</Citation><ArticleIdList><ArticleId IdType="pubmed">31687078</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Jan;136(1-2):110-116</Citation><ArticleIdList><ArticleId IdType="pubmed">21962564</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Behav. 2016 Jul;60:153-157</Citation><ArticleIdList><ArticleId IdType="pubmed">27206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:23-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24468642</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS J. 2012 Apr;279(8):1356-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22248144</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):469-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15826743</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2018 Feb 01;9:30</Citation><ArticleIdList><ArticleId IdType="pubmed">29449810</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2020 Apr;19(4):224-225</Citation><ArticleIdList><ArticleId IdType="pubmed">32203290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18514146</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[The schizotypal personality disorder: historical origins and current status].</ArticleTitle><Pagination><MedlinePgn>17-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2007.07.007</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The schizotypal personality disorder is a recent psychiatric nosological concept developed by Spitzer at the end of the 1970s, based on the analysis of the characteristics of relatives of schizophrenic subjects included in the adoption studies carried out in the same decade by Kety, Wender and Rosenthal.</AbstractText><AbstractText Label="HISTORICAL ASPECTS" NlmCategory="BACKGROUND">However, this entity is based on older observations, at the beginning of the past century, showing common behavioural characteristics in relatives of schizophrenics. Its status within our current nosography remains dubious, sometimes classified among personality disorders, sometimes in the schizophrenia spectrum disorders. It is interesting to present the origins of this concept that stem from two complementary approaches: a family approach and a clinical approach of sporadic cases and then to redefine the framework within which the diagnostic approach was based and its continuity, up until our current classifications, the DSM and CIM.</AbstractText><AbstractText Label="CURRENT STATUS" NlmCategory="RESULTS">The historical origins cannot summarize the disorder and it appears important to redefine the multidimensional characteristics of the schizotypal personality disorder, generally a three-factor model. Indeed, dimensional models of psychosis are becoming established as conceptually and clinically useful. Recent studies on the dimensionality of psychosis show an evolution of the schizotypal concept, initially defined as being part of the schizophrenia spectrum and which now appears to be more broadly linked to a concept of unitary psychosis, including the bipolar disorder.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dimensions of psychosis seem to be associated with different familial aggregation and risk of psychosis, suggesting that they are underlined by different physiopathological processes. Hence, the dimensional approach can help to disentangle the genetic heterogeneity of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laguerre</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département hospitalo-universitaire de psychiatrie adulte, hôpital Albert-Chenevier, AP-HP, 40 rue Mesly, groupe Henri-Mondor-Albert-Chenevier, 94000 Créteil, France. audrey.laguerre@ach.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schürhoff</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>La schizotypie: évolution d'un concept.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>41</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18514146</ArticleId><ArticleId IdType="pii">S0013-7006(07)00049-8</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2007.07.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7918509</PMID><DateCompleted><Year>1994</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1054-139X</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>1994</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of adolescent health : official publication of the Society for Adolescent Medicine</Title><ISOAbbreviation>J Adolesc Health</ISOAbbreviation></Journal><ArticleTitle>Mania or panic associated with dexamethasone chemotherapy in adolescents.</ArticleTitle><Pagination><MedlinePgn>345-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>T K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Illinois at Chicago 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sylvester</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Manaligod</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Adolesc Health</MedlineTA><NlmUniqueID>9102136</NlmUniqueID><ISSNLinking>1054-139X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber><NameOfSubstance UI="D007099">Imipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016584" MajorTopicYN="N">Panic Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7918509</ArticleId><ArticleId IdType="pii">1054-139X(94)90609-2</ArticleId><ArticleId IdType="doi">10.1016/1054-139x(94)90609-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18211555</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1351-0126</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of psychiatric and mental health nursing</Title><ISOAbbreviation>J Psychiatr Ment Health Nurs</ISOAbbreviation></Journal><ArticleTitle>Promotion of choice in the care of people with bipolar disorder: a mental health nursing perspective.</ArticleTitle><Pagination><MedlinePgn>87-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2850.2007.01208.x</ELocationID><Abstract><AbstractText>Inpatient nurse prescribing is proving to be a useful mechanism by which patients can have their medicines prescribed. A case study is described that outlines how a nurse prescriber worked with a patient who had been diagnosed with bipolar disorder. Key issues that have arisen from this case study include the importance of multidisciplinary team working, informed medicines management interventions and the ability to work with patients to promote patient choice. The case study will draw out the difficulties in managing bipolar conditions but enable other nurse prescribers to adopt similar values in their prescribing practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Surrey and Borders Partnership NHS Trust, The Ridgewood Centre, Frimley, Surrey, UK. mynyddisa@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Ment Health Nurs</MedlineTA><NlmUniqueID>9439514</NlmUniqueID><ISSNLinking>1351-0126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="Y">Choice Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18211555</ArticleId><ArticleId IdType="pii">JPM1208</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2850.2007.01208.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15208770</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[Case series with childhood bipolar disorder phenotype features].</ArticleTitle><Pagination><MedlinePgn>148-54</MedlinePgn></Pagination><Abstract><AbstractText>Although outcomes of bipolar disorder with onset in late adolescence and adulthood have been reported, little is known about childhood and prepubertal onset mania. There is a considerable overlap between the diagnostic criteria for mania and disruptive behavioral disorders, particularly attention deficit hyperactivity disorder (ADHD). The overlapping diagnostic boundaries need to be described. We aimed to determine the frequency and severity of symptoms and cycling features in our patients. We reported 7 cases (between 7 and 15 years old) with bipolar phenotype features who were being followed in our unit. The Washington University at St. Louis-Kiddie and Young Adult Schedule for Affective Disorders and Schizophrenia-Present state and lifetime-B. Geller et al.1996 (WASH-U-KSADS) was used for the assessment of psychiatric diagnoses and symptomatology. The Turgay DSM-IV Disruptive Behaviour Disorders Scale was used to determine the frequency of comorbidity between ADHD symptoms and bipolar disorder phenotype features. The most frequent severe symptoms observed at the end of the assessment by WASH-U-KSADS were grandiosity, distractibility, and unusual energy. Four of the cases had mixed cycling features. Five of the cases had ultradian cycling features. All these findings suggest that more research should be carried out on psychosocial and psychopharmacological strategies and pathogenetic mechanisms for mania during the prepubertal and early adolescent years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inal Emiroğlu</LastName><ForeName>F Neslihan</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Dokuz Eylül U Cocuk ve Ergen Psikiyatrisi AD., Izmir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Cocukluk Caği Bipolar Bozukluk Fenotip Ozellikleri Gösteren Bir Olgu Serisi.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15208770</ArticleId><ArticleId IdType="pii">469</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7454308</PMID><DateCompleted><Year>1981</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2009</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0030-6002</ISSN><JournalIssue CitedMedium="Print"><Volume>121</Volume><Issue>33</Issue><PubDate><Year>1980</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Orvosi hetilap</Title><ISOAbbreviation>Orv Hetil</ISOAbbreviation></Journal><ArticleTitle>[Distribution of ABO blood groups in patients with manic-depressive psychosis].</ArticleTitle><Pagination><MedlinePgn>1993-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rihmer</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Arató</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Az ABO vércsoportrendszer allotípusainak megoszlása mániás-depressziós betegeknél.</VernacularTitle></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Orv Hetil</MedlineTA><NlmUniqueID>0376412</NlmUniqueID><ISSNLinking>0030-6002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000017">ABO Blood-Group System</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007126">Immunoglobulin Allotypes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000017" MajorTopicYN="N">ABO Blood-Group System</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007126" MajorTopicYN="N">Immunoglobulin Allotypes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>8</Month><Day>17</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>8</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7454308</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">728699</PMID><DateCompleted><Year>1979</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>133</Volume><PubDate><Year>1978</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Sweat lithium in manic-depression.</ArticleTitle><Pagination><MedlinePgn>477-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>E B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Pain</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Skripal</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>01MI4Q9DI3</RegistryNumber><NameOfSubstance UI="D010862">Pilocarpine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010862" MajorTopicYN="N">Pilocarpine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013542" MajorTopicYN="N">Sweat</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013546" MajorTopicYN="N">Sweating</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">728699</ArticleId><ArticleId IdType="pii">S0007125000198824</ArticleId><ArticleId IdType="doi">10.1192/bjp.133.5.477b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29228982</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Electroconvulsive therapy for manic state with mixed and psychotic features in a teenager with bipolar disorder and comorbid episodic obsessive-compulsive disorder: a case report.</ArticleTitle><Pagination><MedlinePgn>345</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-017-1508-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Comorbidity of bipolar disorder and obsessive-compulsive disorder is common in adolescence. Obsessive-compulsive disorder symptoms may be episodic and secondary to alterations in mood, and display specific features. Management of pediatric bipolar disorder-obsessive-compulsive disorder is challenging, as pharmacotherapy of obsessive-compulsive disorder may induce or exacerbate manic episodes and there is limited evidence of treatment efficacy. Electroconvulsive therapy is sparsely used in children and adolescents, but is documented to be a safe and efficacious intervention in adults with bipolar disorder. In view of the severity of symptoms in juvenile mania, studies on treatment strategies are warranted. We report a case of an adolescent with bipolar disorder-obsessive-compulsive disorder who was successfully treated with electroconvulsive therapy during an episode of severe mania.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 16-year-old girl of Middle East origin first presented to us with depressed mood, irritability, and increased obsessive-compulsive disorder symptoms, which were initially interpreted in the context of acute stress secondary to migration. She had been diagnosed with bipolar disorder and obsessive-compulsive disorder in her previous home country, but had difficulties in accounting for earlier psychiatric history. During hospitalization her mood switched to a manic state with mixed and psychotic features, at times showing aggression toward others. Interruption in her lithium treatment for a short period and possibly the introduction of an atypical antipsychotic could in part have been triggering factors. After 8 weeks of in-patient care and psychotropic drug trials, electroconvulsive therapy was initiated and administered every second or third day for 4 weeks, with marked positive response. No apparent side effects were reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This case demonstrates the need for a detailed medical history, taking special note of periodicity and character of obsessive-compulsive disorder symptoms, in adolescents with mood disorders. When treating culturally diverse patients, extra consideration should be taken. Special concerns in the pharmacological treatment to avoid the patient's condition from worsening must be addressed, including giving priority to mood stabilization before obsessive-compulsive disorder symptoms. There are potential benefits in considering electroconvulsive therapy in young patients with severe mania where first-line treatment options have failed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rask</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Division of Pediatrics, Lund University, Lund, Sweden. olof.rask@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office for Healthcare 'Sund', Child &amp; Adolescent Psychiatry, Unit for Pediatric Bipolar &amp; Psychotic Disorders, Lund, Sweden. olof.rask@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suneson</LastName><ForeName>Klara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Division of Psychiatry, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office for Healthcare 'Sund', Child &amp; Adolescent Psychiatry, Regional Inpatient Care, Emergency Unit, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmström</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Office for Healthcare 'Sund', Child &amp; Adolescent Psychiatry, Regional Inpatient Care, Emergency Unit, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bäckström</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office for Healthcare 'Sund', Child &amp; Adolescent Psychiatry, Unit for Pediatric Bipolar &amp; Psychotic Disorders, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Björn Axel</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Division of Child &amp; Adolescent Psychiatry, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office for Healthcare 'Sund', Child &amp; Adolescent Psychiatry, Regional Inpatient Care, Emergency Unit, Malmö, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008877" MajorTopicYN="N">Middle East</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012036" MajorTopicYN="Y">Refugees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N">Sweden</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescents</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</Keyword><Keyword MajorTopicYN="N">Electroconvulsive therapy</Keyword><Keyword MajorTopicYN="N">Obsessive-compulsive disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29228982</ArticleId><ArticleId IdType="doi">10.1186/s13256-017-1508-8</ArticleId><ArticleId IdType="pii">10.1186/s13256-017-1508-8</ArticleId><ArticleId IdType="pmc">PMC5725801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 2014 May;129(5):343-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24506190</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Neuropsychol Adult. 2017 Nov-Dec;24(6):481-492</Citation><ArticleIdList><ArticleId IdType="pubmed">27383249</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2011 Mar;76(3):395-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21129852</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Case Rep. 2015 Sep 21;9:200</Citation><ArticleIdList><ArticleId IdType="pubmed">26388066</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Board Fam Med. 2015 Jan-Feb;28(1):154-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25567837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Feb;18(1):19-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26748678</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Mar;156:206-13</Citation><ArticleIdList><ArticleId IdType="pubmed">24439831</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Dec 30;230(3):800-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26561371</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Feb;47(2):121-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23125399</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2011 Jan;11(1):127-37</Citation><ArticleIdList><ArticleId IdType="pubmed">21158560</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Jan;125(1):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22150101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Sep;76(9):e1151-2</Citation><ArticleIdList><ArticleId IdType="pubmed">26455688</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2016 Sep;26(7):632-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26784386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Mar;12(2):185-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20402711</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Psychiatr. 2016 Apr;20:12-4</Citation><ArticleIdList><ArticleId IdType="pubmed">27025465</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2009;23(3):241-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19320532</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Sep;76(9):1168-73</Citation><ArticleIdList><ArticleId IdType="pubmed">25938268</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Clin Pract. 2012 Mar;16(1):2-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22122647</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1970;215:1-98</Citation><ArticleIdList><ArticleId IdType="pubmed">5271208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Feb;10(1 Pt 2):194-214</Citation><ArticleIdList><ArticleId IdType="pubmed">18199237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25479050</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>174</Volume><PubDate><Year>2015</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Augmenting psychoeducation with a mobile intervention for bipolar disorder: a randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>23-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.10.053</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00685-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychosocial interventions for bipolar disorder are frequently unavailable and resource intensive. Mobile technology may improve access to evidence-based interventions and may increase their efficacy. We evaluated the feasibility, acceptability and efficacy of an augmentative mobile ecological momentary intervention targeting self-management of mood symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a randomized single-blind controlled trial with 82 consumers diagnosed with bipolar disorder who completed a four-session psychoeducational intervention and were assigned to 10 weeks of either: 1) mobile device delivered interactive intervention linking patient-reported mood states with personalized self-management strategies, or 2) paper-and-pencil mood monitoring. Participants were assessed at baseline, 6 weeks (mid-point), 12 weeks (post-treatment), and 24 weeks (follow up) with clinician-rated depression and mania scales and self-reported functioning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Retention at 12 weeks was 93% and both conditions were associated with high satisfaction. Compared to the paper-and-pencil condition, participants in the augmented mobile intervention condition showed significantly greater reductions in depressive symptoms at 6 and 12 weeks (Cohen׳s d for both were d=0.48). However, these effects were not maintained at 24-weeks follow up. Conditions did not differ significantly in the impact on manic symptoms or functional impairment.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This was not a definitive trial and was not powered to detect moderators and mediators.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Automated mobile-phone intervention is feasible, acceptable, and may enhance the impact of brief psychoeducation on depressive symptoms in bipolar disorder. However, sustainment of gains from symptom self-management mobile interventions, once stopped, may be limited.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Depp</LastName><ForeName>Colin A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA; VA San Diego Healthcare System, USA. Electronic address: cdepp@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceglowski</LastName><ForeName>Jenni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Vicki C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaghouti</LastName><ForeName>Faraz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mausbach</LastName><ForeName>Brent T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Wesley K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granholm</LastName><ForeName>Eric L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA, USA; VA San Diego Healthcare System, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH100417</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH091260</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040421" MajorTopicYN="Y">Cell Phone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018670" MajorTopicYN="N">Monitoring, Ambulatory</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="Y">Self Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Ecological momentary assessment</Keyword><Keyword MajorTopicYN="N">Internet-based treatments</Keyword><Keyword MajorTopicYN="N">Psychotherapy</Keyword><Keyword MajorTopicYN="N">Technology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25479050</ArticleId><ArticleId IdType="pii">S0165-0327(14)00685-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.10.053</ArticleId><ArticleId IdType="pmc">PMC4339469</ArticleId><ArticleId IdType="mid">NIHMS646535</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Methods. 2009 Mar;14(1):43-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19271847</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2010 Oct;198(10):715-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20921861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1997 Sep-Oct;31(5):509-17</Citation><ArticleIdList><ArticleId IdType="pubmed">9368193</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Nov;30(6):1391-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11097079</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>Community Ment Health J. 2009 Jun;45(3):179-87</Citation><ArticleIdList><ArticleId IdType="pubmed">19067162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 May;138(3):409-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22316565</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2001 Oct;39(10):1097-104</Citation><ArticleIdList><ArticleId IdType="pubmed">11567172</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):937-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16816277</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Nov;40(6):1244-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24609454</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 2013 Jul-Aug;35(4):332-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23664503</ArticleId></ArticleIdList></Reference><Reference><Citation>Pers Soc Psychol Rev. 1998;2(2):124-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15647140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Nov;16(7):669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24903771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Jun;73(6):803-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22795205</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Modif. 2014 Jul;38(4):497-515</Citation><ArticleIdList><ArticleId IdType="pubmed">24402464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Sep;9(6):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17845279</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Nov;72(2):177-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12200208</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Jan;35(1):13-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15842025</ArticleId></ArticleIdList></Reference><Reference><Citation>Comput Inform Nurs. 2011 Feb;29(2):81-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21164337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2006 Apr;40(3):221-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16300791</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Internet Res. 2011;13(3):e65</Citation><ArticleIdList><ArticleId IdType="pubmed">21979293</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2008;4:1-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18509902</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Dec;167(12):1456-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20686187</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Health Psychol. 2010 Feb;15(Pt 1):1-39</Citation><ArticleIdList><ArticleId IdType="pubmed">19646331</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 May;38(3):414-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22080492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Dual Diagn. 2012 Jan 1;8(4):326-332</Citation><ArticleIdList><ArticleId IdType="pubmed">23646035</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Internet Res. 2011;13(3):e55</Citation><ArticleIdList><ArticleId IdType="pubmed">21840837</ArticleId></ArticleIdList></Reference><Reference><Citation>Telemed J E Health. 2012 Mar;18(2):137-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22381060</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2008 Jul;53(7):441-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18674402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32609945</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>05</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Markedly increased prevalence of migraine headaches in adolescents with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>255-262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12972</ELocationID><Abstract><AbstractText Label="OBJECTIVE">There is substantial evidence of increased prevalence of migraines, and negative psychiatric correlates of migraines, in adults with bipolar disorder (BD). Given the paucity of data on this topic in youth, we investigated the prevalence and correlates of migraine in a large sample of adolescents with BD.</AbstractText><AbstractText Label="METHOD">The study included 165 adolescents with BD-I, -II, or -not otherwise specified (NOS), diagnosed via the KSADS-PL semi-structured interview, and 89 healthy controls (HCs). Non-migraine headache and migraine headache was evaluated using the validated ID-Migraine 3-item screener.</AbstractText><AbstractText Label="RESULTS">Although the prevalence of non-migraine headaches did not differ between adolescents with BD (24.2%) and HCs (32.6%; P = .15), migraine was significantly more prevalent among adolescents with BD (38.2%) compared to HCs (3.4%; adjusted odds ratio 14.76, 95% confidence interval 4.39-49.57; P &lt; .001). Within BD, migraine was associated with female sex, BD-II/-NOS subtype, less severe worst past functioning, higher past depression severity, higher self-reported affective lability, higher body mass index, and less use of lithium and second-generation antipsychotics.</AbstractText><AbstractText Label="DISCUSSION">Migraine is much more prevalent among adolescents with BD compared to HCs; the magnitude of this association exceeds what has been reported in adult samples. Correlates of migraine in youth BD are similar to those found for adults, including the link with the depressive polarity of BD. Future prospective studies are warranted to evaluate temporal associations between migraine and mood symptoms, and to evaluate neurobiological and cardiovascular underpinnings of these associations.</AbstractText><CopyrightInformation>© 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehrhof</LastName><ForeName>Sara Z</ForeName><Initials>SZ</Initials><Identifier Source="ORCID">0000-0001-8267-3898</Identifier><AffiliationInfo><Affiliation>Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiksenbaum</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bettridge</LastName><ForeName>Ariel M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><Identifier Source="ORCID">0000-0003-0340-349X</Identifier><AffiliationInfo><Affiliation>Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Heart and Stroke Foundation of Canada</Agency><Country/></Grant><Grant><Agency>University of Toronto Department of Psychiatry</Agency><Country/></Grant><Grant><Agency>Fondation Brain Canada</Agency><Country/></Grant><Grant><Agency>Ontario Institute of Research, Innovation and Technology</Agency><Country/></Grant><Grant><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Michael Albert Garron Foundation</Agency><Country/></Grant><Grant><Agency>Brain and Behavior Research Foundation</Agency><Country/></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><Agency>Great Gulf Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008881" MajorTopicYN="Y">Migraine Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">adolescents</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">headache</Keyword><Keyword MajorTopicYN="Y">migraine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32609945</ArticleId><ArticleId IdType="doi">10.1111/bdi.12972</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Headache Disorders. World. Health Organization website. https://www.who.int/news-room/fact-sheets/detail/headache-disorders. Accessed April 8, 2019.</Citation></Reference><Reference><Citation>Leonardi M, Raggi A. Burden of migraine: international perspectives. Neurological Sciences. 2013;34:117-118.</Citation></Reference><Reference><Citation>Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55:629-635.</Citation></Reference><Reference><Citation>Merikangas KR, Angst J, Isler H. Migraine and psychopathology: results of the zurich cohort study of young adults. Arch Gen Psychiatry. 1990;47:849-853.</Citation></Reference><Reference><Citation>Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders-a national population-based study. Headache: The Journal of Head and Face Pain. 2008;48:501-516.</Citation></Reference><Reference><Citation>Ratcliffe GE, Enns MW, Jacobi F, Belik SL, Sareen J. The relationship between migraine and mental disorders in a population-based sample. Gen Hosp Psychiatry. 2009;31:14-19.</Citation></Reference><Reference><Citation>Oedegaard KJ, Dilsaver SC, Hundal Ø, et al. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the Norwegian prescription database. J Clin Psychopharmacol. 2011;31:734-739.</Citation></Reference><Reference><Citation>McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatric Services. 2006;57:1140-1144.</Citation></Reference><Reference><Citation>Holland J, Agius M, Zaman R. Prevalence of co-morbid bipolar disorder and migraine in a regional hospital psychiatric outpatient department. Psychiatria Danubina. 2011;23:23-24.</Citation></Reference><Reference><Citation>Mahmood T, Romans S, Silverstone T. Prevalence of migraine in bipolar disorder. J Affect Disord. 1999;52:239-241.</Citation></Reference><Reference><Citation>Fasmer O. The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia. 2001;21:894-899.</Citation></Reference><Reference><Citation>Ortiz A, Cervantes P, Zlotnik G, et al. Cross-prevalence of migraine and bipolar disorder. Bipolar Disord. 2010;12:397-403.</Citation></Reference><Reference><Citation>Low NC, Du Fort GG, Prevalence CP. clinical correlates, and treatment of migraine in bipolar disorder. Headache: The journal of head and face pain. 2003;43:940-949.</Citation></Reference><Reference><Citation>Leo RJ, Singh J. Migraine headache and bipolar disorder comorbidity: A systematic review of the literature and clinical implications. Scandinavian J pain. 2016;11:136-145.</Citation></Reference><Reference><Citation>Fornaro M, Stubbs B. A meta-analysis investigating the prevalence and moderators of migraines among people with bipolar disorder. J Affect Disord. 2015;178:88-97.</Citation></Reference><Reference><Citation>Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307-315.</Citation></Reference><Reference><Citation>Baptista T, Uzcátegui E, Arapé Y, et al. Migraine life-time prevalence in mental disorders: concurrent comparisons with first-degree relatives and the general population. Investigacionclinica. 2012;53:38-51.</Citation></Reference><Reference><Citation>McIntyre RS, Konarski JZ, Wilkins K, Bouffard B, Soczynska JK, Kennedy SH. The prevalence and impact of migraine headache in bipolar disorder: Results from the Canadian community health survey. Cme. Headache: The Journal of Head and Face Pain. 2006;46:973-982.</Citation></Reference><Reference><Citation>Saunders EF, Nazir R, Kamali M, et al. Gender differences, clinical correlates and longitudinal outcome of bipolar disorder with co-morbid migraine. J clin Psychia. 2014;75:512-519.</Citation></Reference><Reference><Citation>Fasmer OB, Oedegaard KJ. Clinical characteristics of patients with major affective disorders and comorbid migraine. World J Biol Psychia. 2001;2:149-155.</Citation></Reference><Reference><Citation>Gordon-Smith K, Forty L, Chan C, et al. Rapid cycling as a feature of bipolar disorder and comorbid migraine. J Affect Disord. 2015;175:320-324.</Citation></Reference><Reference><Citation>Nguyen TV, Low NC. Comorbidity of migraine and mood episodes in a nationally representative population-based sample. Headache: The Journal of Head and Face. Pain. 2013;53:498-506.</Citation></Reference><Reference><Citation>Gigante A, Barenboim I, Dias RDS, et al. Rapid cycling bipolar disorder is associated with a higher lifetime prevalence of migraine. Acta Psychia Scand. 2015;132(4):308-309.</Citation></Reference><Reference><Citation>Brietzke E, Moreira CLRL, Duarte SVB, et al. Impact of comorbid migraine on the clinical course of bipolar disorder. Compr Psychiatry. 2012;53:809-812.</Citation></Reference><Reference><Citation>Jerrell JM, McIntyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychia. 2010;71:1518-1525.</Citation></Reference><Reference><Citation>Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychia. 1997;7:980-988.</Citation></Reference><Reference><Citation>Chambers WJ, Puig-Antich J, Hirsch M, et al. The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry. 1985;42:696-702.</Citation></Reference><Reference><Citation>Axelson D, Birmaher BJ, Brent D, et al. A Preliminary Study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children Mania Rating Scale for Children and Adolescents. J Child Adolesc Psychopharmacol. 2003;13:463-470.</Citation></Reference><Reference><Citation>Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63:1139-1148.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology. 2003;61:375-382.</Citation></Reference><Reference><Citation>Hollingshead A. Four factor index of social status. Yale J Sociol. 2011;8:21-53.</Citation></Reference><Reference><Citation>Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry. 1983;40:1228-1231.</Citation></Reference><Reference><Citation>Gerson AC, Gerring JP, Freund L, et al. The Children’s Affective Lability Scale: A psychometric evaluation of reliability. Psychiatry Res. 1996;65:189-198.</Citation></Reference><Reference><Citation>Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. Brief screening for family psychiatric history: The family history screen. Arch Gen Psychiatry. 2000;57:675-682.</Citation></Reference><Reference><Citation>Islam AH, Metcalfe AWS, MacIntosh BJ, Korczak DJ, Goldstein BI. Greater body mass index is associated with reduced frontal cortical volumes among adolescents with bipolar disorder. J Psychiatry Neurosci. 2018;43:120-130.</Citation></Reference><Reference><Citation>Gordon KE, Dooley JM, Wood EP. Prevalence of reported migraine headaches in Canadian adolescents. Can J Neurol Sci. 2004;31:324-327.</Citation></Reference><Reference><Citation>O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol. 1994;23:1020-1026.</Citation></Reference><Reference><Citation>Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67:252-257.</Citation></Reference><Reference><Citation>Anda R, Tietjen G, Schulman E, Felitti V, Croft J. Adverse childhood experiences and frequent headaches in adults. Headache: The Journal of Head and Face. Pain. 2010;50:1473-1481.</Citation></Reference><Reference><Citation>Dilsaver SC, Benazzi F, Oedegaard KJ, Fasmer OB, Akiskal HS. Is a family history of bipolar disorder a risk factor for migraine among affectively ill patients? Psychopathology. 2009;42:119-123.</Citation></Reference><Reference><Citation>Oedegaard KJ, Greenwood TA, Johansson S, et al. Akiskal HS, Bipolar Genome Study (BiGS), Haavik J, Kelsoe, JR. A genome-wide association study of bipolar disorder and comorbid migraine. Genes Brain Behav. 2010;9:673-680.</Citation></Reference><Reference><Citation>Oedegaard KJ, Greenwood TA, Lunde A, Fasmer OB, Akiskal HS, Kelsoe JR. NIMH Genetics Initiative Bipolar Disorder Consortium. A genome-wide linkage study of bipolar disorder and co-morbid migraine: replication of migraine linkage on chromosome 4q24, and suggestion of an overlapping susceptibility region for both disorders on chromosome 20p11. J Affect Disord. 2010;122:14-26.</Citation></Reference><Reference><Citation>Hamel E, Currents H. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27:1293-1300.</Citation></Reference><Reference><Citation>Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord. 2001;66:1-11.</Citation></Reference><Reference><Citation>Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999;84:133-156.</Citation></Reference><Reference><Citation>Goldstein BI. Bipolar disorder and the vascular system: mechanisms and new prevention opportunities. Can J Cardiol. 2017;33:1565-1576.</Citation></Reference><Reference><Citation>Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010;74:628-635.</Citation></Reference><Reference><Citation>Toma S, Fiskenbaum L, Danielle O, Goldstein B. Elevated Familial Cardiovascular Burden Among Adolescents With Familial Bipolar Disorder. Front Psychia. 2019;10:8.</Citation></Reference><Reference><Citation>Scher AI, Terwindt GM, Verschuren WMM, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol. 2006;59(2):372-375.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32306467</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lifetime cocaine use is a potential predictor for conversion from major depressive disorder to bipolar disorder: A prospective study.</ArticleTitle><Pagination><MedlinePgn>418-423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.13012</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We aimed to identify whether lifetime cocaine use is a risk factor for conversion from major depressive disorder (MDD) to bipolar disorder (BD) in an outpatient sample of adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective cohort study included 585 subjects aged 18 to 60 years who had been diagnosed with MDD as assessed by the Mini International Neuropsychiatric Interview (MINI-Plus) at baseline (2012-2015). Subjects were reassessed a mean of 3 years later (2017-2018) for potential conversion to BD as assessed by the MINI-Plus. Lifetime cocaine use was assessed using the Alcohol, Smoking, and Substance Involvement Screening Test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the second wave, we had 117 (20%) losses, and 468 patients were reassessed. The rate of conversion from MDD to BD in 3 years was 12.4% (n = 58). A logistic regression analysis showed that the risk for conversion from MDD to BD was 3.41-fold higher (95% confidence interval, 1.11-10.43) in subjects who reported lifetime cocaine use at baseline as compared to individuals who did not report lifetime cocaine use at baseline, after adjusting for demographic and clinical confounders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings showed that lifetime cocaine use is a potential predictor of conversion to BD in an MDD cohort. Further studies are needed to assess the possible underlying mechanisms linking exposure to cocaine with BD conversion.</AbstractText><CopyrightInformation>© 2020 The Authors Psychiatry and Clinical Neurosciences © 2020 Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Azevedo Cardoso</LastName><ForeName>Taiane</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mood Disorders Program, Department of Psychiatry &amp; Behavioural Neurosciences, McMaster University, Hamilton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mondin</LastName><ForeName>Thaise C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Federal University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrotti Moreira</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lima Bach</LastName><ForeName>Suelen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Ricardo A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9114-7037</Identifier><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mattos Souza</LastName><ForeName>Luciano D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Health and Behavior, Catholic University of Pelotas, Pelotas, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balanzá-Martínez</LastName><ForeName>Vicent</ForeName><Initials>V</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7772-7396</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Valencia, CIBERSAM, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Benicio N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Mood Disorders Program, Department of Psychiatry &amp; Behavioural Neurosciences, McMaster University, Hamilton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Women's Health Concerns Clinic, St. Joseph's Healthcare, Hamilton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mood Disorders Program, Department of Psychiatry &amp; Behavioural Neurosciences, McMaster University, Hamilton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019970" MajorTopicYN="N">Cocaine-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cocaine</Keyword><Keyword MajorTopicYN="N">conversion</Keyword><Keyword MajorTopicYN="N">major depressive disorder</Keyword><Keyword MajorTopicYN="N">prospective study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32306467</ArticleId><ArticleId IdType="doi">10.1111/pcn.13012</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Merikangas KR, Jin R, He J-P et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey initiative. Arch. Gen. Psychiatry 2011; 68: 241-251.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L, Visioli C. First-episode types in bipolar disorder: Predictive associations with later illness. Acta Psychiatr. Scand. 2014; 129: 383-392.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20: 97-170.</Citation></Reference><Reference><Citation>Fritz K, Russell AMT, Allwang C, Kuiper S, Lampe L, Malhi GS. Is a delay in the diagnosis of bipolar disorder inevitable? Bipolar Disord. 2017; 19: 396-400.</Citation></Reference><Reference><Citation>Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 Survey of Individuals with Bipolar Disorder. J. Clin. Psychiatry 2003; 64: 161-174.</Citation></Reference><Reference><Citation>Gazalle FK, Andreazza AC, Ceresér KM, Hallal PC, Santin A, Kapczinski F. Clinical impact of late diagnose [sic] of bipolar disorder. J. Affect. Disord. 2005; 86: 313-316.</Citation></Reference><Reference><Citation>Ratheesh A, Davey C, Hetrick S et al. A systematic review and meta-analysis of prospective transition from major depression to bipolar disorder. Acta Psychiatr. Scand. 2017; 135: 273-284.</Citation></Reference><Reference><Citation>Kessing LV, Willer I, Andersen PK, Bukh JD. Rate and predictors of conversion from unipolar to bipolar disorder: A systematic review and meta-analysis. Bipolar Disord. 2017; 19: 324-335.</Citation></Reference><Reference><Citation>Hughes A, Williams MR, Lipari RN, Van Horn S. The CBHSQ Report: State estimates of past year cocaine use among young adults: 2014 and 2015. 2016. [Cited 1 December 2019.] Available from URL: https://www.samhsa.gov/data/report/state-estimates-past-year-cocaine-use-among-young-adults-2014-and-2015</Citation></Reference><Reference><Citation>Abdalla RR, Madruga CS, Ribeiro M, Pinsky I, Caetano R, Laranjeira R. Prevalence of cocaine use in Brazil: Data from the II Brazilian National Alcohol and Drugs Survey (BNADS). Addict. Behav. 2014; 39: 297-301.</Citation></Reference><Reference><Citation>Stankowski RV, Kloner RA, Rezkalla SH. Cardiovascular consequences of cocaine use. Trends Cardiovasc. Med. 2015; 25: 517-526.</Citation></Reference><Reference><Citation>Cisler JM, Elton A, Kennedy AP et al. Altered functional connectivity of the insular cortex across prefrontal networks in cocaine addiction. Psychiatry Res. 2013; 213: 39-46.</Citation></Reference><Reference><Citation>Roncero C, Daigre C, Grau-López L et al. Cocaine-induced psychosis and impulsivity in cocaine-dependent patients. J. Addict. Dis. 2013; 32: 263-273.</Citation></Reference><Reference><Citation>García-Marchena N, Ladrón de Guevara-Miranda D, Pedraz M et al. Higher impulsivity as a distinctive trait of severe cocaine addiction among individuals treated for cocaine or alcohol use disorders. Front. Psychiatry 2018; 9: 26.</Citation></Reference><Reference><Citation>Spronk DB, van Wel JHP, Ramaekers JG, Verkes RJ. Characterizing the cognitive effects of cocaine: A comprehensive review. Neurosci. Biobehav. Rev. 2013; 37: 1838-1859.</Citation></Reference><Reference><Citation>Narvaez JCM, Pechansky F, Jansen K et al. Quality of life, social functioning, family structure, and treatment history associated with crack cocaine use in youth from the general population. Rev. Bras. Psiquiatr. 2015; 37: 211-218.</Citation></Reference><Reference><Citation>Narvaez JCM, Jansen K, Pinheiro RT et al. Psychiatric and substance-use comorbidities associated with lifetime crack cocaine use in young adults in the general population. Compr. Psychiatry 2014; 55: 1369-1376.</Citation></Reference><Reference><Citation>Khantzian EJ. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. Am. J. Psychiatry 1985; 142: 1259-1264.</Citation></Reference><Reference><Citation>Inciardi JA, Surratt HL. Drug use, street crime and sex-trading among cocaine-dependent women: Implications for public health and criminal justice policy. J. Psychoactive Drugs 2001; 33: 379-389.</Citation></Reference><Reference><Citation>Paim Kessler FH, Barbosa Terra M, Faller S et al. Crack users show high rates of antisocial personality disorder, engagement in illegal activities and other psychosocial problems. Am. J. Addict. 2012; 21: 370-380.</Citation></Reference><Reference><Citation>Hunt GE, Malhi GS, Cleary M, Lai HMX, Sitharthan T. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: Systematic review and meta-analysis. J. Affect. Disord. 2016; 206: 321-330.</Citation></Reference><Reference><Citation>de Cardoso TA, Mondin TC, de Souza LDM et al. Functioning in bipolar disorder with substance abuse/dependence in a community sample of young adults. J. Affect. Disord. 2015; 187: 179-182.</Citation></Reference><Reference><Citation>de Cardoso TA, Jansen K, Zeni CP, Quevedo J, Zunta-Soares G, Soares JC. Clinical outcomes in children and adolescents with bipolar disorder and substance use disorder comorbidity. J. Clin. Psychiatry 2017; 78: e230-e233.</Citation></Reference><Reference><Citation>Ratheesh A, Cotton SM, Betts JK et al. Prospective progression from high-prevalence disorders to bipolar disorder: Exploring characteristics of pre-illness stages. J. Affect. Disord. 2015; 183: 45-48.</Citation></Reference><Reference><Citation>Post RM. Preventing the malignant transformation of bipolar disorder. JAMA 2018; 319: 1197-1198.</Citation></Reference><Reference><Citation>Amorim P. MINI International Neuropsychiatric Interview (MINI): Validation of a short structured diagnostic psychiatric interview. Rev. Bras. Psiquiatr. 2000; 22: 106-115.</Citation></Reference><Reference><Citation>Brazilian Association of Research Companies (ABEP). 2003. [Cited 1 December 2019.] Available from URL: http://www.abep.org/criterio-brasil</Citation></Reference><Reference><Citation>Henrique IFS, De Micheli D, de Lacerda RB, de Lacerda LA, de MLO F. Validation of the Brazilian version of Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Rev. Assoc. Med. Bras. 2004; 50: 199-206.</Citation></Reference><Reference><Citation>Dean A, Sullivan K, Soe M. OpenEpi: Open source epidemiologic statistics for public health. [Cited 1 December 2019.] Available from URL: www.OpenEpi.com</Citation></Reference><Reference><Citation>Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. The developmental trajectory of bipolar disorder. Br. J. Psychiatry 2014; 204: 122-128.</Citation></Reference><Reference><Citation>Chen M-H, Chen Y-S, Hsu J-W et al. Comorbidity of ADHD and subsequent bipolar disorder among adolescents and young adults with major depression: A nationwide longitudinal study. Bipolar Disord. 2015; 17: 315-322.</Citation></Reference><Reference><Citation>Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 1992; 149: 999-1010.</Citation></Reference><Reference><Citation>Post RM, Kalivas P. Bipolar disorder and substance misuse: Pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br. J. Psychiatry 2013; 202: 172-176.</Citation></Reference><Reference><Citation>Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J. Clin. Psychiatry 2008; 69: 1751-1757.</Citation></Reference><Reference><Citation>Hanlon CA, Beveridge TJR, Porrino LJ. Recovering from cocaine: Insights from clinical and preclinical investigations. Neurosci. Biobehav. Rev. 2013; 37: 2037-2046.</Citation></Reference><Reference><Citation>McCabe SE, West BT, Jutkiewicz EM, Boyd CJ. Multiple DSM-5 substance use disorders: A national study of US adults. Hum. Psychopharmacol. 2017; 32: e2625.</Citation></Reference><Reference><Citation>James A, Wotton CJ, Duffy A, Hoang U, Goldacre M. Conversion from depression to bipolar disorder in a cohort of young people in England, 1999-2011: A national record linkage study. J. Affect. Disord. 2015; 185: 123-128.</Citation></Reference><Reference><Citation>Woo YS, Shim IH, Wang H-R, Song HR, Jun T-Y, Bahk W-M. A diagnosis of bipolar spectrum disorder predicts diagnostic conversion from unipolar depression to bipolar disorder: A 5-year retrospective study. J. Affect. Disord. 2015; 174: 83-88.</Citation></Reference><Reference><Citation>Sharma V, Xie B, Campbell MK et al. A prospective study of diagnostic conversion of major depressive disorder to bipolar disorder in pregnancy and postpartum. Bipolar Disord. 2014; 16: 16-21.</Citation></Reference><Reference><Citation>Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Phenomenology and prognostic significance of delusions in major depressive disorder: A 10-year prospective follow-up study. J. Clin. Psychiatry 2007; 68: 1411-1417.</Citation></Reference><Reference><Citation>Bega S, Schaffer A, Goldstein B, Levitt A. Differentiating between bipolar disorder types I and II: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J. Affect. Disord. 2012; 138: 46-53.</Citation></Reference><Reference><Citation>Joyce PR. Age of onset in bipolar affective disorder and misdiagnosis as schizophrenia. Psychol. Med. 1984; 14: 145-149.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9105958</PMID><DateCompleted><Year>1997</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>2-3</Issue><PubDate><Year>1997</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Personality differences between patients with major depression and bipolar disorder--the impact of minor symptoms on self-ratings of personality.</ArticleTitle><Pagination><MedlinePgn>169-77</MedlinePgn></Pagination><Abstract><AbstractText>The study explores whether minor symptoms of patients in recovery from a mood disorder have an impact on self-ratings of personality with special consideration of potential differences between diagnostic groups. 90 recovered DSM-III-R major unipolar depressives and 167 recovered bipolars were compared with respect to scale values of the Munich Personality Test (MPT). Major depressives showed significantly higher scores on the MPT scales Rigidity and Orientation towards Social Norms, and lower scores on Extraversion than the bipolar patients. Using a LISREL-model, psychopathology was found to have a significant impact on Neuroticism and Extraversion, but not on Rigidity and on Orientation towards Social Norms. Controlling for symptomatology, the differences in the MPT scale values of the two diagnostic groups remained significant and can hardly be sufficiently explained by residual symptomatology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sauer</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Czernik</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ludwig-Mayerhofer</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Schöchlin</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Greil</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>von Zerssen</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1806D8D52K</RegistryNumber><NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003674" MajorTopicYN="N">Defense Mechanisms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9105958</ArticleId><ArticleId IdType="pii">S0165-0327(96)01408-5</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(96)01408-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10402625</PMID><DateCompleted><Year>1999</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>7</Issue><PubDate><Year>1999</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>John Cade and lithium.</ArticleTitle><Pagination><MedlinePgn>969</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>Q</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Cade</LastName><ForeName>J</ForeName><Initials>J</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10402625</ArticleId><ArticleId IdType="doi">10.1176/ps.50.7.969</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11426515</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A meta-analysis of the use of typical antipsychotic agents in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>85-93</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The potential benefits of typical antipsychotic agents in bipolar disorder are offset by serious treatment-associated side effects. Despite these concerns and the availability of mood stabilizing agents, the treatment of bipolar disorder with typical antipsychotic agents appears to be widespread.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A Medline search identified 16 publications that outlined medication use among 2378 bipolar disorder patients. Meta-analysis was used to estimate a weighted average of the relative proportions of the treatment use, where the weights were the reciprocals of the estimated variances for each study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 84.7% of bipolar patients received typical antipsychotic agents, with a loading toward a greater in-patient (90.7%) relative to out-patient (65.3%) use. Monotherapy accounted for 53.8% of typical antipsychotic use, and typical antipsychotic/mood stabilizer combination therapy accounted for 47.4%. In four studies where length of treatment data were available, the median of minimum typical antipsychotic use was 2.5 months, with 96.0% of the patients receiving typical antipsychotic agents.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The meta-analytic technique employed in this analysis is limited by the possible inclusion of studies with unreliable study designs or biased treatment practices, publication bias in which some studies may not have been reported, and possible lack of identification of all relevant studies.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Typical antipsychotic agents are commonly used in the treatment of bipolar disorder, possibly due to dissatisfaction with mood stabilizer monotherapy especially in psychotic mania, the high prevalence of psychotic symptoms in acute mania, inappropriate continuation of typical antipsychotic agents after initial stabilization, and/or unavailability or unfamiliarity with new treatments. These findings also suggest that typical antipsychotics may have not only antipsychotic effects in mania but perhaps also antimanic properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Indianapolis, IN 46285, USA. tohen_mauricio_f@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>C C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sanger</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tollefson</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11426515</ArticleId><ArticleId IdType="pii">S0165032700001622</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(00)00162-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14746203</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0174-108X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>10-12</Issue><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>Krankenpflege Journal</Title><ISOAbbreviation>Krankenpfl J</ISOAbbreviation></Journal><ArticleTitle>[Mood stabilization as the goal. Expectations for ideal drug therapy of bipolar illnesses].</ArticleTitle><Pagination><MedlinePgn>225</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lemke</LastName><ForeName>Matthias R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList><VernacularTitle>Stimmungsstabilisierung als Ziel. Anforderungen an eine ideale medikamentöse Therapie bipolarer Erkrankungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Krankenpfl J</MedlineTA><NlmUniqueID>8006304</NlmUniqueID><ISSNLinking>0174-108X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>1</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>1</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14746203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25892256</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>227</Volume><Issue>2-3</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Differentiating risk for mania and borderline personality disorder: The nature of goal regulation and impulsivity.</ArticleTitle><Pagination><MedlinePgn>347-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2015.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(15)00071-2</ELocationID><Abstract><AbstractText>Researchers and clinicians have long noted the overlap among features and high comorbidity of bipolar disorder and borderline personality disorder. The shared features of impulsivity and labile mood in both disorders make them challenging to distinguish. We tested the hypothesis that variables related to goal dysregulation would be uniquely related to risk for mania, while emotion-relevant impulsivity would be related to risk for both disorders. We administered a broad range of measures related to goal regulation traits and impulsivity to 214 undergraduates. Findings confirmed that risk for mania, but not for borderline personality disorder, was related to higher sensitivity to reward and intense pursuit of goals. In contrast, borderline personality disorder symptoms related more strongly than did mania risk with threat sensitivity and with impulsivity in the context of negative affect. Results highlight potential differences and commonalities in mania risk versus borderline personality disorder risk. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fulford</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Department of Psychiatry, 401 Parnassus Ave., San Francisco, CA 94143, USA; Palo Alto Medical Foundation Research Institute, 2350 West El Camino Real, Mountain View, CA 94040, USA. Electronic address: daniel.fulford@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisner</LastName><ForeName>Lori R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Bipolar Clinic and Research Program, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, 50 Staniford St., Ste 580, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sheri L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>University of California, Berkeley, Department of Psychology, 3417 Tolman Hall, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006040" MajorTopicYN="N">Goals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="Y">Impulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Approach/avoidance motivation</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Borderline personality disorder</Keyword><Keyword MajorTopicYN="N">Goal regulation</Keyword><Keyword MajorTopicYN="N">Impulsivity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>02</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25892256</ArticleId><ArticleId IdType="pii">S0165-1781(15)00071-2</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2015.02.001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2084785</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4-6</Issue><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Development and structure of the DCR Budapest-Nashville.</ArticleTitle><Pagination><MedlinePgn>316-30</MedlinePgn></Pagination><Abstract><AbstractText>The DCR Budapest-Nashville was developed by adopting a differentiated concept of the 'full disease entity'. The so-called small disease entity is a preliminary stage in the search for more complicated disease entities. In its present form, the DCR is a diagnostic method for identifying small disease entities in the spectrum of reactive (i.e. psychogenic) and functional (i.e. endogenous) psychoses. The nosological concept of the DCR can be characterized by thirteen paradigms: (1) a nonkraepelinian clinical classificatory system given by Leonhard; (2) the index-psychosis paradigm as opposed to the end-state paradigm; (3) conceptual differentiation of the disease entities as opposed both to the full disease entity paradigm and to the only-one-psychosis (or no disease entity) paradigm, respectively; (4) an aristotelian distinction between content (meaning) and form as opposed to the paradigm of ideas; (5) three-aspect approach to the psychopathological phenomena instead of choosing only one or two of the aspects of experience, of the behavior and of the achievement as special paradigm; (6) gestalt paradigm specified in different ways, as completing the associationist paradigm; (7) structural paradigm, especially concerning the delusions; (8) method of understanding in contrast to the method of causal explanation in distinguishing reactive (i.e. psychogenic) psychoses from functional (i.e. endogenous) psychoses; (9) behavioral symptoms overrule experiential symptoms in the decision-tree process concerning schizophrenias; (10) erosive psychotic phenomena ('minus symptoms') overrule productive phenomena ('plus symptoms') in the decision-tree process concerning hebephrenias in the group of systematic schizophrenias; (11) three-dimensional (polarity, rhythmicity, deterioration) assessment of course of illness; (12) sociological paradigm in reformulation of types of 'defect'; (13) psychosis paradigm concerning the operationalization of applicability of DCR to patients. Some empirical investigations are mentioned concerning the validity of the DCR.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pethö</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry Semmelweis Medical University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>54</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2084785</ArticleId><ArticleId IdType="doi">10.1159/000284676</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17156154</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations.</ArticleTitle><Pagination><MedlinePgn>677-85</MedlinePgn></Pagination><Abstract><AbstractText>Classic Kraepelian observations and contemporary epidemiological studies have noted a high prevalence rate between bipolar disorder and alcoholism. The extent to which these two illnesses are comorbid (i.e., two distinct disease processes each with an independent course of illness), genetically linked, or different phenotypic expressions of bipolar illness itself continues to be investigated. It is increasingly clear that co-occurring alcohol abuse or dependence in bipolar disorder phenomenologically changes the illness presentation with higher rates of mixed or dysphoric mania, rapid cycling, increased symptom severity, and higher levels of novelty seeking, suicidality, aggressivity, and impulsivity. It is very encouraging that interest and efforts at evaluating pharmacotherapeutic compounds has substantially increased over the past few years in this difficult-to-treat patient population. This article will review the clinical studies that have evaluated the effectiveness of conventional mood stabilizers (lithium, carbamazepine, divalproex, and atypical antipsychotics) in the treatment of alcohol withdrawal and relapse prevention in patients with alcoholism and in the treatment of bipolar disorder with comorbid alcoholism. A number of add-on, adjunctive medications, such as naltrexone, acamprosate, topiramate, and the atypical antipsychotics quetiapine and clozapine, may be candidates for further testing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA, USA. mfrye@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloum</LastName><ForeName>Ihsan M</ForeName><Initials>IM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH079261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17156154</ArticleId><ArticleId IdType="pii">BDI370</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2006.00370.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25066202</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>15</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis.</ArticleTitle><Pagination><MedlinePgn>3239-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291714000774</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive dysfunction is a core feature of psychotic disorders; however, substantial variability exists both within and between subjects in terms of cognitive domains of dysfunction, and a clear 'profile' of cognitive strengths and weaknesses characteristic of any diagnosis or psychosis as a whole has not emerged. Cluster analysis provides an opportunity to group individuals using a data-driven approach rather than predetermined grouping criteria. While several studies have identified meaningful cognitive clusters in schizophrenia, no study to date has examined cognition in a cross-diagnostic sample of patients with psychotic disorders using a cluster approach. We aimed to examine cognitive variables in a sample of 167 patients with psychosis using cluster methods.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Subjects with schizophrenia (n = 41), schizo-affective disorder (n = 53) or bipolar disorder with psychosis (n = 73) were assessed using a battery of cognitive and clinical measures. Cognitive data were analysed using Ward's method, followed by a K-means cluster approach. Clusters were then compared on diagnosis and measures of clinical symptoms, demographic variables and community functioning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A four-cluster solution was selected, including a 'neuropsychologically normal' cluster, a globally and significantly impaired cluster, and two clusters of mixed cognitive profiles. Clusters differed on several clinical variables; diagnoses were distributed amongst all clusters, although not evenly.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Identification of groups of patients who share similar neurocognitive profiles may help pinpoint relevant neural abnormalities underlying these traits. Such groupings may also hasten the development of individualized treatment approaches, including cognitive remediation tailored to patients' specific cognitive profiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>K E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program,McLean Hospital,115 Mill Street, Belmont, MA 02478,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperry</LastName><ForeName>S H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program,McLean Hospital,115 Mill Street, Belmont, MA 02478,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>B M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program,McLean Hospital,115 Mill Street, Belmont, MA 02478,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ongür</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program,McLean Hospital,115 Mill Street, Belmont, MA 02478,USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH091210</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH094594</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23MH91210</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH094594</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25066202</ArticleId><ArticleId IdType="pii">S0033291714000774</ArticleId><ArticleId IdType="doi">10.1017/S0033291714000774</ArticleId><ArticleId IdType="pmc">PMC5572146</ArticleId><ArticleId IdType="mid">NIHMS643543</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schizophr Res. 1993 Mar;9(1):49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">8096391</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment. 1999 Jun;6(2):147-78</Citation><ArticleIdList><ArticleId IdType="pubmed">10335019</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Aug;148(1-3):34-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23791391</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Clin Neuropsychol. 1990;5(3):251-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14589685</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2011 Oct;33(8):929-36</Citation><ArticleIdList><ArticleId IdType="pubmed">21644139</ArticleId></ArticleIdList></Reference><Reference><Citation>Percept Mot Skills. 1991 Oct;73(2):539-50</Citation><ArticleIdList><ArticleId IdType="pubmed">1766784</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychology. 1997 Jul;11(3):437-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9223148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Oct;67(10):e12</Citation><ArticleIdList><ArticleId IdType="pubmed">17107235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2003 Jan;9(1):56-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12570358</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2009 Aug;11(4):313-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19635240</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2002 Sep;24(6):765-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12424651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1996 Jul;21(1):13-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8998271</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Dec;133(1-3):212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21996265</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Cogn. 1997 Nov;35(2):207-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9356162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1999 Jul;187(7):414-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10426461</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 1998 Jul;4(4):353-62</Citation><ArticleIdList><ArticleId IdType="pubmed">9656609</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Dec 30;200(2-3):272-80</Citation><ArticleIdList><ArticleId IdType="pubmed">22925372</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2009 Jan-Feb;50(1):13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19059508</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Rev. 2001 Mar;11(1):45-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11392562</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1995 Dec;18(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">8929762</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Clin Neuropsychol. 2005 Mar;20(2):153-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15708725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8722244</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>1</Issue><PubDate><MedlineDate>1996 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Pharmacotherapy in depression during conversion from depression to mania in patients with bipolar affective disorder].</ArticleTitle><Pagination><MedlinePgn>113-25</MedlinePgn></Pagination><Abstract><AbstractText>Frequency of occurrence of mania directly after depression during antidepressant treatment with drugs of different pharmacological characteristics was examined. 210 depressive episodes (in 118 patients) finished with switching from depression to mania were analyzed. It was found that this phenomenon occurs more frequently during therapy with classical tricyclic drugs (amitryptyline, imipramine) than with the second generation antidepressant drugs. A group of patients in whom the switch from depression to mania occurs independently of the kind of applied therapy, was observed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koszewska</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Z II Kliniki Psychiatrycznej IPiN w Warszawie.</Affiliation></AffiliationInfo></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Farmakoterapia depresji w czasie zmiany fazy depresyjnej w maniakalna u osób z choroba afektywna dwubiegunowa.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8722244</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7159802</PMID><DateCompleted><Year>1983</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><PubDate><Year>1982</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The clinical picture of bipolar affective disorder in its depressed phase. A report from London and Chicago.</ArticleTitle><Pagination><MedlinePgn>558-62</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brockington</LastName><ForeName>I F</ForeName><Initials>IF</Initials></Author><Author ValidYN="Y"><LastName>Altman</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hillier</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Meltzer</LastName><ForeName>H Y</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Nand</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 30,938</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 47,808</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002641" MajorTopicYN="N" Type="Geographic">Chicago</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="N">Thinking</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7159802</ArticleId><ArticleId IdType="pii">S0007125000113571</ArticleId><ArticleId IdType="doi">10.1192/bjp.141.6.558</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12880514</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Clinical implications of antidepressant and stimulant use on switching from depression to mania in children.</ArticleTitle><Pagination><MedlinePgn>201-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craney</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Washington University, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geller</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>10</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12880514</ArticleId><ArticleId IdType="doi">10.1089/104454603322163925</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8823350</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>57 Suppl 9</Volume><PubDate><Year>1996</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antipsychotics in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>49-52</MedlinePgn></Pagination><Abstract><AbstractText>Antipsychotics are commonly added to lithium for relief of severe psychotic symptoms and behavioral disruption during an acute manic episode. In general, lithium is superior in stabilizing mood and ideation, whereas neuroleptics are better in controlling hyperactivity, and the course of clinical response is faster to antipsychotics than to lithium. The effects of neuroleptics on bipolar depression need further study. Traditional neuroleptics carry the risk of extrapyramidal symptoms, and concern exists over neurotoxicity from the combination of lithium and a neuroleptic. Roles for clozapine, risperidone, and newer atypical neuroleptics, which may carry a lower risk of associated extrapyramidal side effects, will become clear with additional study and clinical experience. Long-term antipsychotic therapy in the maintenance phase of bipolar disorder is common; the efficacy, however, remains unclear and the risk of tardive movement disorders is substantial. Otherwise treatment-resistant patients who receive maintenance antipsychotic therapy to prevent recurrent episodes of mania should be followed closely, with regular screening for early signs of movement disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gelenberg</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Arizona Health Sciences Center, Tucson 85724, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>38</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8823350</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2211537</PMID><DateCompleted><Year>1990</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>10</Issue><PubDate><Year>1990</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and Crohn's disease.</ArticleTitle><Pagination><MedlinePgn>407-9</MedlinePgn></Pagination><Abstract><AbstractText>Despite an extensive literature examining the relationship between Crohn's disease and psychiatric illness, there is only one published report of mania in a patient with Crohn's disease. The authors describe seven patients, six men and one woman, with both bipolar disorder and Crohn's disease. The age at onset of Crohn's disease was highly correlated with the age at onset of affective disorder (r = .89, p = .016) and mania (r = .79, p = .06). Four patients received prednisone therapy for Crohn's disease from 3 to 52 weeks before their first manic episode. The authors discuss the relationship of the two illnesses, including possible common provoking factors, the possible role of steroids, and the genetics of the disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holroyd</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Baltimore, Md 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DePaulo</LastName><ForeName>J R</ForeName><Initials>JR</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH42243</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychiatry. 1992 Jan;53(1):29</RefSource><PMID Version="1">1737739</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2211537</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15895952</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-2640</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[Bipolar disorders and psychiatric comorbidity].</ArticleTitle><Pagination><MedlinePgn>501-6</MedlinePgn></Pagination><Abstract><AbstractText>Comorbidity is very frequent in bipolar disorders. The most frequently psychiatric disorders associated with bipolar disorders are substance use disorders (particularly alcohol abuse) and anxiety disorders. Obsessive-compulsive disorder, impulse control disorders, personality disorders and eating disorders co-occur also with bipolar disorder. Comorbidity complicates the diagnosis and the treatment of bipolar disorder and worsen the prognosis. For every bipolar patient, it is necessary to search for a comorbid psychiatric disorder, and vice-versa. There is a noticeable paucity of controlled studies to guide selection of the most effective treatment approches for these patients. The expert consensus guidelines about treatment of bipolar disorder propose divalproex as first-line treatment when bipolar disorder co-occurres with substance abuse, panic disorder or posttraumatic stress disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipski</LastName><ForeName>Héloise</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire Vulnérabilité, Adaptation et Psychopathologie, CNRS UMR 7593, Groupe Hospitalier La Pitie-La Salpêtrière, 75651 Paris. heloiselipski@yahoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baylé</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Troubles bipolaires et comorbidité psychiatrique.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>16</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15895952</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17451018</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2941</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychological reports</Title><ISOAbbreviation>Psychol Rep</ISOAbbreviation></Journal><ArticleTitle>Treatment of acute mania with ambient air anionization: variants of climactic heat stress and serotonin syndrome.</ArticleTitle><Pagination><MedlinePgn>157-63</MedlinePgn></Pagination><Abstract><AbstractText>High concentrations of ambient anions (O2-) were used to augment treatment for 20 acutely manic male patients. Anions were produced by an anion generator in a sealed room. A double-blind crossover design was used, and responses were evaluated with the Brief Psychiatric Rating Scale by 2 blinded raters. This produced a significant antimanic effect: total rating scores declined with anion treatment. Presham and postsham total scores for these 5 were 31.3 and 31.6, respectively. Pretreatment and posttreatment total scores were 31.6 and 26.3, respectively. Previous research indicates a role for serotonin in producing this antimanic effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>A James</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Ohio State University Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>Jocelyn D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Melemis</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>Juliette N</ForeName><Initials>JN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychol Rep</MedlineTA><NlmUniqueID>0376475</NlmUniqueID><ISSNLinking>0033-2941</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000838">Anions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000390" MajorTopicYN="Y">Air Ionization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000838" MajorTopicYN="N">Anions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001272" MajorTopicYN="N">Atmosphere</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018882" MajorTopicYN="N">Heat Stress Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020230" MajorTopicYN="N">Serotonin Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17451018</ArticleId><ArticleId IdType="doi">10.2466/pr0.100.1.157-163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23842019</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Unmet needs in the assessment and management of bipolar I depression.</ArticleTitle><Pagination><MedlinePgn>e11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.12065tx1c</ELocationID><Abstract><AbstractText>Bipolar depression remains challenging for clinicians to assess and manage during routine office visits. When patients complete assessments before their office visits, clinicians are able to quickly review the results beforehand and spend more time engaging and assessing the patient. After completing the differential diagnosis, clinicians can focus on discussing treatment goals and expectations with patients, educate them about viable treatment options, and help them select a proven option that will best promote treatment adherence. Collaborating with patients and care partners enables patients to be active participants in the management process. Systematically using assessment tools provides clinicians with measurable data to gauge the effectiveness and tolerability for each treatment and then to guide the next treatment decisions. Patients with bipolar depression value individualized care and rely on the expertise of clinicians to help them achieve remission. </AbstractText><CopyrightInformation>© Copyright 2013 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, and the Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychiatry. 2014 May;75(5):e413-6</RefSource><PMID Version="1">24922493</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23842019</ArticleId><ArticleId IdType="doi">10.4088/JCP.12065tx1c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11153963</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>250</Volume><Issue>6</Issue><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Developmental precursors and biological markers for schizophrenia and affective disorders: specificity and public health implications.</ArticleTitle><Pagination><MedlinePgn>286-91</MedlinePgn></Pagination><Abstract><AbstractText>Schizophrenia's developmental dimension includes causes being active early in life. Precursors are manifest before psychosis begins, and there is an emerging public health agenda including prediction and prevention. We discuss the specificity of some developmental precursors to schizophrenia as an outcome, with particular reference to longitudinal birth cohort studies. Underlying structural brain abnormalities are considered. Differences from controls are found in schizophrenia and, to a lesser extent, before affective disorder on many measures. This apparent lack of specificity may not be the case in neurobiological terms, as underlying mechanisms may be different; parsimony suggests not. This same lack of specificity may be an advantage in public health terms, raising the possibility of strategies to predict and prevent a range of psychiatric disorders, not just schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>University of Cambridge, Dept. of Psychiatry, Addenbrooke' Hospital, UK. pbj21@hermes.cam.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarrant</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>28</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11153963</ArticleId><ArticleId IdType="doi">10.1007/s004060070003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26892940</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>173</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>07</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Toward the Definition of a Bipolar Prodrome: Dimensional Predictors of Bipolar Spectrum Disorders in At-Risk Youths.</ArticleTitle><Pagination><MedlinePgn>695-704</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2015.15040414</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The authors sought to assess dimensional symptomatic predictors of new-onset bipolar spectrum disorders in youths at familial risk of bipolar disorder ("at-risk" youths).</AbstractText><AbstractText Label="METHOD">Offspring 6-18 years old of parents with bipolar I or II disorder (N=359) and community comparison offspring (N=220) were recruited. At baseline, 8.4% of the offspring of bipolar parents had a bipolar spectrum disorder. Over 8 years, 14.7% of offspring for whom follow-up data were available (44/299) developed a new-onset bipolar spectrum disorder (15 with bipolar I or II disorder). Measures collected at baseline and follow-up were reduced using factor analyses, and factors (both at baseline and at the visit prior to conversion or last contact) were assessed as predictors of new-onset bipolar spectrum disorders.</AbstractText><AbstractText Label="RESULTS">Relative to comparison offspring, at-risk and bipolar offspring had higher baseline levels of anxiety/depression, inattention/disinhibition, externalizing, subsyndromal manic, and affective lability symptoms. The strongest predictors of new-onset bipolar spectrum disorders were baseline anxiety/depression, baseline and proximal affective lability, and proximal subsyndromal manic symptoms (p&lt;0.05). While affective lability and anxiety/depression were elevated throughout follow-up in those who later developed a bipolar spectrum disorder, manic symptoms increased up to the point of conversion. A path analysis supported the hypothesis that affective lability at baseline predicts a new-onset bipolar spectrum disorder in part through increased manic symptoms at the visit prior to conversion; earlier parental age at mood disorder onset was also significantly associated with an increased risk of conversion. While youths without anxiety/depression, affective lability, and mania (and with a parent with older age at mood disorder onset) had a 2% predicted chance of conversion to a bipolar spectrum disorder, those with all risk factors had a 49% predicted chance of conversion.</AbstractText><AbstractText Label="CONCLUSIONS">Dimensional measures of anxiety/depression, affective lability, and mania are important predictors of new-onset bipolar spectrum disorders in at-risk youths. These symptoms emerged from among numerous other candidates, underscoring the potential clinical and research utility of these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hafeman</LastName><ForeName>Danella M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merranko</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monk</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickey</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakolsky</LastName><ForeName>Dara</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diler</LastName><ForeName>Rasim</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Satish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brent</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and the Department of Statistics, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Nationwide Children's Hospital and Ohio State University, Columbus; and the Department of Psychiatry, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH060952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH018951</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26892940</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2015.15040414</ArticleId><ArticleId IdType="pmc">PMC4930393</ArticleId><ArticleId IdType="mid">NIHMS796658</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Psychiatr Pract. 2008 May;14 Suppl 2:31-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18677197</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):542-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23429906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Apr;49(4):388-96</Citation><ArticleIdList><ArticleId IdType="pubmed">20410731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Sep;40(9):1094-102</Citation><ArticleIdList><ArticleId IdType="pubmed">11556634</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Oct;34(10):1229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">911222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):1001-16.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">21961775</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2013 Jan;58(1):22-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23327753</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Feb;121(1-2):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19541368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Aug;14(5):565-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22805501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 May;15(3):253-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23551755</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Jul;172(7):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 May;15(3):240-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23521542</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Oct;126(1-2):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19883943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 Oct;39(10):1245-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11026178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Dec 20;65(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">9029668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):463-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14977459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 1;173:39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25462394</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):265-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16449480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Feb;63(2):120-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11874212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">24797824</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014 Feb;204(2):122-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24262817</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Jan;168(1):40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21078709</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):522-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23453672</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 May;44(5):441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3579495</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Jan;65(1):28-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18180426</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Feb;52(2):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jan;152-154:347-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24144583</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2003 Jul;42(7):786-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12819438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):637-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19689506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10761347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Feb 1;172:300-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25451429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):828-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18076532</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Psychiatry Hum Dev. 2007 Jun;38(1):47-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17160586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17324469</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Suicide Res. 2011;15(3):207-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21827311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Oct;77(1):71-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14550937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):623-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16403188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 15;142(1-3):186-92</Citation><ArticleIdList><ArticleId IdType="pubmed">22771141</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Oct;68(10):1012-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21969459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2014 Apr;53(4):408-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24655650</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1994 Aug;31(4):281-94</Citation><ArticleIdList><ArticleId IdType="pubmed">7989643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Nov-Dec;13(7-8):670-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22085480</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12507732</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>1-2</Issue><PubDate><Year>2003</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity?</ArticleTitle><Pagination><MedlinePgn>1-5</MedlinePgn></Pagination><Abstract><AbstractText>The unitary Kraepelian concept of manic-depressive illness which incorporated attenuated forms, personal dispositions to mood instability, as well as much of the terrain of remitting depressions, may be considered by many to be too broad. On the other hand, the presently preferred unipolar-bipolar dichotomy in official nosology fails to account for the very common occurrence of clinical and subclinical conditions in the interface of major depressive disorders and bipolarity. The emerging concept of the bipolar spectrum represents a provocative working hypothesis to account for these conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>University of California at San Diego and VA Psychiatry Service (116A), 3350 La Jolla Village Drive, San Diego, CA 92161, USA. hakiskal@ucsd.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12507732</ArticleId><ArticleId IdType="pii">S0165032702003907</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(02)00390-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9217412</PMID><DateCompleted><Year>1997</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3182</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>4</Issue><PubDate><MedlineDate>1997 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Psychosomatics</Title><ISOAbbreviation>Psychosomatics</ISOAbbreviation></Journal><ArticleTitle>CADASIL presenting as bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>397-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>S K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Mahr</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychosomatics</MedlineTA><NlmUniqueID>0376506</NlmUniqueID><ISSNLinking>0033-3182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015161" MajorTopicYN="N">Dementia, Multi-Infarct</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9217412</ArticleId><ArticleId IdType="pii">S0033-3182(97)71452-X</ArticleId><ArticleId IdType="doi">10.1016/s0033-3182(97)71452-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8175248</PMID><DateCompleted><Year>1994</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-2174</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>1993</Year></PubDate></JournalIssue><Title>International journal of psychiatry in medicine</Title><ISOAbbreviation>Int J Psychiatry Med</ISOAbbreviation></Journal><ArticleTitle>Lithium side effects in the medically ill.</ArticleTitle><Pagination><MedlinePgn>357-82</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This review will include the general pharmacology of lithium and discuss its effects on various organ systems, with emphasis on the medically ill patient as well as the geriatric patient with multiple medical problems.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A full literature review on the side effects of lithium was performed. Attention is focused on the medically ill and possible drug interactions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This review points to the numerous problems which can result in toxicity in the medically ill or the geriatric patient.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Serious side effects can be avoided with proper drug monitoring and knowledge of potential drug interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morton</LastName><ForeName>W A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonne</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Lydiard</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Psychiatry Med</MedlineTA><NlmUniqueID>0365646</NlmUniqueID><ISSNLinking>0091-2174</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>149</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8175248</ArticleId><ArticleId IdType="doi">10.2190/VDLL-D9LH-EVE9-D1K2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16199011</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological functioning in youth with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>540-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known about the neuropsychological status of youth with bipolar disorder (BPD) or whether cognitive deficits in this population are accounted for by comorbidity with attention deficit/hyperactivity disorder (ADHD). We compared neuropsychological and academic functioning of youth with and without DSM-IV BPD, controlling for effects of comorbid ADHD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-seven youth with BPD and 46 healthy control subjects were assessed on a battery of clinical neuropsychological measures including subtests from the Wechsler Intelligence Scales for Children and Adults (Third Editions), the Stroop, the Wisconsin Card Sorting Test, the Rey-Osterreith Complex Figure, an auditory working memory Continuous Performance Test, a measure of verbal learning, and the Wide Range Achievement Test-Third Edition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar disorder was associated with impairments on subtests reflecting sustained attention, working memory, and processing speed after controlling for ADHD. Additionally, decrements of moderate effect sizes were found for measures of interference control, abstract problem solving, and verbal learning but did not meet criteria for statistical significance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After controlling for ADHD, youth with BPD show neuropsychological deficits similar to impairments found in adults with the disorder. Further studies are needed to understand the clinical implications of these impairments as well as their role in the underlying risk for pediatric BPD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Alysa E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA. doylea@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilens</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Seidman</LastName><ForeName>Larry J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>Stephen V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Fried</LastName><ForeName>Ronna</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Swezey</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08-MH-66072</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA12945</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16199011</ArticleId><ArticleId IdType="pii">S0006-3223(05)00908-X</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2005.07.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12068370</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>2-A</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Arquivos de neuro-psiquiatria</Title><ISOAbbreviation>Arq Neuropsiquiatr</ISOAbbreviation></Journal><ArticleTitle>[Autism, bipolar disorder and mental retardation in a male adolescent with congenital rubella: case report].</ArticleTitle><Pagination><MedlinePgn>324-7</MedlinePgn></Pagination><Abstract><AbstractText>We describe an autistic male adolescent with congenital rubella who has developed bipolar disorder, discussing possible diagnostic and therapeutic implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assumpcao</LastName><ForeName>Francisco Baptista</ForeName><Initials>FB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuczynski</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Autismo infantil, transtorno bipolar e retardo mental em portador de síndrome da rubéola congênita: relato de caso.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Neuropsiquiatr</MedlineTA><NlmUniqueID>0125444</NlmUniqueID><ISSNLinking>0004-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001321" MajorTopicYN="N">Autistic Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012410" MajorTopicYN="N">Rubella Syndrome, Congenital</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12068370</ArticleId><ArticleId IdType="pii">S0004-282X2002000200028</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22727729</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Temperament and character traits in patients with bipolar disorder and associations with attempted suicide.</ArticleTitle><Pagination><MedlinePgn>1096-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2012.05.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-440X(12)00080-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study was intended to investigate temperament and character traits in bipolar disorder patients with or without a history of attempted suicide.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred nineteen patients diagnosed with euthymic bipolar disorder based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and with no accompanying Axis I and II comorbidity, and 103 healthy controls were included. Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Axis I and II disorders were used to exclude Axis I and II comorbidity. Temperament and character traits of bipolar patients with a history attempted suicide (25.2%, n = 30) or without (74.8%, n = 89) and of the healthy volunteers were determined using the Temperament and Character Inventory. The association between current suicide ideation and temperament and character traits was also examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar patients with or without a history of attempted suicide had higher harm avoidance (HA) scores compared with the healthy controls. Persistence scores of bipolar patients with no history of attempted suicide were lower than those of the healthy controls. Self-directedness (SD) scores of the bipolar patients with a history of attempted suicide were lower than those of patients with no such history. Self-transcendence scores of bipolar patients with no history of attempted suicide were lower than those of both the healthy controls and of those patients with a history of attempted suicide. A positive correlation was determined between current suicidal ideation scale scores and HA, and a negative correlation between SD and cooperativeness was determined.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High harm avoidance may be a temperament trait specific to bipolar disorder patients. However, it may not be correlated with attempted suicide in such patients. These may have low persistence, high SD and low self-transcendence temperament and character traits that protect against attempted suicide. Harm avoidance, SD, and cooperativeness may be correlated with current suicidal ideation.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarısoy</LastName><ForeName>Gökhan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Psychiatry Department, Ondokuz Mayis University School of Medicine, Tıp Fakültesi Psikiyatri Anabilim Dalı, Samsun, Turkey. gokhansarisoy@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaçar</LastName><ForeName>Omer Faruk</ForeName><Initials>OF</Initials></Author><Author ValidYN="Y"><LastName>Pazvantoğlu</LastName><ForeName>Ozan</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Oztürk</LastName><ForeName>Arif</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Korkmaz</LastName><ForeName>Işıl Zabun</ForeName><Initials>IZ</Initials></Author><Author ValidYN="Y"><LastName>Kocamanoğlu</LastName><ForeName>Birsen</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Böke</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Sahin</LastName><ForeName>Ahmet Rifat</ForeName><Initials>AR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002605" MajorTopicYN="Y">Character</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="N">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22727729</ArticleId><ArticleId IdType="pii">S0010-440X(12)00080-6</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2012.05.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26667844</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Alterations in neural Theory of Mind processing in euthymic patients with bipolar disorder and unaffected relatives.</ArticleTitle><Pagination><MedlinePgn>880-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12352</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Behavioral deficits in the Theory of Mind (ToM) have been robustly demonstrated in bipolar disorder. These deficits may represent an intermediate phenotype of the disease. The aim of this study was: (i) to investigate alterations in neural ToM processing in euthymic patients with bipolar disorder, and (ii) to examine whether similar effects are present in unaffected relatives of patients with bipolar disorder suggesting that ToM functional activation may be, in part, due to genetic risk for the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 24 euthymic patients with bipolar disorder, 21 unaffected first-degree relatives, and 81 healthy controls completed a ToM task while undergoing functional magnetic resonance imaging.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed reduced bilateral activation of the temporoparietal junction (TPJ) and diminished functional fronto-temporoparietal connectivity in patients compared to controls. Relatives tended towards intermediate temporoparietal activity and functional coupling with medial prefrontal areas. There was also evidence for a potentially compensatory enhanced recruitment of the right middle temporal gyrus and stronger connectivity between this region and the medial prefrontal cortex in relatives.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings provide further evidence of altered neural ToM processing in euthymic patients with bipolar disorder. Further, our findings in relatives lend support to the idea that altered ToM processing may act as an intermediate phenotype of the disorder.</AbstractText><CopyrightInformation>© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willert</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohnke</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9177-6394</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erk</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnell</LastName><ForeName>Knut</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romanczuk-Seiferth</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinlivan</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiter</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spengler</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herold</LastName><ForeName>Dorrit</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wackerhagen</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romund</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbusow</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lett</LastName><ForeName>Tristram</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adli</LastName><ForeName>Mazda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fliedner Klinik Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bermpohl</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066553" MajorTopicYN="N">Problem Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056345" MajorTopicYN="N">Theory of Mind</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">affective disorders</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">intermediate phenotype</Keyword><Keyword MajorTopicYN="N">medial prefrontal cortex</Keyword><Keyword MajorTopicYN="N">mentalizing</Keyword><Keyword MajorTopicYN="N">neuroimaging</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword><Keyword MajorTopicYN="N">temporoparietal junction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26667844</ArticleId><ArticleId IdType="doi">10.1111/bdi.12352</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26926128</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>173</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>"Jinn Possession" and Delirious Mania in a Pakistani Woman.</ArticleTitle><Pagination><MedlinePgn>219-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2015.15030281</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Qurat ul ain</ForeName><Initials>Qu</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and Behavioral Sciences, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanober</LastName><ForeName>Aisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and Behavioral Sciences, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="Y">Delirium</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007514" MajorTopicYN="N">Islam</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010154" MajorTopicYN="N" Type="Geographic">Pakistan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012067" MajorTopicYN="Y">Religion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026443" MajorTopicYN="N">Spiritual Therapies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029181" MajorTopicYN="Y">Spirituality</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26926128</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2015.15030281</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12364668</PMID><DateCompleted><Year>2002</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>10</Issue><PubDate><Year>2002</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>Good, better, and the best psychiatric care I've received... and what has gone wrong.</ArticleTitle><Pagination><MedlinePgn>1241-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Deborah Michelle</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>deborahmichelle@earthlink.net</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008329" MajorTopicYN="N">Managed Care Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011361" MajorTopicYN="N">Professional Competence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="Y">Professional-Patient Relations</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>12</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12364668</ArticleId><ArticleId IdType="doi">10.1176/appi.ps.53.10.1241</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9084893</PMID><DateCompleted><Year>1997</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>7</Issue><PubDate><Year>1997</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Identification of differentially expressed RNA transcripts in neuropsychiatric disorders.</ArticleTitle><Pagination><MedlinePgn>759-61</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Yolken</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AF017336</AccessionNumber><AccessionNumber>AF017337</AccessionNumber><AccessionNumber>AF017338</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9084893</ArticleId><ArticleId IdType="pii">S0006-3223(96)00553-7</ArticleId><ArticleId IdType="doi">10.1016/S0006-3223(96)00553-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2903142</PMID><DateCompleted><Year>1988</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>49 Suppl</Volume><PubDate><Year>1988</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The role of neuroleptics in manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>12-4</MedlinePgn></Pagination><Abstract><AbstractText>Neuroleptic drugs are a common treatment for acute mania. Although lithium alone may be effective, for those patients with moderate or severe agitation neuroleptics appear to be superior. Low-potency and high-potency neuroleptics are equally effective in mania, as in schizophrenia. Patients with affective disorders, however, may be highly susceptible to the pseudoparkinsonian or extrapyramidal side effects that can occur with neuroleptics. Moderate doses of neuroleptics can be effective in most patients and can reduce the likelihood of serious side effects. Many bipolar patients have manic relapses despite adequate serum lithium levels, and many of those patients are subsequently maintained on a regimen of neuroleptic drugs in addition to lithium. Using the lowest possible dose of the neuroleptic may decrease the high, long-term risk of tardive dyskinesia. More clinical research is needed to determine the most appropriate use of neuroleptic drugs in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hillside Hospital, Glen Oaks, NY 11004.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>5</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2903142</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19102673</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2008</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Assessment and treatment of suicide risk in bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>109-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/14737175.9.1.109</ELocationID><Abstract><AbstractText>Completed suicide and suicide attempts are major issues in the management of bipolar disorders. There is evidence that suicide rates among these patients are more than 20-fold higher than the general population and, furthermore, suicidal behavior is much more lethal in bipolar disorder than in the general population. Patients with mood disorders may sometimes exhibit highly perturbed mixed states, which usually increase the risk of suicide. Such states are particularly frequent in bipolar II patients, especially if patients are treated with antidepressant monotherapy (unprotected by mood stabilizers), when depression switches into mania (or vice versa), or when depression lifts and functioning approaches normality. Researchers worldwide agree that treatment involving lithium is the best way to protect patients from suicide risk. Psychosocial activities, including psychoeducation, can protect bipolar patients either directly or, more probably, indirectly by increasing adherence to treatment and helping in daily difficulties that otherwise may lead to demoralization or hopelessness. An extensive understanding of the psychosocial circumstances and the psychopathology of bipolar patients (including temperament) may help clinicians describe the clinical picture accurately and prevent suicidal behavior in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pompili</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McLean Hospital-Harvard Medical School, Boston, MA, USA. maurizio.pompili@uniroma1.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rihmer</LastName><ForeName>Zoltán</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Innamorati</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lester</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tatarelli</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>307</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19102673</ArticleId><ArticleId IdType="doi">10.1586/14737175.9.1.109</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10507527</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>1999</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Comparative pharmacology of bipolar disorder and schizophrenia.</ArticleTitle><Pagination><MedlinePgn>153-8; discussion 163</MedlinePgn></Pagination><Abstract><AbstractText>The treatment of acute mania and schizophrenia overlap considerably in terms of the typical and atypical neuroleptics, but begin to diverge with the recognized mood stabilizers for bipolar affective illness--lithium, carbamazepine, and valproate--which are substantially less effective in schizophrenia than in affective illness. Moreover, the L-type calcium channel blocker verapamil is reported to be effective in mania, but it may exacerbate schizophrenia. A series of new putative mood stabilizing anticonvulsants (such as lamotrigine, gabapentin, and topiramate) and possible second-messenger targeted treatments (tamoxifen and omega-3 fatty acids) deserve further study in both affective and schizophrenic syndromes. Repeated transcranial magnetic stimulation (rTMS) of the brain offers considerable promise in the treatment of a variety of neuropsychiatric syndromes, especially with preliminary evidence of frequency-dependent effects on regional cerebral blood flow. New insights about the potential neurotrophic effects of lithium and the gene transcriptional effects of other psychotropics offer exciting new targets for therapeutics and strategies for future clinical trials and therapeutic applications in both syndromes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892-1272, USA. robert.post@nih.gov</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004599" MajorTopicYN="N">Electric Stimulation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008280" MajorTopicYN="N">Magnetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10507527</ArticleId><ArticleId IdType="pii">S0920996499001152</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(99)00115-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9858079</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>2-3</Issue><PubDate><Year>1998</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Social anxiety, hypomania and the bipolar spectrum: data, theory and clinical issues.</ArticleTitle><Pagination><MedlinePgn>203-13</MedlinePgn></Pagination><Abstract><AbstractText>Reports in the literature indicate a subtle but consistent relationship between panic and bipolar II disorder. The possible connection between social phobia and bipolarity is less investigated. When we studied the treatment outcome of 32 social phobic patients administered either the reversible monoamine oxidase inhibitor (RIMA) meclobomide or the irreversible inhibitor MAOI phenelzine, we found that eighteen had remission &gt; 50% of their socially anxious symptoms. Moreover, 14/18 of those improved became hypomanic, according to the Raskin Mania Scale (RMS) and the Young Mania Scale (YMS) coupled with expert clinical diagnosis. These findings possibly allude to a relationship of social phobia to bipolarity. Treatment with RIMA or MAOI exposed these subjects as having an atypical bipolar syndrome which is part of the bipolar spectrum. We then compared this special subset of subjects to the 18 socially phobic patients who failed to respond to RIMA's or MAOI's and to 26 patients with generalized anxiety disorder (GAD). Eleven of the 14 hypomanic responders gave histories of serious developmental deprivation (anaclisis); only 5/18 social phobics and 3/26 GADs without hypomanic responses had anaclitic histories. The author raises the possibility that anaclisis may have interacted with the impediment of volition of uncomplicated bipolar depression to produce social inhibition and anxiety. Finally, the author upholds the central role of depressive inhibition in bipolar disorder, which during antidepressant therapy often overshoots in a hypomanic direction; even in the absence of prior spontaneous hypomania, such disinhibition should classify this special subset of social phobic patients within the bipolar spectrum.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Himmelhoch</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010698" MajorTopicYN="N">Phobic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>12</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>12</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9858079</ArticleId><ArticleId IdType="pii">S0165-0327(98)00139-6</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(98)00139-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24574307</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery.</ArticleTitle><Pagination><MedlinePgn>516-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbu013</ELocationID><Abstract><AbstractText>A growing body of research suggests that schizophrenia and bipolar disorder share overlapping clinical, neurobiological, and genetic features, raising important questions about the boundaries and distinctiveness of these 2 major psychiatric disorders. A generalized cognitive impairment has long been understood to be a core feature of schizophrenia. More recently, it has become apparent that cognitive impairment also occurs in bipolar disorder, particularly in those patients with a history of psychotic symptoms. Whether a generalized deficit exists across a spectrum of psychotic disorders is less clearly established. Additionally, in the context of a broad impairment, it remains a significant challenge to identify deficits in specific cognitive processes that may have distinct neurochemical or regional brain substrates and linkages to particular risk-associated genetic factors. In this article, we review the findings from neuropsychological studies across a spectrum that includes schizophrenia, schizoaffective and bipolar disorders, and conclude the available evidence strongly supports that a generalized deficit is present across psychotic disorders that differs in severity more so than form. We then consider the implications of generalized and specific deficits in psychosis for 2 areas of research--the evaluation of pharmacological treatments targeting cognitive deficits, and the investigation of cognitive intermediate phenotypes in family genetic studies. Examples from the literature that touch on the relevance of the generalized deficit in these contexts are provided, as well as consideration for the continued need to identify specific impairments that are separable from the generalized deficit in order to advance drug and gene discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reilly</LastName><ForeName>James L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>*To whom correspondence should be addressed; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 446 East Ontario Street Suite 7-100, Chicago, IL, US; tel: 312-503-4809, fax: 312-503-0527, e-mail: james.reilly@northwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH077862</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH083126</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">endophenotype</Keyword><Keyword MajorTopicYN="N">neuropsychology</Keyword><Keyword MajorTopicYN="N">schizoaffective disorder</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword><Keyword MajorTopicYN="N">treatment effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24574307</ArticleId><ArticleId IdType="pii">sbu013</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbu013</ArticleId><ArticleId IdType="pmc">PMC3984526</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schizophr Bull. 2007 Sep;33(5):1131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17630405</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Jan 1;53(1-2):31-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11728836</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2003 Oct;25(7):949-64</Citation><ArticleIdList><ArticleId IdType="pubmed">13680442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Jan;107(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18786811</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychology. 1998 Jul;12(3):426-45</Citation><ArticleIdList><ArticleId IdType="pubmed">9673998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dialogues Clin Neurosci. 2010;12(3):383-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20954432</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Oct;64(10):1115-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17909123</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2009 Aug;11(4):313-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19635240</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2005;74(2):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15741761</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Feb;69(2):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18232725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2000 Jul-Oct;34(4-5):333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11104847</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Jan;37(1):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19443616</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jul;195(1):67-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19567899</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Sep;35(5):1022-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18495643</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):532-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17485605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Sep;45(9):984-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23933821</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17161829</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Nov 30;129(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15572184</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Mar;153(3):321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8610818</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17543288</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 15;63(8):776-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18191110</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 May;34(3):494-506</Citation><ArticleIdList><ArticleId IdType="pubmed">17932088</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Mar;39(2):257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23236079</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Apr;35(5):1053-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20090669</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Feb;41(2):225-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20836900</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2008 Mar;14(2):209-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18282319</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Oct 15;56(8):560-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15476685</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 1;62(7):818-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17300756</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Apr;36(4):485-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16388703</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Feb;165(2):203-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18172019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Affect Behav Neurosci. 2014 Mar;14(1):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24037621</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Schizophr Relat Psychoses. 2012 Oct;6(3):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23006239</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2000 Mar 17;287(5460):2020-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10720329</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Oct 30;169(3):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19758705</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Feb;125(2-3):161-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21075600</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2006 Dec;2(4):531-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19412501</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Nov;64(11):1242-50</Citation><ArticleIdList><ArticleId IdType="pubmed">17984393</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Nov;106(1):50-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18053687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Sep;40(5):1011-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24080895</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 May 1;68(1):49-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15037339</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2003 Nov-Dec;37(6):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">14563379</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):104-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22199092</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">23771174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):117-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16542181</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Jul;164(7):1061-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17606658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):144-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22101961</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Mar;39(2):263-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23211397</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Nov 1;64(9):823-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18472089</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2013 Dec;43(12):2535-45</Citation><ArticleIdList><ArticleId IdType="pubmed">23522057</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Aug;101(1-3):201-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17224185</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):114-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22124089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2004 Jul;192(7):464-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15232316</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Jan 15;57(2):145-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15652873</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14601037</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Sep;113(2-3):167-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19450952</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Nov;63(11):1189-97</Citation><ArticleIdList><ArticleId IdType="pubmed">17088499</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 May 1;68(1):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15037336</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Jul;147(2-3):315-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23664590</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Mar 30;196(1):38-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22342122</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1973 Jun;79(6):380-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4707457</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):125-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22021658</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Oct 1;48(7):674-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11032979</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 May;186:378-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15863741</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Dec 15;72(1):1-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15531401</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2001 Mar;103(3):181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11240574</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2010 Jan;10(1):43-57</Citation><ArticleIdList><ArticleId IdType="pubmed">20021320</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 May;34(6):897-921</Citation><ArticleIdList><ArticleId IdType="pubmed">19954751</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Mar;10(3):376-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17277774</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):135-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22101963</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Sep;157(9):1453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10964862</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Jun 15;69(12):e89-99</Citation><ArticleIdList><ArticleId IdType="pubmed">21489408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11883727</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Siblings of schizophrenia patients could be distinguished from siblings of bipolar patients.</ArticleTitle><Pagination><MedlinePgn>181-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gooding</LastName><ForeName>Diane C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Tallent</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Psychol Med. 2001 Jul;31(5):915-22</RefSource><PMID Version="1">11459389</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009679" MajorTopicYN="N">Nuclear Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010470" MajorTopicYN="N">Perceptual Masking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11883727</ArticleId><ArticleId IdType="doi">10.1017/s0033291701004871</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24060589</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Risks associated with gender differences in bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>1033-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.08.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00665-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have demonstrated that bipolar patients may differ in several features according to gender, but a number of the differences found remain controversial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The demographic, illness course, clinical, comorbidity and temperament characteristics of a total of 1090 consecutive DSM-IV bipolar I manic inpatients were compared according to gender.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar illness in women was characterised by the predominance of depression, as indicated by a depressive polarity at onset, higher rates of mixed mania, more suicidal behaviour, and a greater number of temperaments with depressive propensities. In contrast, the manic component was found to predominate in men. Men also had an earlier onset of their illness. Women displayed more comorbidities with eating, anxiety, and endocrine/metabolic disorders, whereas men were more comorbid with alcoholism and other forms of substance abuse, neurological, and cancer disorders. The following independent variables were associated with male gender: being single (+), depressive temperament (-), excessive alcohol use (+), cyclothymic temperament (-), excessive other substance use (+), mood congruent psychotic features (+), and manic polarity at onset (+).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The retrospective design and the sample being potentially not representative of the bipolar disorder population are limitations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Findings from this study tend to confirm most of the differences previously observed among bipolar men and women. Furthermore, these results draw attention to the risks that may be specifically linked to gender differences in bipolar I patients.</AbstractText><CopyrightInformation>© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sainte Marguerite Hospital, Marseille, France. Electronic address: jazorin@ap-hm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belzeaux</LastName><ForeName>Raoul</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kaladjian</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Adida</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hantouche</LastName><ForeName>Elie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lancrenon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fakra</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001068" MajorTopicYN="N">Feeding and Eating Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Gender</Keyword><Keyword MajorTopicYN="N">Men</Keyword><Keyword MajorTopicYN="N">Sex</Keyword><Keyword MajorTopicYN="N">Women</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24060589</ArticleId><ArticleId IdType="pii">S0165-0327(13)00665-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.08.031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8232837</PMID><DateCompleted><Year>1993</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>1993</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Calcium antagonists in manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>184-92</MedlinePgn></Pagination><Abstract><AbstractText>Increased free intracellular calcium ion concentration ([Ca2+]i) has been found in lymphocytes and blood platelets of patients with bipolar affective disorders when they are acutely ill, but not after recovery. Because lithium alters intracellular calcium ion dynamics and lowers platelet [Ca2+]i in affectively ill patients but not controls, drugs whose primary action is to modulate [Ca2+]i in hyperactive cells have been used as antimanic agents. The best studied of these is verapamil, a calcium channel blocking agent (CCB) that appears most effective for lithium-responsive patients. Because they interact with different central CCB receptors, second-generation CCBs may have a different spectrum of action. CCBs are usually well tolerated and may be useful for a number of other psychiatric, neurological and medical conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubovsky</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Denver, CO 80262.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>78</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8232837</ArticleId><ArticleId IdType="pii">118978</ArticleId><ArticleId IdType="doi">10.1159/000118978</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32579284</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>03</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Latent class analysis of bipolar disorder symptoms and suicidal ideation and behaviors.</ArticleTitle><Pagination><MedlinePgn>186-195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12967</ELocationID><Abstract><AbstractText>Individuals with bipolar disorder are at increased risk of dying by suicide compared to healthy controls and those with unipolar depression. Previous studies show that depressive symptoms and mixed episodes of mania and depression are related to suicide. However, most of these studies adopt a variable-centered approach to understanding how specific symptoms relate to suicidal ideation, without addressing how these symptoms and symptom profiles relate to suicidal behaviors.</AbstractText><AbstractText Label="OBJECTIVES">Using latent class analysis, this study adopts a person-centered approach to examine whether subtypes of patients with bipolar disorder differ in their levels of suicidal ideation and behaviors.</AbstractText><AbstractText Label="METHODS">A total of 150 patients from a behavioral health outpatient clinic were recruited. Latent classes were generated based on self reports of their depressive and manic symptoms.</AbstractText><AbstractText Label="RESULTS">Five classes of patients with bipolar disorder were identified, namely, a minimal symptom, mania, moderately depressed, severely depressed, and mixed depression-mania subtypes. Those in the severely depressed and mixed depression-mania groups reported significantly higher levels of suicidal ideation and behaviors compared to the other groups.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings provide further support for the strong relationship between depressive symptoms and suicidality. These findings are significant as they shed light on the different suicide risk profiles among a heterogenous group of patients with bipolar disorder. Name of clinical trial: Suicidal Behavior in Patients Diagnosed with Bipolar Disorder: The Roles of Biological and Childhood and Adult Environmental Risk Factors. ClinicalTrials.gov Identifier: NCT02604277.</AbstractText><CopyrightInformation>© 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Josephine S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-2392-9141</Identifier><AffiliationInfo><Affiliation>Child and Adolescent Psychiatry Division, McLean Hospital/Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez de Andino</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekawi</LastName><ForeName>Yara</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9181-2324</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverstein</LastName><ForeName>Madison W</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0002-2258-732X</Identifier><AffiliationInfo><Affiliation>Department of Psychological Sciences, Loyola University New Orleans, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamis</LastName><ForeName>Dorian A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-5405-0239</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02604277</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000068397">Clinical Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="Y">Depressive Disorder</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077272" MajorTopicYN="N">Latent Class Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="N">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">latent class analysis</Keyword><Keyword MajorTopicYN="Y">mania</Keyword><Keyword MajorTopicYN="Y">suicidal ideation</Keyword><Keyword MajorTopicYN="Y">suicide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32579284</ArticleId><ArticleId IdType="doi">10.1111/bdi.12967</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Michaels MS, Balthrop T, Pulido A, et al. Is the higher number of suicide attempts in bipolar disorder vs. major depressive disorder attributable to illness severity? Arch Suicide Res. 2018;22(1):46-56.</Citation></Reference><Reference><Citation>Pompili M, Shrivastava A, Serafini G, et al. Bereavement after the suicide of a significant other. Indian J Psychiatry. 2013;55(3):256.</Citation></Reference><Reference><Citation>Fiedorowicz JG, Persons JE, Assari S, et al. Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. J Affect Disord. 2019;246:775-782.</Citation></Reference><Reference><Citation>Persons JE, Coryell WH, Solomon DA, Keller MB, Endicott J, Fiedorowicz JG. Mixed state and suicide: Is the effect of mixed state on suicidal behavior more than the sum of its parts? Bipolar Disord. 2018;20(1):35-41.</Citation></Reference><Reference><Citation>Balázs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 2006;91(2-3):133-138.</Citation></Reference><Reference><Citation>Isometsä E. Suicidal behaviour in mood disorders-who, when, and why? Can J Psychiatry. 2014;59(3):120-130.</Citation></Reference><Reference><Citation>Costa LDS, Alencar ÁP, Neto PJN, et al. Risk factors for suicide in bipolar disorder: A systematic review. J Affect Disord. 2015;170:237-254. https://doi.org/10.1016/j.jad.2014.09.003</Citation></Reference><Reference><Citation>Plans L, Barrot C, Nieto E, et al. Association between completed suicide and bipolar disorder: A systematic review of the literature. J Affect Disord. 2018;2019(242):111-122.</Citation></Reference><Reference><Citation>May AM, Klonsky ED. What distinguishes suicide attempters from suicide ideators? A meta-analysis of potential factors. Clin Psychol Sci Pract. 2016;23(1):5-20.</Citation></Reference><Reference><Citation>Nock MK, Borges G, Bromet EJ, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192(2):98-105.</Citation></Reference><Reference><Citation>Muthén LK, Muthén BO. Mplus: Statistical Analysis with Latent Variables - User’s Guide. Statmodel.com. Published 2018. https://www.statmodel.com/download/usersguide/Mplus%20Users%20Guide%20v6.pdf. Accessed 2019.</Citation></Reference><Reference><Citation>Muthén B, Muthén LK. Integrating person-centered and variable-centered analyses: Growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res. 2000;24(6):882-891.</Citation></Reference><Reference><Citation>Little RJA, Rubin DB Statistical Analysis with Missing Data. Hoboken, NJ: Wiley; 1987.</Citation></Reference><Reference><Citation>DiStefano C, Kamphaus RW. Investigating subtypes of child development: A comparison of cluster analysis and latent class cluster analysis in typology creation. Educ Psychol Measur. 2006;66(5):778-794.</Citation></Reference><Reference><Citation>Birmaher B, Gill MK, Axelson DA, et al. Longitudinal trajectories and associated baseline predictors in youths with bipolar spectrum disorders. Am J Psychiatry. 2014;171(9):990-999.</Citation></Reference><Reference><Citation>Bora E, Hıdıroğlu C, Özerdem A, et al. Executive dysfunction and cognitive subgroups in a large sample of euthymic patients with bipolar disorder. Eur Neuropsychopharmacol. 2016;26(8):1338-1347.</Citation></Reference><Reference><Citation>Kaplan KA, Mcglinchey EL, Soehner A, et al. Hypersomnia subtypes, sleep and relapse in bipolar disorder. Psychol Med. 2015;45(8):1751-1763.</Citation></Reference><Reference><Citation>Perich T, Hadzi-Pavlovic D, Frankland A, et al. Are there subtypes of bipolar depression? Acta Psychiatr Scand. 2016;134(3):260-267.</Citation></Reference><Reference><Citation>Monahan PO, Stump T, Coryell WH, et al. Confirmatory test of two factors and four subtypes of bipolar disorder based on lifetime psychiatric co-morbidity. Psychol Med. 2015;45(10):2181-2196.</Citation></Reference><Reference><Citation>Vaidyanathan U, Patrick CJ, Iacono WG. Examining the overlap between bipolar disorder, nonaffective psychosis, and common mental disorders using latent class analysis. Psychopathology. 2012;45(6):361-365.</Citation></Reference><Reference><Citation>Tsai HC, Lu MK, Yang YK, et al. Empirically derived subgroups of bipolar I patients with different comorbidity patterns of anxiety and substance use disorders in Han Chinese population. J Affect Disord. 2012;136(1-2):81-89.</Citation></Reference><Reference><Citation>Fagiolini A, Frank E, Rucci P, et al. Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder. Bipolar Disord. 2007;9(5):462-467.</Citation></Reference><Reference><Citation>Reinares M, Papachristou E, Harvey P, et al. Towards a clinical staging for bipolar disorder: Defining patient subtypes based on functional outcome. J Affect Disord. 2013;144(1-2):65-71.</Citation></Reference><Reference><Citation>Uher R, Mantere O, Suominen K, et al. Typology of clinical course in bipolar disorder based on 18-month naturalistic follow-up. Psychol Med. 2013;43(4):789-799.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, D.C.: American Psychiatric Association; 2013.</Citation></Reference><Reference><Citation>Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873-1875.</Citation></Reference><Reference><Citation>Carvalho AF, Takwoingi Y, Sales PMG, et al. Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. J Affect Disord. 2015;172:337-346.</Citation></Reference><Reference><Citation>Hirschfeld RM, Cass AR, Holt DC, et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract. 2005;18(4):233-239.</Citation></Reference><Reference><Citation>Olfson M, Das AK, Gameroff MJ, et al. Bipolar depression in a low-income primary care clinic. Am J Psychiatry. 2005;162(11):2146-2151.</Citation></Reference><Reference><Citation>Beck AT, Ghisi M. BDI-II: Beck Depression Inventory - II. Firenze: Giunti O.S.; 2012.</Citation></Reference><Reference><Citation>Altman EG, Hedeker D, Peterson JL, et al. The Altman self-rating mania scale. Biol Psychiat. 1997;42(10):948-955.</Citation></Reference><Reference><Citation>Beck AT, Steer RA. BSS: Beck Scale for Suicide Ideation: Manual. San Antonio (Tex.): Psychological Corp.; 1991.</Citation></Reference><Reference><Citation>Pinninti N, Steer RA, Rissmiller DJ, et al. Use of the Beck Scale for Suicide Ideation with psychiatric inpatients diagnosed with schizophrenia, schizoaffective, or bipolar disorders. Behav Res Ther. 2002;40(9):1071-1079.</Citation></Reference><Reference><Citation>Taylor NJ, Mitchell SM, Roush JF, et al. Thwarted interpersonal needs and suicide ideation: Comparing psychiatric inpatients with bipolar and non-bipolar mood disorders. Psychiatry Res. 2016;246:161-165.</Citation></Reference><Reference><Citation>Osman A, Bagge CL, Gutierrez PM, et al. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): Validation with clinical and nonclinical samples. Assessment. 2001;8(4):443-454.</Citation></Reference><Reference><Citation>Hill RM, Pettit JW. Perceived burdensomeness and suicide-related behaviors in clinical samples: Current evidence and future directions. J Clin Psychol. 2014;70(7):631-643.</Citation></Reference><Reference><Citation>George D, Mallery P. SPSS for Windows Step by Step: A Simple Guide and Reference, 17.0 Update. Boston: Allyn &amp; Bacon; 2010.</Citation></Reference><Reference><Citation>Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical variables: One-step versus three-step estimators. Political Anal. 2004;12(1):3-27.</Citation></Reference><Reference><Citation>Asparouhov T, Muthén B. Auxiliary variables in mixture modeling: Using the BCH method in Mplus to estimate a distal outcome model and an arbitrary secondary model. Statmodel.com. Published July 16, 2018. http://www.statmodel.com/examples/webnotes/webnote21.pdf. Accessed 2019.</Citation></Reference><Reference><Citation>Asparouhov T, Muthén B. Pearson and Log-likelihood Chi-square Test of Fit for Latent Class Analysis Estimated with Complex Samples. Statmodel.com. Published December 22, 2008. https://www.statmodel.com/download/Chi2Complex4.pdf. Accessed 2019.</Citation></Reference><Reference><Citation>Asparouhov T, Muthén B. Using Mplus TECH11 and TECH14 to test the number of latent classes. Statmodel.com. Published May 22, 2012. http://www.statmodel.com/examples/webnotes/webnote14.pdf. Accessed 2019.</Citation></Reference><Reference><Citation>Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535-569.</Citation></Reference><Reference><Citation>Porcu M, Giambona F. Introduction to latent class analysis with applications. J Early Adolesc. 2016;37(1):129-158.</Citation></Reference><Reference><Citation>D'Unger AV, Land KC, McCall PL, et al. How many latent classes of delinquent/criminal careers? Results from mixed Poisson regression analyses. Am J Sociol. 1998;103(6):1593-1630.</Citation></Reference><Reference><Citation>Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. J Classif. 1996;13(2):195-212.</Citation></Reference><Reference><Citation>Asparouhov T, Muthén B. Auxiliary variables in mixture modeling: Three-step approaches using Mplus. Struct Eq Model Multi J. 2014;21:329-341.</Citation></Reference><Reference><Citation>Algorta GP, Youngstrom EA, Frazier TW, et al. Suicidality in pediatric bipolar disorder predictor or outcomes of family processes and mixed mood presentation? Bipolar Disord. 2011;13(1):76-83.</Citation></Reference><Reference><Citation>Marchetti I, Everaert J, Dainer-Best J, et al. Specificity and overlap of attention and memory biases in depression. J Affect Disord. 2018;225:404-412.</Citation></Reference><Reference><Citation>Pompili M, Gonda X, Serafini G, et al. Epidemiology of suicide in bipolar disorders: A systematic review of the literature. Bipolar Disord. 2013;15(5):457-490.</Citation></Reference><Reference><Citation>Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry. 2007;20:17-22.</Citation></Reference><Reference><Citation>Orri M, Perret LC, Turecki G, et al. Association between irritability and suicide-related outcomes across the life-course. Systematic review of both community and clinical studies. J Affect Disord. 2018;239:220-233.</Citation></Reference><Reference><Citation>Hall RC, Platt DE, Hall RC. Suicide risk assessment: A review of risk factors for suicide in 100 patients who made severe suicide attempts: Evaluation of suicide risk in a time of managed care. Psychosomatics. 1999;40(1):18-27.</Citation></Reference><Reference><Citation>Mulholland C, Cooper S. The symptom of depression in schizophrenia and its management. Adv Psychiatr Treat. 2000;6(3):169-177.</Citation></Reference><Reference><Citation>Norton PJ, Temple SR, Pettit JW. Suicidal ideation and anxiety disorders: Elevated risk or artifact of comorbid depression? J Behav Ther Exp Psychiatry. 2008;39(4):515-525.</Citation></Reference><Reference><Citation>Frank E. Interpersonal and social rhythm therapy: A means of improving depression and preventing relapse in bipolar disorder. J Clin Psychol. 2007;63:463-473.</Citation></Reference><Reference><Citation>Jobes DA, Chalker SA. One size does not fit all: A comprehensive clinical approach to reducing suicidal ideation, attempts, and deaths. Int J Environ Res Public Health. 2019;16:14.</Citation></Reference><Reference><Citation>Kupfer DJ, Frank E, Grochockinski V, et al. African-American participants in a bipolar disorder registry: Clinical and treatment characteristics. Bipolar Disord. 2005;7(1):82-88.</Citation></Reference><Reference><Citation>Ribeiro JD, Franklin JC, Fox KR, et al. Self-injurious thoughts and behaviors as risk factors for future suicide ideation, attempts, and death: A meta-analysis of longitudinal studies. Psychol Med. 2016;46(2):225-236.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26231750</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2015</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Patients' perspectives of the feasibility, acceptability and impact of a group-based psychoeducation programme for bipolar disorder: a qualitative analysis.</ArticleTitle><Pagination><MedlinePgn>184</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-015-0556-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although there is some quantitative evidence to suggest the benefits of group psychoeducation for people with bipolar disorder, patients' perspectives and experiences of group psychoeducation require in-depth exploration to enable us to better understand the feasibility, acceptability and impact of these interventions, the potential facilitators and barriers to engagement, and how to improve these interventions in the future.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In-depth, semi-structured interviews were conducted with 13 participants of a psychoeducation programme for bipolar disorder in Wales, following their involvement in the programme. The data were recorded and transcribed verbatim and analysed using thematic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Findings demonstrate that group psychoeducation may impact on participants' perceived social support, knowledge and acceptance of bipolar disorder, personal insights, attitude towards medication and access to services. Key recommendations for improvement included: allowing more time for group discussions, offering group sessions to family members and avoiding use of hospital or university venues for the groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first qualitative study of patients' perspectives of a UK-based group psychoeducation programme for people with bipolar disorder, and findings present an in-depth account of how group psychoeducation may be experienced by patients. The recommendations for improving the content and delivery of group psychoeducation for bipolar disorder may enhance engagement and widen access to such programmes. Future research into psychoeducation for bipolar disorder should explore how to target and engage people of diverse ethnic backgrounds and those in lower socioeconomic groups who are less likely to access healthcare services.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>Ria</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>DECIPHer, School of Social Sciences, Cardiff University, 1-3 Museum Place, Cardiff, CF10 3BD, UK. PooleR3@cardiff.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Mental Health and Wellbeing, University of Glasgow, Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, G12 0XH, UK. Daniel.smith@glasgow.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, 200 Renfield Street, Glasgow, G2 3QB, UK. sharon.simpson@glasgow.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_13027</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12017/14</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032882" MajorTopicYN="N">Comprehension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26231750</ArticleId><ArticleId IdType="doi">10.1186/s12888-015-0556-0</ArticleId><ArticleId IdType="pii">10.1186/s12888-015-0556-0</ArticleId><ArticleId IdType="pmc">PMC4522139</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 2009 Mar;194(3):260-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Aug-Sep;13(5-6):571-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22017225</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Jul;196(7):568-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18626298</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 May;63(5):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16651507</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2012;12:139</Citation><ArticleIdList><ArticleId IdType="pubmed">22971042</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):927-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16816276</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):937-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16816277</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2011;11:172</Citation><ArticleIdList><ArticleId IdType="pubmed">22044486</ArticleId></ArticleIdList></Reference><Reference><Citation>Implement Sci. 2009 Feb 09;4:4</Citation><ArticleIdList><ArticleId IdType="pubmed">19203373</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2009;9:50</Citation><ArticleIdList><ArticleId IdType="pubmed">19674448</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Jan;35(1):13-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15842025</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Endocrinol Lett. 2013;34(4):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23803872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16175758</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>4</Issue><PubDate><MedlineDate>2005 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Attitudes regarding the collaborative practice model and treatment adherence among individuals with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>272-7</MedlinePgn></Pagination><Abstract><AbstractText>An emerging literature suggests that a collaborative care model, in which patients are active managers of their illness within a supportive social environment, is a beneficial approach for individuals with bipolar disorder. One aspect of treatment that is often suboptimal among individuals with bipolar disorder is treatment adherence. Establishing an ideal collaborative model may offer an opportunity to enhance treatment adherence among individuals with bipolar disorder. This paper presents results from a qualitative exploration of patients' attitudes towards the collaborative care model and how individuals with bipolar disorder perceive treatment adherence within the context of the collaborative care model. All participants were actively enrolled in outpatient treatment at a Community Mental Health Center and part of a larger study that evaluated the Life Goals Program, a manual-driven structured group psychotherapy for bipolar disorder that is based on the collaborative practice model. The Life Goals Program is designed to assist individuals to participate more effectively in the management of their bipolar illness and to improve their social and work-related problems. Individuals were queried regarding their opinions on the ingredients for an effective client-provider relationship. Quantitative data were collected on baseline treatment adherence as well. Individuals treated for bipolar disorder in a community mental health clinic identified 12 key elements that they felt were critical ingredients to a positive collaborative experience with their mental health care provider. The authors conceptualized these elements around 3 emerging themes: patient-centered qualities, provider-centered qualities, and interactional qualities. Individuals with bipolar disorder perceived the ideal collaborative model as one in which the individual has specific responsibilities such as coming to appointments and sharing information, whereas the provider likewise has specific responsibilities such as keeping abreast of current "state-of-the-arf" prescribing practices and being a good listener. Treatment adherence was identified as a self-managed responsibility within the larger context of the collaborative model. Individuals with bipolar disorder in this study placed substantial emphasis on the interactional component within the patient-provider relationship, particularly with respect to times when the individual may be more symptomatic and more impaired. It is important that clinicians and care providers gather information related to patients' perceptions of the patient-provider relationship when designing or evaluating services aimed at enhancing treatment adherence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. martha.sajatovic@uhhs.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hays</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Safavi</LastName><ForeName>Roknedin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Janis</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16175758</ArticleId><ArticleId IdType="pii">S0010-440X(04)00178-6</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2004.10.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29065864</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>10</Month><Day>24</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Do some anxiety disorders belong to the prodrome of bipolar disorder? A clinical study combining retrospective and prospective methods to analyse the relationship between anxiety disorder and bipolar disorder from the perspective of biorhythms.</ArticleTitle><Pagination><MedlinePgn>351</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-017-1509-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">In clinical practice, some patients diagnosed with anxiety disorder (AD) may develop bipolar disorder (BD) many years later, and some cases of AD may be cured by the use of mood stabilizers. However, the relationship between AD and BD should be explored further.</AbstractText><AbstractText Label="METHOD">To track how many cases of AD turned to BD and to discover the differences between them, we recruited 48 patients diagnosed with BD, who were assigned to the BD group for the retrospective analysis, and we also recruited 186 patients diagnosed with AD at enrolment; this latter group was asked to complete follow-up surveys conducted 3 months, 6 months, 12 months and 18 months after the primary stage of the study. We defined another two groups according to the usage of mood stabilizers, the rates of reduction in scores on the Hamilton Anxiety Scale and Yale-Brown Obsessive Compulsive Scale, and the changes in Clinical Global Impression scores at different follow-up times: the anxiety group and the atypical BD group (who used mood stabilizers to treat AD). All subjects also completed the NEO Five-Factor Inventory and supplied blood samples to be tested for several endocrine indices (TSH, T3, FT3, T4, FT4, ACTH,PTC) and inflammatory cytokines (IL-6, IL-8, IL-10, TNF-α, CRP) at enrolment.</AbstractText><AbstractText Label="RESULTS">In total, 14 subjects developed BD by the end of the study. One hundred eleven subjects were included in the anxiety group. Sixty-three subjects were assigned to the atypical BD group, and they had similar features to the 48 subjects in the BD group in terms of personality traits, abnormality rates of endocrine indices and levels of inflammatory cytokines. From the anxiety group to the atypical BD group and then the BD group, the age of first onset gradually decreased, while the frequency of onset and the score of suicidal ideation gradually increased. Furthermore, the atypical BD group showed markedly higher levels of TSH, IL-6, TNF-α and CRP than the other two groups.</AbstractText><AbstractText Label="CONCLUSIONS">Some ADs with unique features might belong to the prodromal stage or the atypical presentation of BD, and recognizing these ADs early will economize many medical resources.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Fourth People's Hospital of Chengdu, Chengdu, 610031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ya-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xue-Li</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, 610041, China. sunxueli2015@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="Y">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anxiety disorders</Keyword><Keyword MajorTopicYN="Y">Biorhythm</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29065864</ArticleId><ArticleId IdType="doi">10.1186/s12888-017-1509-6</ArticleId><ArticleId IdType="pii">10.1186/s12888-017-1509-6</ArticleId><ArticleId IdType="pmc">PMC5655950</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 2013 May;170(5):542-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23429906</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2011 May;28(5):412-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21400640</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2015 Feb;41(1):10-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24094986</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Aug;41(8):1593-604</Citation><ArticleIdList><ArticleId IdType="pubmed">21134316</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2002 Jan 1;57(1):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11827739</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2010 Jul;11(7):779-87</Citation><ArticleIdList><ArticleId IdType="pubmed">20571973</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Apr 02;4:21</Citation><ArticleIdList><ArticleId IdType="pubmed">23565098</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 1995 Dec;21 Spec No 6:37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">8582316</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Oct;126(1-2):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19883943</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Oct;157(10):1679-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11007724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2000 Apr;20(2):204-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10770459</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):330-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19419390</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2008 Feb;35(2):206-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18085743</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2011 Jan;36(1):133-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20537805</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Endocrinol (Oxf). 1990 Dec;33(6):777-86</Citation><ArticleIdList><ArticleId IdType="pubmed">2128925</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Nov;151(2):551-60</Citation><ArticleIdList><ArticleId IdType="pubmed">23932736</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2011 Dec;13(6):493-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21850462</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Nov;56(1):61-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10626781</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Oct 1;185:219-29</Citation><ArticleIdList><ArticleId IdType="pubmed">26241867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Jan;64(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12590624</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2005 Jun;8(2):255-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15850501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):455-70</Citation><ArticleIdList><ArticleId IdType="pubmed">24636153</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Oct;168:314-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25086290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):478-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24597782</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Pol. 2010 Jan-Feb;44(1):27-38</Citation><ArticleIdList><ArticleId IdType="pubmed">20449978</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Jan;51(1):8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17141745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Mar;85(1-2):135-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15780684</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2012 Sep;12(9):1143-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23039393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Feb;136(3):1000-10</Citation><ArticleIdList><ArticleId IdType="pubmed">21802741</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2012 Oct 2;1476:58-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22541166</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Mar;85(1-2):207-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15780691</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jan 10;144(1-2):129-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22842021</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2012;18(4):358-75</Citation><ArticleIdList><ArticleId IdType="pubmed">22239567</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1989 Jan;25(1):67-74</Citation><ArticleIdList><ArticleId IdType="pubmed">2912510</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2010 Jul;23(4):363-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20404728</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18771602</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2008 Jul;33(6):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18407426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Symp Quant Biol. 2007;72:579-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18419318</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 1996 Mar-Apr;22(2):85-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8706626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):436-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14636367</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Feb;128(3):185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20471692</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2014;47(4):252-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24481376</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1996 Jul 16;35(28):9060-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8703909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Feb;10(1):56-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18199242</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25827034</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Validation of electronic health record phenotyping of bipolar disorder cases and controls.</ArticleTitle><Pagination><MedlinePgn>363-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2014.14030423</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study was designed to validate use of electronic health records (EHRs) for diagnosing bipolar disorder and classifying control subjects.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">EHR data were obtained from a health care system of more than 4.6 million patients spanning more than 20 years. Experienced clinicians reviewed charts to identify text features and coded data consistent or inconsistent with a diagnosis of bipolar disorder. Natural language processing was used to train a diagnostic algorithm with 95% specificity for classifying bipolar disorder. Filtered coded data were used to derive three additional classification rules for case subjects and one for control subjects. The positive predictive value (PPV) of EHR-based bipolar disorder and subphenotype diagnoses was calculated against diagnoses from direct semistructured interviews of 190 patients by trained clinicians blind to EHR diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The PPV of bipolar disorder defined by natural language processing was 0.85. Coded classification based on strict filtering achieved a value of 0.79, but classifications based on less stringent criteria performed less well. No EHR-classified control subject received a diagnosis of bipolar disorder on the basis of direct interview (PPV=1.0). For most subphenotypes, values exceeded 0.80. The EHR-based classifications were used to accrue 4,500 bipolar disorder cases and 5,000 controls for genetic analyses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Semiautomated mining of EHRs can be used to ascertain bipolar disorder patients and control subjects with high specificity and predictive value compared with diagnostic interviews. EHRs provide a powerful resource for high-throughput phenotyping for genetic and clinical research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Victor M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>From Research Information Systems and Computing, Partners HealthCare System, Boston; the Laboratory of Computer Science, the Department of Neurology, the Department of Psychiatry, the Center for Anxiety and Traumatic Stress Disorders, the Center for Experimental Drugs and Diagnostics, and the Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston; the Center for Biomedical Informatics, Harvard Medical School, Boston; the Department of Biostatistics, Harvard School of Public Health, Boston; the Psychotic Disorders Division, McLean Hospital, Belmont, Mass.; the Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland; and the Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minnier</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shawn N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Kohane</LastName><ForeName>Isaac</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Churchill</LastName><ForeName>Susanne E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Gainer</LastName><ForeName>Vivian</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Tianxi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hoffnagle</LastName><ForeName>Alison G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yael</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Block</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Weill</LastName><ForeName>Sydney R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Nadal-Vicens</LastName><ForeName>Mireya</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pollastri</LastName><ForeName>Alisha R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Rosenquist</LastName><ForeName>J Niels</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Goryachev</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ongur</LastName><ForeName>Dost</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sklar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Smoller</LastName><ForeName>Jordan W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><CollectiveName>International Cohort Collection for Bipolar Disorder Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 MH094614</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH-094614</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH100286</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH-085542</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH-100286</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH085542</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2015 Apr;172(4):310-1</RefSource><PMID Version="1">25827027</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Smoller</LastName><ForeName>Jordan W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Phil Hyoun</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castro</LastName><ForeName>Victor M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffnagle</LastName><ForeName>Alison G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sklar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stahl</LastName><ForeName>Eli A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Purcell</LastName><ForeName>Shaun M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruderfer</LastName><ForeName>Douglas M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charney</LastName><ForeName>Alexander W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roussos</LastName><ForeName>Panos</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pato</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pato</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medeiros</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobel</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craddock</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forty</LastName><ForeName>Liz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiFlorio</LastName><ForeName>Arianna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunjewski</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landén</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hultman</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juréus</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Svantesson</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moran</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smoller</LastName><ForeName>Jordan W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chambert</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belliveau</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Suffix>Jr</Suffix></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25827034</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2014.14030423</ArticleId><ArticleId IdType="pmc">PMC4441333</ArticleId><ArticleId IdType="mid">NIHMS663967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Genet. 2013 Oct;45(10):1150-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23974872</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Jan;170(1):59-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23111466</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jan;42(1):41-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21682950</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Inform Decis Mak. 2006;6:30</Citation><ArticleIdList><ArticleId IdType="pubmed">16872495</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2010 Mar;33(3):526-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20009093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2012 Mar-Apr;19(2):181-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22081225</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2011 Jan 7;88(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21211616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Inform. 2012 Jun;45(3):419-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22223081</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2011 Jul-Aug;18(4):387-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21672908</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2011 Jul;90(1):133-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21613990</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2012 Mar 30;2(2):e000544</Citation><ArticleIdList><ArticleId IdType="pubmed">22466034</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1996 Mar;26(2):401-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8685296</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Res. 2009 Sep;19(9):1675-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19602638</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Jan;16(1):2-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20351715</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 Oct;43(10):977-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21926972</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2014 Feb;15(2):122-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22540406</ArticleId></ArticleIdList></Reference><Reference><Citation>AMIA Annu Symp Proc. 2007;:548-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18693896</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2012 Jun;19(e1):e162-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22374935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genet. 2014 Jan;133(1):95-109</Citation><ArticleIdList><ArticleId IdType="pubmed">24026423</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2013 Mar;65(3):571-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23233247</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2011 Jun;12(6):417-28</Citation><ArticleIdList><ArticleId IdType="pubmed">21587298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Stat. 2009;37(4):1733-1751</Citation><ArticleIdList><ArticleId IdType="pubmed">20445770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Sep;72(9):1207-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21903033</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Aug;59(8):736-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12150650</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2012 Feb;91(2):257-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22190063</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Mar 30;211(3):202-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23149041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2008 May;40(5):638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">18372903</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Oct;169(10):1065-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23032386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Oct;70(10):1432-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19538905</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2010 Apr 9;86(4):560-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20362271</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Nov;168(11):1186-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21676994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3151399</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0555-5469</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Psychiatrie, Neurologie und medizinische Psychologie. Beihefte</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol Beih</ISOAbbreviation></Journal><ArticleTitle>[Preventive possibilities in monopolar and bipolar psychoses].</ArticleTitle><Pagination><MedlinePgn>57-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leonhard</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prophylaktische Möglichkeiten bei den monopolaren und bipolaren Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol Beih</MedlineTA><NlmUniqueID>0125315</NlmUniqueID><ISSNLinking>0555-5469</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3151399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19596447</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2010</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder as a risk factor for repeat DUI behavior.</ArticleTitle><Pagination><MedlinePgn>253-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.06.015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BD) is more prevalent among people with substance use disorders (SUD) than the general population. SUD among recidivist driving under the influence (DUI) populations are extremely prevalent; not surprisingly, recent evidence suggests that rates of BD also are elevated among DUI offenders. Studies of BD patients with SUD have found high prevalence of other psychiatric disorders and relatively low rate of treatment engagement. This study examines both the prevalence of other mental disorders and treatment status among a cohort of DUI offenders with BD and SUD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A consecutively selected cohort (N=729) of repeat DUI offenders attending a two-week inpatient treatment program completed a standardized diagnostic interview (the Composite International Diagnostic Interview: CIDI). The CIDI generated DSM-IV diagnoses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study yielded three main results for this repeat DUI offender sample: (1) BD is associated with significantly higher lifetime prevalence of alcohol, drug, and non-substance psychiatric disorders (e.g., PTSD); (2) approximately one quarter of BD participants have not discussed their mania with a professional; and (3) only half of the BD participants in this cohort have had mania treatment they consider effective and even fewer have had any treatment during the past twelve months.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Participants were predominantly Caucasian males attending treatment as a sentencing option in a single Massachusetts DUI program.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that clinicians in DUI treatment settings should consider both evaluating for BD and initiating therapy.</AbstractText><CopyrightInformation>Copyright  2009 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Cambridge Health Alliance, Somerville, MA 02143, United States. malbanese@challiance.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Peller</LastName><ForeName>Allyson J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Shaffer</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AA014710-01A1</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000435" MajorTopicYN="N">Alcoholic Intoxication</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001334" MajorTopicYN="N">Automobile Driving</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008404" MajorTopicYN="N" Type="Geographic">Massachusetts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011329" MajorTopicYN="N">Prisoners</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016320" MajorTopicYN="N">Substance Abuse Treatment Centers</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>09</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19596447</ArticleId><ArticleId IdType="pii">S0165-0327(09)00275-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.06.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33641060</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2072</ISSN><JournalIssue CitedMedium="Internet"><Volume>238</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation></Journal><ArticleTitle>The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><MedlinePgn>1729-1736</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-021-05789-9</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">The current pharmacotherapy of bipolar depression often presents limited efficacy and increased risk for adverse events. N-acetylcysteine (NAC) has been suggested as potentially effective and well-tolerated adjunctive treatment for bipolar disorder (BD).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This systematic review and meta-analysis aimed to examine the efficacy of N-acetylcysteine, as an adjunctive therapy, for treating bipolar depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Cochrane Library, Scopus databases, and grey literature were searched for studies retrieval. Randomized controlled trials including patients with a diagnosed bipolar disorder and a current depressive episode were included in the analysis. The measured variables included symptoms, functioning, and quality of life scales. The mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) was set as the primary outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of five studies were included in the analysis. A significant improvement was not observed from the addition of NAC to standard therapy in symptomatology [MADRS (MD = -3.32; 95% CI = -12.79 to 6.16), Young Mania Rating Scale (MD = -0.7; 95% CI = -2.15 to 0.75), Bipolar Depression Rating Scale (MD = -3.19; 95% CI = -15.48 to 9.1), and Clinical Global Impression for severity (MD = -0.13; 95% CI = -0.33 to 0.08)], functioning, [Global Assessment of Functioning Scale (MD = 3.21; 95% CI = -12.55 to 18.97), Social and Occupational Functioning Assessment Scale (MD = 0.47; 95% CI = -4.60 to 5.53), or quality of life [Quality of Life Enjoyment and Satisfaction Questionnaire (MD = 2.27; 95% CI = -9.13 to 13.67)].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is no evidence indicating that NAC has beneficial effects as an adjunctive treatment for bipolar depression. Future trials with improved methodological design and efficient sample sizes are required to draw safer conclusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pittas</LastName><ForeName>Stefanos</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2134-6436</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theodoridis</LastName><ForeName>Xenophon</ForeName><Initials>X</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9810-7583</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haidich</LastName><ForeName>Anna-Bettina</ForeName><Initials>AB</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5100-8799</Identifier><AffiliationInfo><Affiliation>Laboratory of Hygiene, Preventive Medicine, and Medical Statistics, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozikas</LastName><ForeName>Panteleimon-Vasilios</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>2nd Department of Psychiatry, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papazisis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1641-9095</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. papazisg@auth.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WYQ7N0BPYC</RegistryNumber><NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar depression</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">N-acetylcysteine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>28</Day><Hour>20</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33641060</ArticleId><ArticleId IdType="doi">10.1007/s00213-021-05789-9</ArticleId><ArticleId IdType="pii">10.1007/s00213-021-05789-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arakawa M, Ito Y (2007) N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum 6(4):308–314</Citation><ArticleIdList><ArticleId IdType="pubmed">17853088</ArticleId><ArticleId IdType="pmcid">7102236</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldessarini RJ, Vázquez GH, Tondo L (2020) Bipolar depression: a major unsolved challenge. Int J Bipolar Disord 8(1):1</Citation><ArticleIdList><ArticleId IdType="pubmed">31903509</ArticleId><ArticleId IdType="pmcid">6943098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer IE, Green C, Colpo GD et al (2019) A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry 80(1):18m12200</Citation></Reference><Reference><Citation>Berk M, Malhi GS, Catherine C, Catherine Carman A, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB (2007) The bipolar depression rating scale (BDRS): its development, validation and utility. Bipolar Disord 9(6):571–579</Citation><ArticleIdList><ArticleId IdType="pubmed">17845271</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 64(6):468–475</Citation><ArticleIdList><ArticleId IdType="pubmed">18534556</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, Allwang C, Schapkaitz I, Cobb H, Bush AI, Dodd S, Malhi GS (2012) Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med 10:91</Citation><ArticleIdList><ArticleId IdType="pubmed">22891797</ArticleId><ArticleId IdType="pmcid">3482580</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Turner A, Malhi GS et al (2019) Correction to: a randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 17(1):35</Citation></Reference><Reference><Citation>Beurel E, Jope RS (2014) Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry 4(12):e488</Citation><ArticleIdList><ArticleId IdType="pubmed">4270310</ArticleId><ArticleId IdType="pmcid">4270310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitty KM, Lagopoulos J, Lee RSC, Hickie IB, Hermens DF (2013) A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 23(11):1348–1363</Citation></Reference><Reference><Citation>Cohen BM, Öngür D (2018) The urgent need for more research on bipolar depression. Lancet Psychiatry 5(12):e29–e30</Citation><ArticleIdList><ArticleId IdType="pubmed">30477660</ArticleId></ArticleIdList></Reference><Reference><Citation>Coles LD, Tuite PJ, Öz G et al (2018) Repeated-dose oral N-acetylcysteine in Parkinson’s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol 58(2):158–167</Citation><ArticleIdList><ArticleId IdType="pubmed">28940353</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators, Global Burden of Disease Study 2013 (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 386(9995):743–800</Citation></Reference><Reference><Citation>Data-Franco J, Singh A, Popovic D, Ashton M, Berk M, Eduard V, Figueira ML, Dean OM (2017) Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology. Prog Neuro-Psychopharmacol Biol Psychiatry 72:73–86</Citation></Reference><Reference><Citation>Deepmala JS, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (2015) Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 55:294–321</Citation><ArticleIdList><ArticleId IdType="pubmed">25957927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellegaard PK, Licht RW, Nielsen RE, Dean OM, Berk M, Poulsen HE, Mohebbi M, Nielsen CT (2019) The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord 245(June 2018):1043–1051</Citation><ArticleIdList><ArticleId IdType="pubmed">30699846</ArticleId></ArticleIdList></Reference><Reference><Citation>Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29(2):321–326</Citation><ArticleIdList><ArticleId IdType="pubmed">8290681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M (2016) N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry 77(4):e457–e466</Citation><ArticleIdList><ArticleId IdType="pubmed">27137430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari AJ, Stockings E, Khoo J-P, Erskine HE, Degenhardt L, Vos T, Whiteford HA (2016) The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord 18(5):440–450</Citation><ArticleIdList><ArticleId IdType="pubmed">27566286</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande I, Berk M, Birmaher B, Vieta E (2016) Bipolar disorder. Lancet 387(10027):1561–1572</Citation><ArticleIdList><ArticleId IdType="pubmed">26388529</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrer M, Cuijpers P, Furukawa T, Ebert DD (2019) Dmetar: companion R package for the guide ‘doing meta-analysis in R</Citation></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed) 327(7414):557–560</Citation></Reference><Reference><Citation>Higgins JPT, Li T, Deeks JJ (2019a) Choosing effect measures and computing estimates of effect. Cochrane Handbook for Systematic Reviews of Interventions 143–176</Citation></Reference><Reference><Citation>Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC (2019b) Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions 205–228</Citation></Reference><Reference><Citation>Hilsenroth MJ, Ackerman SJ, Blagys MD, Baumann BD, Baity MR, Smith SR, Price JL, Smith CL, Heindselman TL, Mount MK, Holdwick DJ Jr (2000) Reliability and validity of DSM-IV Axis V. Am J Psychiatry 157(11):1858–1863</Citation><ArticleIdList><ArticleId IdType="pubmed">11058486</ArticleId></ArticleIdList></Reference><Reference><Citation>IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25</Citation><ArticleIdList><ArticleId IdType="pubmed">24548571</ArticleId><ArticleId IdType="pmcid">4015721</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SH, Thornicroft G, Coffey M, Dunn G (1995) A brief mental health outcome scale: reliability and validity of the global assessment of functioning (GAF). Br J Psychiatry 166(5):654–659</Citation><ArticleIdList><ArticleId IdType="pubmed">7620753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi T, Miyake N, Okuya M, Sakuma K, Iwata N (2020) N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology. 237:3481–3487</Citation><ArticleIdList><ArticleId IdType="pubmed">32767039</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB (1999) The Range of Impaired Functioning Tool (LIFE-RIFT): A brief measure of functional impairment. Psychol Med 29(4):869–878</Citation><ArticleIdList><ArticleId IdType="pubmed">10473314</ArticleId></ArticleIdList></Reference><Reference><Citation>Leucht S, Fennema H, Engel RR et al (2018) Translating the HAM-D into the MADRS and vice versa with equipercentile linking. J Affect Disord 226:326–331</Citation><ArticleIdList><ArticleId IdType="pubmed">29031182</ArticleId></ArticleIdList></Reference><Reference><Citation>Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr (Sao Paulo, Brazil : 1999) 33(4 CC-Common Mental Disorders):374–378</Citation></Reference><Reference><Citation>Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Rajesh S, Elisabeth Wells J, Zarkov Z (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68(3):241–251</Citation></Reference><Reference><Citation>Miller AH, Raison CL (2016) The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol 16(1):22–34</Citation><ArticleIdList><ArticleId IdType="pubmed">26711676</ArticleId><ArticleId IdType="pmcid">5542678</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci 134:382–389</Citation></Reference><Reference><Citation>Morris G, Walder K, McGee SL, Dean OM, Tye SJ, Maes M, Berk M (2017) A model of the mitochondrial basis of bipolar disorder. Neurosci Biobehav Rev 74(Pt A):1–20</Citation><ArticleIdList><ArticleId IdType="pubmed">28093238</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira C, Chavarria V, Vian J, Ashton MM, Berk M, Marx W, Dean OM (2018) Mitochondrial agents for bipolar disorder. Int J Neuropsychopharmacol 21(6):550–569</Citation><ArticleIdList><ArticleId IdType="pubmed">29596661</ArticleId><ArticleId IdType="pmcid">6007750</ArticleId></ArticleIdList></Reference><Reference><Citation>Raison CL, Rutherford RE, Woolwine BJ et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry 70(1):31–41</Citation></Reference><Reference><Citation>Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, Goldstein BI, Mcintyre RS (2016) Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 18(2):89–101</Citation><ArticleIdList><ArticleId IdType="pubmed">26990051</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer G (2007) Meta: an R package for meta-analysis. R News 7:40–45</Citation></Reference><Reference><Citation>Sigitova E, Fišar Z, Hroudová J, Cikánková T, Raboch J (2017) Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 71(2):77–103</Citation><ArticleIdList><ArticleId IdType="pubmed">27800654</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W (1997) Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73(3):159–171</Citation><ArticleIdList><ArticleId IdType="pubmed">9481807</ArticleId></ArticleIdList></Reference><Reference><Citation>Soron TR (2017) Validation of bangla montgomery asberg depression rating scale (MADRSB). Asian J Psychiatr 28:41–46</Citation><ArticleIdList><ArticleId IdType="pubmed">28784395</ArticleId></ArticleIdList></Reference><Reference><Citation>Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, Kuss O, Higgins JPT, Langan D, Salanti G (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 7(1):55–79</Citation><ArticleIdList><ArticleId IdType="pubmed">26332144</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O’Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 Guidelines for the Management of Patients with Bipolar Disorder. Bipolar Disord 20(2):97–170</Citation><ArticleIdList><ArticleId IdType="pubmed">29536616</ArticleId><ArticleId IdType="pmcid">5947163</ArticleId></ArticleIdList></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci 133:429–435</Citation></Reference><Reference><Citation>Zimmerman M, Chelminski I, Posternak M (2004) A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol 19(1):1–7</Citation><ArticleIdList><ArticleId IdType="pubmed">15101563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, Pardo-Hernandez H, Etxeandia-Ikobaltzeta I, Qaseem A, Williams JW, Jr., Peter Tugwell, Signe Flottorp, Yaping Chang, Yuqing Zhang, Reem A. Mustafa, María Ximena Rojas, Feng Xie, and Holger J. Schünemann. (2019) GRADE Guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences— inconsistency, imprecision, and other domains. J Clin Epidemiol 111:83–93</Citation><ArticleIdList><ArticleId IdType="pubmed">29800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Zhang QE, Cai DB, Yang XH, Qiu Y, Ungvari GS, Ng CH, Berk M, Ning YP, Xiang YT (2018) N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand 137(5):391–400</Citation><ArticleIdList><ArticleId IdType="pubmed">29457216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4037131</PMID><DateCompleted><Year>1985</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>10</Issue><PubDate><Year>1985</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Preadolescent alcohol abuse and dependence.</ArticleTitle><Pagination><MedlinePgn>1187-9</MedlinePgn></Pagination><Abstract><AbstractText>The authors document 10 cases of children who met the criteria for a DSM-III axis I diagnosis of alcohol abuse or dependence by the age of 13. They present one case report to demonstrate the family history of affective disorder, especially bipolar disorder, and alcoholism that characterized these 10 patients. Most of the children with bipolar disorder responded well to psychotropics. The authors suggest that there may be a relationship between early-onset alcohol abuse and the development of major affective disorders in adolescence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Famularo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Popper</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4037131</ArticleId><ArticleId IdType="doi">10.1176/ajp.142.10.1187</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10761347</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychiatric phenomenology of child and adolescent bipolar offspring.</ArticleTitle><Pagination><MedlinePgn>453-60</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To establish prodromal signs of and risk factors for childhood bipolar disorder (BD) by characterizing youths at high risk for BD.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Structured diagnostic interviews were performed on 60 biological offspring of at least one parent with BD. Demographics, family histories, and parental history of childhood disruptive behavioral disorders were also assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-one percent of bipolar offspring had a psychiatric disorder, most commonly attention-deficit/hyperactivity disorder (ADHD), major depression or dysthymia, and BD. BD in offspring tended to be associated with earlier parental symptom onset when compared with offspring without a psychiatric diagnosis. Bipolar parents with a history of childhood ADHD were more likely to have children with BD, but not ADHD. Offspring with bilineal risk had increased severity of depressed and irritable mood, lack of mood reactivity, and rejection sensitivity, while severity of grandiosity, euphoric mood, and decreased need for sleep were not preferentially associated with such offspring.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar offspring have high levels of psychopathology. Parental history of early-onset BD and/or childhood ADHD may increase the risk that their offspring will develop BD. Prodromal symptoms of childhood BD may include more subtle presentations of mood regulation difficulties and less presence of classic manic symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>K D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, CA 94305-5540, USA. kchang88@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5 T32 MH19908-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10761347</ArticleId><ArticleId IdType="pii">S0890-8567(09)66188-8</ArticleId><ArticleId IdType="doi">10.1097/00004583-200004000-00014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19707957</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2009</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4 Pt 3</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Stroop and emotional Stroop interference in unaffected relatives of patients with schizophrenic and bipolar disorders: distinct markers of vulnerability?</ArticleTitle><Pagination><MedlinePgn>809-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15622970903131589</ELocationID><Abstract><AbstractText>Reduced inhibition has been demonstrated in both schizophrenic and bipolar patients through the findings of increased interference on the Stroop Colour-Word Task (SCWT) and increased emotional interference on specific versions of the Emotional Stroop Task (EST). Despite previous findings of enhanced interference in unaffected relatives of schizophrenic and bipolar patients, it remains unclear whether interference might be a candidate endophenotype to both disorders. Moreover, data regarding emotional interference in unaffected relatives are critically lacking. In the present study, we aimed to compare unaffected relatives of patients with schizophrenia (SZ-rel, N = 30) and bipolar disorder (BD-rel, N= 30) with normal controls (N = 60) when performing the SCWT and an EST designed with neutral, depressive, paranoid and manic words. SZ-rel exhibited greater interference effect on both the SCWT and the EST as compared to either BD-rel or normal controls. BD-rel, and by contrast to SZ-rel and controls, showed increased emotional interference effect on the EST that was specifically associated to the disease-related words. The findings support the hypothesis of different markers of vulnerability to schizophrenic and bipolar disorders; impairment in cognitive inhibition could characterize high-risk individuals for schizophrenia whereas an emotional bias towards mood-related information could be a trait marker of bipolar disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Besnier</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pôle de Psychiatrie, Hôpital Sainte Marguerite, Marseille, France. nathalie.besnier@ap-hm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Floriane</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zendjidjian</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Kaladjian</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mazzola-Pomietto</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Adida</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057190" MajorTopicYN="Y">Stroop Test</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19707957</ArticleId><ArticleId IdType="pii">914182822</ArticleId><ArticleId IdType="doi">10.1080/15622970903131589</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2768205</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>9</Issue><PubDate><Year>1989</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment.</ArticleTitle><Pagination><MedlinePgn>356-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arana</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Knax</LastName><ForeName>E P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Ballenger</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2768205</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9585715</PMID><DateCompleted><Year>1998</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>155</Volume><Issue>5</Issue><PubDate><Year>1998</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders.</ArticleTitle><Pagination><MedlinePgn>638-45</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Effects of long-term lithium treatment for depressive and manic phases of type I and type II bipolar disorders were compared.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Clinical research records of 317 patients with DSM-IV-defined bipolar disorder (188 with type I and 129 with type II) were analyzed for frequency and duration of affective episodes and hospitalizations before (mean = 8.38 years) versus during (mean = 6.35 years) lithium maintenance treatment. Treatment effects were also assessed by survival analysis of interepisode intervals and by multivariate regression testing for factors associated with response to treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar I and bipolar II patients were ill before treatment a similar percentage of time, but the subtype distinction was supported descriptively. Lithium had superior benefits in type II patients, with significantly greater reduction of episodes per year and of the percentage of time ill. Reduction of depressive morbidity was similarly strong in both diagnostic types. During treatment, bipolar II patients had 5.9-fold longer interepisode intervals and were twice as likely as type I patients to have no new episodes. Starting lithium maintenance earlier predicted greater improvement.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lithium maintenance yielded striking long-term reductions of depressive as well as manic morbidity in both bipolar disorder subtypes, with greater overall benefits in type II patients and with earlier treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Hennen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Floris</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-47370</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2001 Oct;158(10):1740</RefSource><PMID Version="1">11579023</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9585715</ArticleId><ArticleId IdType="doi">10.1176/ajp.155.5.638</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21185425</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 4</Volume><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Formalized expert recommendations. Screening and management of bipolar disorders].</ArticleTitle><Pagination><MedlinePgn>S77-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(10)70035-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamon</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><VernacularTitle>Recommandations Formalisées d'Experts (RFE). Dépistage et prise en charge du trouble bipolaire. Éditorial.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="N">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21185425</ArticleId><ArticleId IdType="pii">S0013-7006(10)70035-X</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(10)70035-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25554538</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>The prestige model of spectrum bipolarity.</ArticleTitle><Pagination><MedlinePgn>122-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2014.12.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(14)00440-X</ELocationID><Abstract><AbstractText>Because affective pathogenesis is a hard problem for psychiatry, it behoves researchers to develop and test novel models of causality. We examine the notion that the adaptive drive to social investment - prestige - provides clues to the bipolar spectrum. A seven node bipolar spectrum is proposed, based on a putative gradient of "bipolarity". It is conceived that this gradient may correlate with the drive to social investment (prestige). In order to test this hypothesis with proof of concept data, a case control study categorised 228 subjects into a seven node bipolar spectrum. Whilst controlling for mood elevation and depression, differences in strategic prestige (leadership) motivation (MSPM) between spectrum groups were examined. The bipolar I (S1) node had a greater strategic prestige (leadership) motivation score than the controls (S7) by 21.17 points, 95% CI [8.16, 34.18], p&lt;.001, d=1.05, while the bipolar II (S2) node was higher than the control group by 16.73 points, 95% CI [0.92, 32.54], p=.030, d=0.84. Whilst the pseudounipolar (S3) node (those with depression and bipolar family histories; n=17) had only a marginally statistical difference in MSPM compared to controls (p=.051), the mean difference (16.98) and d value (0.86) indicated an elevated MSPM level. Prestige (leadership) motivation score positively correlated with dimensional lifetime bipolarity (Mood Disorder Questionnaire) score (rp=0.47), supporting the spectrum prestige motivation gradient notion. Evidence is presented for a genetic disposition to elevated strategic prestige (leadership) motivation. Sensitivity to Social Inclusion (MSIS), Contingency of Self-Worth (CSW.av) and tension significantly predicted strategic prestige (leadership) motivation (MSPM) score in a multiple regression. - suggesting that a vulnerability of the social self may be a feature of bipolar disorders. The prestige model of spectrum bipolarity offers a new conceptualisation of affective disorders and has received preliminary support. </AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Bas</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The University of Melbourne, Melbourne, Australia; Monash University, Melbourne, Australia; Peninsula Health, Melbourne, Australia. Electronic address: james.lebas@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The University of Melbourne, Melbourne, Australia; Monash University, Melbourne, Australia; Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sore</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Statistical Consulting Centre, University of Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castle</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The University of Melbourne, Melbourne, Australia; St Vincent's Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007857" MajorTopicYN="Y">Leadership</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="Y">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25554538</ArticleId><ArticleId IdType="pii">S0306-9877(14)00440-X</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2014.12.005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">34166526</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>10</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Cognitive performance in older-age bipolar disorder: Investigating psychiatric characteristics, cardiovascular burden and psychotropic medication.</ArticleTitle><Pagination><MedlinePgn>392-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.13342</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study aimed to explore a large range of candidate determinants of cognitive performance in older-age bipolar disorder (OABD).</AbstractText><AbstractText Label="METHODS">A cross-sectional study was performed in 172 BD patients aged ≥50 years. Demographics, psychiatric characteristics and psychotropic medication use were collected using self-report questionnaires and structured interviews. The presence of cardiovascular risk factors was determined by combining information from structured interviews, physical examination and laboratory assessments. Cognitive performance was investigated by an extensive neuropsychological assessment of 13 tests, covering the domains of attention, learning/ memory, verbal fluency and executive functioning. The average of 13 neuropsychological test Z-scores resulted in a composite cognitive score. A linear multiple regression model was created using forward selection with the composite cognitive score as outcome variable. Domain cognitive scores were used as secondary outcome variables.</AbstractText><AbstractText Label="RESULTS">The final multivariable model (N = 125), which controlled for age and education level, included number of depressive episodes, number of (hypo)manic episodes, late onset, five or more psychiatric admissions, lifetime smoking, metabolic syndrome and current use of benzodiazepines. Together, these determinants explained 43.0% of the variance in composite cognitive score. Late onset and number of depressive episodes were significantly related to better cognitive performance whereas five or more psychiatric admissions and benzodiazepine use were significantly related to worse cognitive performance.</AbstractText><AbstractText Label="CONCLUSION">Psychiatric characteristics, cardiovascular risk and benzodiazepine use are related to cognitive performance in OABD. Cognitive variability in OABD thus seems multifactorial. Strategies aimed at improving cognition in BD should include cardiovascular risk management and minimizing benzodiazepine use.</AbstractText><CopyrightInformation>© 2021 The Authors. Acta Psychiatrica Scandinavica published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beunders</LastName><ForeName>Alexandra J M</ForeName><Initials>AJM</Initials><Identifier Source="ORCID">0000-0001-9620-2579</Identifier><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>Tokie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korten</LastName><ForeName>Nicole C M</ForeName><Initials>NCM</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oudega</LastName><ForeName>Mardien L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekman</LastName><ForeName>Aartjan T F</ForeName><Initials>ATF</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stek</LastName><ForeName>Max L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schouws</LastName><ForeName>Sigfried N T M</ForeName><Initials>SNTM</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols</LastName><ForeName>Annemiek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Neuroscience Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">benzodiazepines</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognitive dysfunction</Keyword><Keyword MajorTopicYN="Y">heart disease risk factors</Keyword><Keyword MajorTopicYN="Y">neuropsychological tests</Keyword><Keyword MajorTopicYN="Y">psychotropic drugs</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>06</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>17</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34166526</ArticleId><ArticleId IdType="doi">10.1111/acps.13342</ArticleId><ArticleId IdType="pmc">PMC8518600</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Geriatr Psychiatry. 2009 Jun;17(6):508-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19461259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Sep;70(9):931-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23863861</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2016 Dec 15;16(1):448</Citation><ArticleIdList><ArticleId IdType="pubmed">27978821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Sep;125(1-3):330-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20079932</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2019 Sep;131(7):415-422</Citation><ArticleIdList><ArticleId IdType="pubmed">31424301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):45-59</Citation><ArticleIdList><ArticleId IdType="pubmed">11869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Dec;12(8):851-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21176032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2018 Nov;106:31-37</Citation><ArticleIdList><ArticleId IdType="pubmed">30261412</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Oct 1;257:166-172</Citation><ArticleIdList><ArticleId IdType="pubmed">31301619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Sep;15(6):633-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23651122</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005;66 Suppl 2:9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15762814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2020 Feb;22(1):13-27</Citation><ArticleIdList><ArticleId IdType="pubmed">31408230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2019 Aug;6(8):675-712</Citation><ArticleIdList><ArticleId IdType="pubmed">31324560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2017 Oct;205(10):743-756</Citation><ArticleIdList><ArticleId IdType="pubmed">28961594</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2019 Jun;49(8):1299-1307</Citation><ArticleIdList><ArticleId IdType="pubmed">30043716</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2015 Feb;25(2):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">25172270</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2014 Nov;22(11):1066-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24495405</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Sep;134(3):241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27329743</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2021 Oct;144(4):392-406</Citation><ArticleIdList><ArticleId IdType="pubmed">34166526</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):262-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14754775</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2004;(422):7-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15330934</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2020 Jan;34(1):29-46</Citation><ArticleIdList><ArticleId IdType="pubmed">31808104</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2007 Aug 15;166(4):367-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17573335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Nov;17(7):689-704</Citation><ArticleIdList><ArticleId IdType="pubmed">26384588</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Jul 15;180:142-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25909752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Oct;6(5):343-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15383127</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2012 Mar;25(1):20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22467842</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Endocrinol Lett. 2015;36(3):294-300</Citation><ArticleIdList><ArticleId IdType="pubmed">26313398</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Mar 15;229:125-134</Citation><ArticleIdList><ArticleId IdType="pubmed">29306692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Sci (Lond). 2017 Jun 1;131(11):1059-1068</Citation><ArticleIdList><ArticleId IdType="pubmed">28515342</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2007 Sep 4;69(10):998-1005</Citation><ArticleIdList><ArticleId IdType="pubmed">17785668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2021 Jan 1;278:556-562</Citation><ArticleIdList><ArticleId IdType="pubmed">33022441</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2017 Mar;17(3):277-285</Citation><ArticleIdList><ArticleId IdType="pubmed">27659841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Sep;131(1-3):101-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21741216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 Aug;19(5):363-374</Citation><ArticleIdList><ArticleId IdType="pubmed">28691361</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Sep/Oct;78(8):e924-e932</Citation><ArticleIdList><ArticleId IdType="pubmed">28994517</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2017 Mar;25(3):272-276</Citation><ArticleIdList><ArticleId IdType="pubmed">28041763</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Mar;18(2):148-54</Citation><ArticleIdList><ArticleId IdType="pubmed">26961121</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2000 Apr 22;320(7242):1087-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10775202</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2019 Nov 25;7(1):25</Citation><ArticleIdList><ArticleId IdType="pubmed">31761966</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2019 Apr;49(5):738-749</Citation><ArticleIdList><ArticleId IdType="pubmed">30326979</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2020 May;28(5):530-541</Citation><ArticleIdList><ArticleId IdType="pubmed">31761661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):33-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11869751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22339488</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-7610</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of child psychology and psychiatry, and allied disciplines</Title><ISOAbbreviation>J Child Psychol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive dysfunction is worse among pediatric patients with bipolar disorder Type I than Type II.</ArticleTitle><Pagination><MedlinePgn>775-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1469-7610.2011.02519.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">  Impaired profiles of neurocognitive function have been consistently demonstrated among pediatric patients with bipolar disorder (BD), and may aid in the identification of endophenotypes across subtypes of the disorder. This study aims to determine phenotypic cognitive profiles of patients with BD Type I and II.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">  Subjects (N = 79) consisted of BD I (n = 27) and BD II (n = 19) patients and demographic and intellectually matched healthy controls (HC; n = 33) that completed a battery of neurocognitive tasks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">  Bipolar disorder Type I patients performed significantly more poorly compared to HC on all domains of cognitive function including attention, executive function, working memory, visual memory, and verbal learning and memory. BD I patients also performed more poorly compared to BD II patients on all domains of cognitive functioning with the exception of working memory, whereas BD II patients did poorly relative to HC only on verbal learning and memory.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">  Findings from the current study indicate that BD I patients are characterized by more severe cognitive impairment relative to BD II patients who show an intermediate pattern of performance between BD I patients and HC. Verbal learning and memory may effectively differentiate pediatric BD patients and controls, regardless of the subtype of BD, and may serve as a cognitive endophenotype for the disorder. Additionally, these findings move us closer to developing effective cognitive interventions tailored to specific subtypes of pediatric BD patients.</AbstractText><CopyrightInformation>© 2012 The Authors. Journal of Child Psychology and Psychiatry © 2012 Association for Child and Adolescent Mental Health.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schenkel</LastName><ForeName>Lindsay S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychology, Rochester Institute of Technology, Rochester, NY 14623, USA. lssgsh@rit.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Amy E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Pavuluri</LastName><ForeName>Mani N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 RR018638</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR013987</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1-RR-13987</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NIH RR018638</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Child Psychol Psychiatry</MedlineTA><NlmUniqueID>0375361</NlmUniqueID><ISSNLinking>0021-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22339488</ArticleId><ArticleId IdType="doi">10.1111/j.1469-7610.2011.02519.x</ArticleId><ArticleId IdType="pmc">PMC3415381</ArticleId><ArticleId IdType="mid">NIHMS395266</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Med. 2008 Jun;38(6):771-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17922938</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Dec;36(12):1799-809</Citation><ArticleIdList><ArticleId IdType="pubmed">16938147</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):171-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15117396</ArticleId></ArticleIdList></Reference><Reference><Citation>J Can Acad Child Adolesc Psychiatry. 2009 Aug;18(3):221-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19718423</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):93-100</Citation><ArticleIdList><ArticleId IdType="pubmed">10743842</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2002 Apr;180:320-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11925354</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):286-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16449483</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Mar 16;5(3):e9714</Citation><ArticleIdList><ArticleId IdType="pubmed">20300526</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Jun;9 Suppl 1:145-59</Citation><ArticleIdList><ArticleId IdType="pubmed">17543033</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2008;4:163-87</Citation><ArticleIdList><ArticleId IdType="pubmed">17716034</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2001 Nov;25(5):766-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11682260</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20133824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Nov;10(7):806-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19032712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):245-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18271903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Mar;12(2):213-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20402714</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Aug;70(8):1178-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19573494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Jan;64(1):86-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12590629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):299-307</Citation><ArticleIdList><ArticleId IdType="pubmed">19182689</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1746-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16135639</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18684514</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2010 Mar;33(1):67-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20159340</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jan 1;55(1):32-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14706422</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):547-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19624394</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Aug;39(8):1253-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19079809</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jan;55(1):41-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9435759</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychology. 2009 Sep;23(5):551-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19702409</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):921-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16839520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):546-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16403180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15117401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):742-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7608047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2008 Dec;18(6):595-605</Citation><ArticleIdList><ArticleId IdType="pubmed">19108664</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Aug;94(1-3):255-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16750271</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2008 Oct;32(8):1426-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18582942</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Nov;106(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17900866</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Apr 1;65(7):586-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19027102</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Oct 1;58(7):540-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16199011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2007 Sep;48(9):852-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17714370</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Dec;60(12):1201-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14662552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 May;44(5):461-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15843768</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2007 Nov;6(8):698-705</Citation><ArticleIdList><ArticleId IdType="pubmed">17309660</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Sep;189:254-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16946361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22729334</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2012</Volume><PubDate><Year>2012</Year><Month>Jun</Month><Day>21</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Quinacrine induced mood disturbance--the unmasking of bipolar affective disorder.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr.02.2012.5842</ELocationID><ELocationID EIdType="pii" ValidYN="Y">bcr0220125842</ELocationID><Abstract><AbstractText>The authors report the case of a 20-year-old man who presented with a de novo episode of hypomania subsequent to the initiation of quinacrine for treatment resistant giardiasis. The hypomanic episode commenced some 20 days after the successful completion of a week long course of quinacrine 100 mg three times daily. The hypomanic episode was treated with olanzapine 10 mg daily. Two months subsequent to this, the patient developed a moderate depressive episode which was treated with escitalopram and olanzapine. One month after the resolution of the depressive episode, he once again presented with a hypomanic episode. The recurring episodes of discrete mood disturbance all occurred within 5 months of the commencement of quinacrine in an individual with no personal history of affective disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lally</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National University of Ireland, Galway (NUIG), Galway, Ireland. john.lally@nuigalway.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Fintan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000981">Antiprotozoal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>H0C805XYDE</RegistryNumber><NameOfSubstance UI="D011796">Quinacrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000981" MajorTopicYN="N">Antiprotozoal Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005873" MajorTopicYN="N">Giardiasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011796" MajorTopicYN="N">Quinacrine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22729334</ArticleId><ArticleId IdType="pii">bcr.02.2012.5842</ArticleId><ArticleId IdType="doi">10.1136/bcr.02.2012.5842</ArticleId><ArticleId IdType="pmc">PMC3387445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Pharm Pharmacol. 1989 Mar;41(3):160-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2568441</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Feb;66(2):199-204</Citation><ArticleIdList><ArticleId IdType="pubmed">15705005</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1981 Aug;30(2):239-45</Citation><ArticleIdList><ArticleId IdType="pubmed">7249508</ArticleId></ArticleIdList></Reference><Reference><Citation>South Med J. 1982 Mar;75(3):359-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7063914</ArticleId></ArticleIdList></Reference><Reference><Citation>South Med J. 2008 May;101(5):550-1</Citation><ArticleIdList><ArticleId IdType="pubmed">18414180</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2004 Nov 29;4:53</Citation><ArticleIdList><ArticleId IdType="pubmed">15569390</ArticleId></ArticleIdList></Reference><Reference><Citation>Trop Geogr Med. 1995;47(4):179-80</Citation><ArticleIdList><ArticleId IdType="pubmed">8560592</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2009 Jan;7(1):2-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19174293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2009 Apr;8(4):334-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19278902</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dermatol. 1984 Jun;120(6):765-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6721543</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1981 Apr;42(4):162-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7204361</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1996 Aug 31;313(7056):525-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8789977</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2001 Jan;14(1):114-28</Citation><ArticleIdList><ArticleId IdType="pubmed">11148005</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Dis Clin North Am. 1993 Sep;7(3):503-25</Citation><ArticleIdList><ArticleId IdType="pubmed">8254157</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2002 Oct;17(7):357-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12415556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22420594</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Facilitated Integrated Mood Management for adults with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>185-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2012.00998.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We describe the development of a five-session psychoeducational treatment, Facilitated Integrated Mood Management (FIMM), which contains many of the core elements of longer evidence-based psychosocial treatments for bipolar disorder. FIMM incorporated a novel mood monitoring program based on mobile phone technology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adult patients with bipolar I and II disorders (N = 19) received six sessions (Pilot I: n = 14) or five sessions (Pilot II: n = 5) of FIMM with pharmacotherapy. Treatment facilitators were novice counselors who were trained in a three-day workshop and supervised for six months. FIMM sessions focused on identifying early signs of recurrence, maintaining regular daily and nightly routines, rehearsing mood management strategies, maintaining adherence to medications, and education about substance abuse. Patients sent daily text messages or e-mails containing ratings of their mood and sleep, and weekly messages containing self-ratings on the Quick Inventory of Depressive Symptomatology (QIDS) and the Altman Self Rating Mania Scale (ASRM). Patients also completed a weekly mood management strategies questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 19 patients, 17 (89.5%) completed FIMM in an average of 9.2 ± 3.4 weeks (Pilot I) and 7.6 ± 0.9 weeks (Pilot II). Patients reported stable moods on the QIDS and ASRM over a 120-day period, and on average responded to 81% of the daily message prompts and 88% of the weekly QIDS and ASRM prompts. Facilitators maintained high levels of fidelity to the FIMM manual. Patients' knowledge of mood management strategies increased significantly between the first and last weeks of treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with bipolar disorder can be engaged in a short program of facilitated mood management. The effects of FIMM on the course of bipolar disorder await evaluation in randomized trials. The program may be a useful adjunct to pharmacotherapy in community centers that cannot routinely administer full courses of psychosocial treatment.</AbstractText><CopyrightInformation>© 2012 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California at Los Angeles Semel Institute, UCLA School of Medicine, Los Angeles, CA 90024-1759, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Rendell</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Budge</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Judit</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Neil M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>McPeake</LastName><ForeName>Lily</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Geddes</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH077856</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH093676</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH077856</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RP-PG-0108-10087</GrantID><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH073871</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH073871</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>088217</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019359" MajorTopicYN="N">Knowledge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060145" MajorTopicYN="N">Text Messaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22420594</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2012.00998.x</ArticleId><ArticleId IdType="pmc">PMC3412076</ArticleId><ArticleId IdType="mid">NIHMS353985</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2004 Mar;61(3):310-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14993119</ArticleId></ArticleIdList></Reference><Reference><Citation>Implement Sci. 2007 Dec 09;2:42</Citation><ArticleIdList><ArticleId IdType="pubmed">18067681</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2008 Sep 29;337:a1655</Citation><ArticleIdList><ArticleId IdType="pubmed">18824488</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2003 Jun;71(3):482-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12795572</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2006 Mar;20(2 Suppl):46-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16551672</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2008 Dec;46(12):1251-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18990364</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 May;63(5):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16651507</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Process. 1998 Spring;37(1):107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9589285</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Sep 15;50(6):468-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11566165</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2008 Mar;14(2):77-85</Citation><ArticleIdList><ArticleId IdType="pubmed">18360193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11 Suppl 2:110-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19538690</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):996-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">16143731</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):573-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12946886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):327-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20565440</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Oct;65(10):1343-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15491237</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Nov;165(11):1408-19</Citation><ArticleIdList><ArticleId IdType="pubmed">18794208</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):937-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16816277</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18519522</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Jan;34(1):73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14971628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002;4 Suppl 1:107-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12479693</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2007 Mar 3;334(7591):455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17332585</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Mar;194(3):260-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 3:5-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15952957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Psychopathol. 2012 Oct 6;3(4):572-581</Citation><ArticleIdList><ArticleId IdType="pubmed">26457175</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2009 Jun;23(4):346-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 15;42(10):948-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9359982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19133966</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Comparison of manic and depressive symptoms between children and adolescents with bipolar spectrum disorders.</ArticleTitle><Pagination><MedlinePgn>52-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2008.00659.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the most severe lifetime (current or past) mood symptoms, duration of illness, and rates of lifetime comorbid disorders among youth with bipolar spectrum disorders [BP (bipolar-I, bipolar-II and bipolar-not otherwise specified)].</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 173 children (&lt;12 years) with BP, 101 adolescents with childhood-onset BP, and 90 adolescents with adolescent-onset BP were evaluated with standardized instruments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Depression was the most common initial and frequent episode for both adolescent groups, followed by mania/hypomania. Adolescents with childhood-onset BP had the longest illness, followed by children and then adolescents with adolescent-onset BP. Adjusting for sex, socioeconomic status, and duration of illness, while manic, both adolescent groups showed more 'typical' and severe manic symptoms. Mood lability was more frequent in childhood-onset and adolescents with early-onset BP. While depressed, both adolescent groups showed more severe depressive symptoms, higher rates of melancholic and atypical symptoms, and suicide attempts than children. Depressed children had more severe irritability than depressed adolescents. Early BP onset was associated with attention-deficit hyperactivity disorder, whereas later BP onset was associated with panic, conduct, and substance use disorders. Above-noted results were similar when each BP subtype was analyzed separately.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Older age was associated with more severe and typical mood symptomatology. However, there were differences and similarities in type, intensity, and frequency of BP symptoms and comorbid disorders related to age of onset and duration of BP and level of psychosocial development. These factors and the normal difficulties youth have expressing and modulating their emotions may explain existing complexities in diagnosing and treating BP in youth, particular in young children, and suggest the need for developmentally sensitive treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. birmaherb@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Strober</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Mary Kay</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mei</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Esposito-Smythers</LastName><ForeName>Christianne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chiapetta</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Henrietta</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059691</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59691</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59977</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059929-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19133966</ArticleId><ArticleId IdType="pii">BDI659</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2008.00659.x</ArticleId><ArticleId IdType="pmc">PMC2828056</ArticleId><ArticleId IdType="mid">NIHMS174671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):939-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17064424</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Dec;63(12):1368-76</Citation><ArticleIdList><ArticleId IdType="pubmed">17146011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Nov;96(1-2):127-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16814395</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):463-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14977459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2005 Nov;39(6):611-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16009376</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15123490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S5-S16</Citation><ArticleIdList><ArticleId IdType="pubmed">15571790</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 May;63(5):414-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12019666</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Jul;42(7):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">4015311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Youth Adolesc. 1988 Apr;17(2):117-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24277579</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Jan;11(1):3-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16172609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):107-125</Citation><ArticleIdList><ArticleId IdType="pubmed">17195735</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2006 Aug;16(4):456-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16958570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Oct;36(10):1378-87; discussion 1387-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9334551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Aug;36(8):1046-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9256584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Aug;3(4):202-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11552959</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Dec;65(12):1654-9; quiz 1760-1</Citation><ArticleIdList><ArticleId IdType="pubmed">15641870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):213-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15725966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Sep;88(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16043229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2007 Dec;17(6):853-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18315456</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1988 Jan;27(1):12-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3343195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):483-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16403174</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Mar;160(3):430-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12611821</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Oct;44(10):854-61</Citation><ArticleIdList><ArticleId IdType="pubmed">3662742</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2006 Oct;15(4):919-37, ix</Citation><ArticleIdList><ArticleId IdType="pubmed">16952768</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):754-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7608049</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):846-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16113615</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Oct;59(10):905-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12365877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15571791</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):197-204</Citation><ArticleIdList><ArticleId IdType="pubmed">17242623</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2000 Fall;10(3):157-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11052405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):281-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11249806</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1994 May;33(4):461-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8005898</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2006 Dec;16(6):679-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17201612</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 May;39(5):549-55</Citation><ArticleIdList><ArticleId IdType="pubmed">7092488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25370283</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>199</Volume><Issue>S6</Issue><PubDate><Year>2013</Year><Month>09</Month><Day>16</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Treatment of bipolar depression.</ArticleTitle><Pagination><MedlinePgn>S32-5</MedlinePgn></Pagination><Abstract><AbstractText>Depression is usually the predominant phase in bipolar disorder, causes the most psychosocial disability, and carries significant risk of suicide. The management of bipolar depression is relatively under-studied and poses significant challenges for clinicians. There is substantial dissent regarding optimal pharmacotherapy for bipolar depression, particularly around the role of antidepressants. Individual and combination pharmacotherapy should be integrated into a personalised psychosocial and lifestyle package of interventions that considers the person's clinical profile and preferences. The relative lack of evidence relating to optimal strategies, especially when bipolar depression occurs with common comorbidities, poses challenges and requires further research. A flexible approach and evidence-based combinations of treatments can provide effective strategies for improving quality of life and reducing morbidity and mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia. seetald@barwonhealth.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davey</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moylan</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giorlando</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ajeet B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Harish</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Seetal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25370283</ArticleId><ArticleId IdType="pii">10.5694/mja12.10611</ArticleId><ArticleId IdType="doi">10.5694/mja12.10611</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15362566</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1434-5161</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>5</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Journal of human genetics</Title><ISOAbbreviation>J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia.</ArticleTitle><Pagination><MedlinePgn>227-31</MedlinePgn></Pagination><Abstract><AbstractText>We have previously reported the altered expressions of HSPF1 and LIM in the lymphoblastoid cell lines (LCLs) derived from Japanese patients with bipolar disorder (bipolar I disorder). The altered expression at the LCL level would be useful for developing diagnostic markers as well as a cellular model for bipolar disorder. In this study, we extended our previous study by measuring their expressions using the following samples: (1) larger number of LCLs from Japanese subjects, (2) LCLs from Caucasian subjects, and (3) LCLs from patients with bipolar II disorder or schizophrenia. We confirmed the increased expression of HSPF1 (P=0.009) and decreased expression of LIM (P=0.001) in the LCLs from patients with Japanese bipolar I disorder. These altered expressions were also observed in those from patients with Japanese bipolar II disorder (P= 0.002 for HSPF1 and P = 0.072 for LIM). We also found the altered expressions of HSPF1 in LCLs from Caucasian patients with bipolar II disorder (P=0.011) and LIM in those from patients with schizophrenia (P = 0.001).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Dynamics of Mental Disorders, Brain Science Institute, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bundo</LastName><ForeName>Miki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Washizuka</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kakiuchi</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 MH46274</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46280</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01MH46282</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Hum Genet</MedlineTA><NlmUniqueID>9808008</NlmUniqueID><ISSNLinking>1434-5161</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060588">LIM Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484380">PDLIM7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="Y">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060588" MajorTopicYN="N">LIM Domain Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15362566</ArticleId><ArticleId IdType="doi">10.1007/s10038-004-0136-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Neuropharmacol. 1996 Feb;19(1):48-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8867516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2003 Sep;43(1):70-84</Citation><ArticleIdList><ArticleId IdType="pubmed">14499463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Nov;6(6):678-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11673796</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Jul 15;46(2):247-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10418700</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1989 Jul;46(7):632-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2735813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Nov;6(6):625-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11673790</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1995;56(5):327-32</Citation><ArticleIdList><ArticleId IdType="pubmed">7837932</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Oct 1;48(7):665-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11032978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2003 Oct;35(2):171-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12949534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Apr;9(4):406-16</Citation><ArticleIdList><ArticleId IdType="pubmed">14743183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2003 Mar;33(3):422-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12567189</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 1998 Jan;41(1):94-100</Citation><ArticleIdList><ArticleId IdType="pubmed">9498636</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2001 Aug;24(8):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">11476888</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1998;62(17-18):1665-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9585154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1999;893:365-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10672268</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2003 Dec;6(4):379-89</Citation><ArticleIdList><ArticleId IdType="pubmed">14604453</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Jul;154(7):976-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9210749</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2002 Jun 21;71(5):581-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12052442</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2001 Jul-Aug;42(4):257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11458299</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 1997 Jan;15(1):29-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9050967</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res. 2001 Jun;40(2):105-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11377748</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2003 Jul 1;120B(1):72-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12815743</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Oct 15;50(8):620-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11690598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2003 May;6(5):468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12665800</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1994;243(5):235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8172937</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1992 Oct 15;32(8):731-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1457629</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Genet. 2001;35:149-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11700281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24282498</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>11</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants.</ArticleTitle><Pagination><MedlinePgn>e75362</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0075362</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">UK Biobank is a landmark cohort of over 500,000 participants which will be used to investigate genetic and non-genetic risk factors for a wide range of adverse health outcomes. This is the first study to systematically assess the prevalence and validity of proposed criteria for probable mood disorders within the cohort (major depression and bipolar disorder).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a descriptive epidemiological study of 172,751 individuals assessed for a lifetime history of mood disorder in relation to a range of demographic, social, lifestyle, personality and health-related factors. The main outcomes were prevalence of a probable lifetime (single) episode of major depression, probable recurrent major depressive disorder (moderate), probable recurrent major depressive disorder (severe), probable bipolar disorder and no history of mood disorder (comparison group). Outcomes were compared on age, gender, ethnicity, socioeconomic status, educational attainment, functioning, self-reported health status, current depressive symptoms, neuroticism score, smoking status and alcohol use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Prevalence rates for probable single lifetime episode of major depression (6.4%), probable recurrent major depression (moderate) (12.2%), probable recurrent major depression (severe) (7.2%) and probable bipolar disorder (1.3%) were comparable to those found in other population studies. The proposed diagnostic criteria have promising validity, with a gradient in evidence from no mood disorder through major depression and probable bipolar disorder in terms of gender distribution, socioeconomic status, self-reported health rating, current depressive symptoms and smoking.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">The validity of our proposed criteria for probable major depression and probable bipolar disorder within this cohort are supported by these cross-sectional analyses. Our findings are likely to prove useful as a framework for a wide range of future genetic and non-genetic studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Institute of Health and Wellbeing, Mental Health and Wellbeing Research Group, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholl</LastName><ForeName>Barbara I</ForeName><Initials>BI</Initials></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Breda</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ul-Haq</LastName><ForeName>Zia</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Jason M R</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gallacher</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hotopf</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Deary</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Pell</LastName><ForeName>Jill P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>093707</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K026992/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700704</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24282498</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0075362</ArticleId><ArticleId IdType="pii">PONE-D-13-22496</ArticleId><ArticleId IdType="pmc">PMC3839907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schizophr Bull. 2014 Jan;40(1):169-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23236081</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Nov 10;282(18):1737-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10568646</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Psychiatr Sci. 2012 Sep;21(3):311-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22794671</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2004 May;184:386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15123501</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2010 Dec 1;172(11):1306-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20843863</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e31660</Citation><ArticleIdList><ArticleId IdType="pubmed">22457710</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 May;109(5):392-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15049775</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Jul 15;76(2-3):135-57</Citation><ArticleIdList><ArticleId IdType="pubmed">15949648</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2012 Sep;159B(6):684-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22628180</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):421-33</Citation><ArticleIdList><ArticleId IdType="pubmed">14636365</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Mar 23;381(9871):997-1020</Citation><ArticleIdList><ArticleId IdType="pubmed">23668584</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1987 Feb;17(1):155-61</Citation><ArticleIdList><ArticleId IdType="pubmed">3575570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1995 Dec 13;35(3):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8749842</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 1985 Jan-Mar;4(1):87-90</Citation><ArticleIdList><ArticleId IdType="pubmed">3992076</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Mar;60(3):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12622659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1987 Jun;48(6):246-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3584081</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Apr;161(4):631-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15056508</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jul 15;60(2):84-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16300747</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2003;12(1):3-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12830306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2012 Jul 14;380(9837):110</Citation><ArticleIdList><ArticleId IdType="pubmed">22794246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Oct-Nov;29(2-3):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8300980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2012 Mar 31;379(9822):1173-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22463865</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2012 Sep;69(9):943-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22566563</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">24246363</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>12</Issue><PubDate><Year>2013</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Brain-behavior biomarkers of illness and illness risk in bipolar disorder: present findings and next steps.</ArticleTitle><Pagination><MedlinePgn>870-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2013.09.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(13)00870-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Mary L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Clinical and Translational Affective Neuroscience Program, Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: phillipsml@upmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Biol Psychiatry. 2013 Dec 15;74(12):908-16</RefSource><PMID Version="1">23684382</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>09</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24246363</ArticleId><ArticleId IdType="pii">S0006-3223(13)00870-6</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2013.09.029</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27520890</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Predominant mania course in Indian patients with bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>22-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2016.04.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(16)30175-7</ELocationID><Abstract><AbstractText>Many long-term follow-up studies suggest that bipolar disorder (BD) is highly recurrent and that depressive episodes are commoner than hypomania/manic episodes. However, some studies from tropical countries including India suggest that the patients experience a greater proportion of manic episodes than depressive episodes. The aim of the present study was to examine the course of BD type 1 (BD I) in a sample of hospitalized Indian subjects. We examined the clinical course of 285 BD I subjects with at least 5 years of illness using standard life charting method. These subjects were hospitalized between October 2010 and October 2012. The predominant polarity (having at least two-thirds of their lifetime episodes at one polarity) was mania (79%). Unipolar mania (≥ 3 mania episodes and no episodes of depression) was observed in 48% of the subjects. The frequency of rapid cycling course was noted in 2.5% of the subjects. Predominant manic polarity group had the illness onset mostly with a manic episode (88.9%) and the predominant depressive polarity group with a depressive episode (73.8%). Mania was the predominant polarity with a high rate of unipolar mania and a majority of the subjects had greater number of manic episodes than depressive/mixed episodes. The onset polarity determined the predominant polarity during the course of illness. Predominantly, mania course could have significant implications in the treatment of bipolar disorder. </AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rangappa</LastName><ForeName>Sushma Bilichodu</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munivenkatappa</LastName><ForeName>Shashidhara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayanaswamy</LastName><ForeName>Janardhanan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Y C Janardhan</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India. Electronic address: ycjreddy@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N">India</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Course</Keyword><Keyword MajorTopicYN="N">Predominant polarity</Keyword><Keyword MajorTopicYN="N">Unipolar mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27520890</ArticleId><ArticleId IdType="pii">S1876-2018(16)30175-7</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2016.04.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20712561</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0025-729X</ISSN><JournalIssue CitedMedium="Print"><Volume>193</Volume><Issue>S4</Issue><PubDate><Year>2010</Year><Month>08</Month><Day>16</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder: diagnostic issues.</ArticleTitle><Pagination><MedlinePgn>S5-9</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorders are cyclical mood disorders with clinical features including distinct sustained periods of mood elevation. Briefer (4 days or more), mild episodes of mood elevation define bipolar II disorder; lengthier (7 days or more), more severe episodes (or those requiring hospitalisation), with or without psychotic features, define bipolar I disorder. Depressive periods are more common and lengthier than manic or hypomanic states, and are the main cause of disability. Bipolar depression may respond poorly to antidepressants and these medications may destabilise the illness. The diagnosis of bipolar disorder should be considered when a patient with depression is treatment resistant. Irritability is a common symptom in bipolar disorder, particularly during mixed states (during which patients have features of mood elevation and depression concurrently) or when there is rapid cycling of mood (more than four episodes of mood disorder per year). Alcohol misuse and use of illicit drugs may simulate mood changes in bipolar disorder. Accurate diagnosis and assessment of bipolar disorder is essential for clinical decision making and determining prognosis and treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tiller</LastName><ForeName>John W G</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Albert Road Clinic, University of Melbourne, Melbourne, VIC. TillerJ@ramsayhealth.com.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweitzer</LastName><ForeName>Isaac</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20712561</ArticleId><ArticleId IdType="pii">til11472_fm</ArticleId><ArticleId IdType="doi">10.5694/j.1326-5377.2010.tb03889.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">426116</PMID><DateCompleted><Year>1979</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>136</Volume><Issue>4A</Issue><PubDate><Year>1979</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Group psychotherapy as an adjunct to lithium maintenance.</ArticleTitle><Pagination><MedlinePgn>455-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shakir</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Volkmar</LastName><ForeName>F R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Bacon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pfefferbaum</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="Y">Psychotherapy, Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">426116</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">837824</PMID><DateCompleted><Year>1977</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-3714</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>1977</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Diseases of the nervous system</Title><ISOAbbreviation>Dis Nerv Syst</ISOAbbreviation></Journal><ArticleTitle>Lithium in the treatment of a manic patient with multiple sclerosis: a case report.</ArticleTitle><Pagination><MedlinePgn>210-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lion</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Magram</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Nerv Syst</MedlineTA><NlmUniqueID>0370666</NlmUniqueID><ISSNLinking>0012-3714</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">837824</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9356772</PMID><DateCompleted><Year>1997</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>8</Issue><PubDate><Year>1997</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical profile of mania in children and adolescents from the Indian subcontinent.</ArticleTitle><Pagination><MedlinePgn>841-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To see whether classic DSM-III-R criteria for mania are applicable to Indian youngsters and to examine the clinical presentation of mania in an Indian child and adolescent psychiatric sample.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Fifty subjects with a diagnosis of functional psychosis as per the definition in ICD-9 were recruited from the population referred during the study period of approximately one year (n = 840) to the Child and Adolescent Psychiatry (CAP) clinic of the National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, South India. The subjects were systematically evaluated using a standardized clinical interview and demographic questionnaire and were classified according to DSM-III-R. The subjects who satisfied DSM-III-R criteria for mania formed the sample for this study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-one subjects received a diagnosis of mania according to DSM-III-R. The most common symptoms of mania included pressure of speech, irritability, elation, distractibility, increased self-esteem, expansive mood, flight of ideas, and grandiose delusions. No subject had comorbid attention-deficit hyperactivity disorder (ADHD). Additionally, 13 (61%) of the 21 manic subjects had delusions and/or hallucinations. The other common symptoms included psychomotor agitation, reduced sleep, anger, temper tantrums, decreased concentration, disobedience, aggression, and hyperactivity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mania was diagnosable in Indian children and adolescents using classic DSM-III-R criteria. The clinical profile appears to be generally similar to that seen in adults. ADHD is not a comorbid condition. The presence of aggressive or disruptive behaviours and hyperactivity in childhood- and adolescent-onset mania, however, could lead to a misdiagnosis of attention-deficit hyperactivity disorder/conduct disorder (ADHD/CD). Similarly, the presence of psychotic features could lead to a misdiagnosis of schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Y C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India. jreddy@nimhans.ren.nic.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girimaji</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Srinath</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>11</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>11</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9356772</ArticleId><ArticleId IdType="doi">10.1177/070674379704200806</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1600908</PMID><DateCompleted><Year>1992</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>18 Spec No 1</Volume><PubDate><Year>1992</Year><Month>Jan</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[5 cases of Cotard's syndrome in adolescents and young adults; symptoms of bipolar manic-depressive psychosis].</ArticleTitle><Pagination><MedlinePgn>65-6</MedlinePgn></Pagination><Abstract><AbstractText>The Cotard's syndrome existence among young adults is a recent notion. Its belonging to schizophrenia or mania depressive psychosis in under debate. From five observations of patients, we propose clinical and evolutive arguments allowing us to link up this symptomatology with bipolar manic depressive disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fillastre</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinique Psychiatrique Universitaire, CHR Bretonneau, Tours.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Depecker</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Degiovanni</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Cinq cas de syndrome de Cotard de l'adolescent et de l'adulte jeune. Symptomatique d'une psychose maniaco-dépressive bipolaire.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1600908</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22945186</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2012</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>24 Suppl 1</Volume><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Mood disorders in epilepsy - diagnostic and methodological considerations.</ArticleTitle><Pagination><MedlinePgn>S44-50</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mood disorders are common in people with epilepsy (PWE) with prevalence rates ranging from 11% to 62%. The variation in epidemiological data results probably from the diversity of methodologies employed and selection of the populations across the studies. Moreover, the symptomathology of mood disorders in epilepsy is often atypical, intermittent and pleomorphic and fails to meet DSM-IV-TR categories. Several studies suggested the existence of distinct interictal dysphoric disorder (IDD) in patients with epilepsy. The majority of research studies in mood disorders in epilepsy were based on screening instruments in the diagnosis of mood disorders in PWE. However, the results in validity and reliability in detecting major depression in epilepsy using self-report inventories of mood symptoms is vague. The aim of this study was to review studies on mood disorders in epilepsy with particular focus on diagnostic methods.</AbstractText><AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">The focus of this Review was on patient studies on mood disorders in epilepsy (2000-2012). We searched PubMed using the following search terms (effective date: 20th May 2012): (epilepsy (Title/Abstract) OR seizure (Title/Abstract)) AND depression (Title/Abstract) OR Dysthymia OR mania OR bipolar disorder OR affective disorder OR Interictal Dysphoric Disorder OR AND (humans (MeSH Terms) AND English (lang) AND (2000/01/01(PDAT): 2012/04/31(PDAT)).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Depression is the most frequent comorbid psychiatric disorder in epilepsy. Recent studies pointed out that bipolar disorders are not rare in epilepsy. Most of the research in PWE did not rely on standardized psychiatric measures and only about 18% of studies were based on diagnostic psychiatric interviews (mainly MINI and SCID-I). Mood disorders in epilepsy excluding the ictal or periictal symptoms can be categorized using standardized measures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Common self-report depression measures may be used to screen for depression in clinical settings. The use of screening instruments in epilepsy must be followed by structured psychiatric interviews designed to establish a DSM-IV-TR diagnoses. Standardized psychiatric interview procedures based on DSM criteria like SCID-I or MINI provide a comprehensive way to diagnose mood disorders in patients with epilepsy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiglusz</LastName><ForeName>Mariusz Stanisław</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland. mwiglusz@gumed.edu.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cubała</LastName><ForeName>Wiesław Jerzy</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Gałuszko-Węgielnik</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jakuszkowiak-Wojten</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Landowski</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22945186</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19594511</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The modern pharmacopoeia: a return to depressive realism?</ArticleTitle><Pagination><MedlinePgn>969-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2008.00632.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA. joseph.goldberg@mssm.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Bipolar Disord. 2008 Dec;10(8):957-68</RefSource><PMID Version="1">19594510</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19594511</ArticleId><ArticleId IdType="pii">BDI632</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2008.00632.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6496149</PMID><DateCompleted><Year>1984</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>3</Issue><PubDate><Year>1984</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Erythrocyte cation transport in endogenous depression: clinical and psychophysiological correlates.</ArticleTitle><Pagination><MedlinePgn>248-53</MedlinePgn></Pagination><Abstract><AbstractText>Clinical (psychometric), psychophysiological and biochemical (erythrocyte membrane transport) variables were studied in 44 patients with endogenous depression (unipolar/bipolar) during acute depressive episode and in remission. All parameters studied showed paralleled and unidirectional changes when depression was compared with remission period. During a depressive episode, unipolar patients had greater intensity of depression than bipolar patients. Ouabain-dependent sodium fluxes were significantly lower in female than in male patients during depression than in remission. In male bipolar patients, the indexes of active transport in erythrocytes showed significant correlations with clinical ratings and with results of psychophysiological tests. The results point to a possible relationship between various levels of physiological functioning in endogenous depression. This suggests a generalised "background" defect of energy-dependent membrane transport pertaining to both erythrocytes and nerve cells, which may be linked to disturbances of activational processes within the central nervous system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strzyzewski</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Potok</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zelechowska-Ruda</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5ACL011P69</RegistryNumber><NameOfSubstance UI="D010042">Ouabain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010042" MajorTopicYN="N">Ouabain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6496149</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1984.tb01205.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23601168</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Reduced functional cerebral lateralization: a biomarker of schizophrenia?</ArticleTitle><Pagination><MedlinePgn>449-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12070</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alary</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CNRS, UMR 6301, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razafimandimby</LastName><ForeName>Annick</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Delcroix</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Leroux</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Delamillieure</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Brazo</LastName><ForeName>Perrine</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dollfus</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="Y">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">functional hemispheric lateraliza-tion</Keyword><Keyword MajorTopicYN="N">functional magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">language</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23601168</ArticleId><ArticleId IdType="doi">10.1111/bdi.12070</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28847296</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6190</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Current neuropharmacology</Title><ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Neuron-glia Interaction as a Possible Pathophysiological Mechanism of Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>519-532</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1570159X15666170828170921</ELocationID><Abstract><AbstractText>Accumulating evidence has shown the importance of glial cells in the neurobiology of bipolar disorder. Activated microglia and inflammatory cytokines have been pointed out as potential biomarkers of bipolar disorder. Indeed, recent studies have shown that bipolar disorder involves microglial activation in the hippocampus and alterations in peripheral cytokines, suggesting a potential link between neuroinflammation and peripheral toxicity. These abnormalities may also be the biological underpinnings of outcomes related to neuroprogression, such as cognitive impairment and brain changes. Additionally, astrocytes may have a role in the progression of bipolar disorder, as these cells amplify inflammatory response and maintain glutamate homeostasis, preventing excitotoxicity. The present review aims to discuss neuron-glia interactions and their role in the pathophysiology and treatment of bipolar disorder.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Jairo Vinicius</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passos</LastName><ForeName>Ives Cavalcante</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Librenza-Garcia</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcon</LastName><ForeName>Grasiela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Maiko Abel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conte</LastName><ForeName>Joao Henrique</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Joao Pedro Abreu</ForeName><Initials>JPA</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Luiza Pereira</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quincozes-Santos</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Federal University of Rio Grande do Sul (UFRGS) (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauer-Sant Anna</LastName><ForeName>Marcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre (RS), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Neuropharmacol</MedlineTA><NlmUniqueID>101157239</NlmUniqueID><ISSNLinking>1570-159X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">brain-blood barrier</Keyword><Keyword MajorTopicYN="N">glia</Keyword><Keyword MajorTopicYN="N">mania</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neuron</Keyword><Keyword MajorTopicYN="N">oligodendrocyte.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28847296</ArticleId><ArticleId IdType="pii">CN-EPUB-85507</ArticleId><ArticleId IdType="doi">10.2174/1570159X15666170828170921</ArticleId><ArticleId IdType="pmc">PMC5997869</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurotox Res. 2017 Nov;32(4):535-543</Citation><ArticleIdList><ArticleId IdType="pubmed">28593525</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2015 Aug;25(8):1091-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26024928</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2001 Jul 15;55(5):611-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11576757</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 Jan 21;4:e350</Citation><ArticleIdList><ArticleId IdType="pubmed">24448212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2005 Sep 26;170(7):1101-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16186256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Feb;15(1):1-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23237061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 Oct;75(10):1078-85; quiz 1085</Citation><ArticleIdList><ArticleId IdType="pubmed">25373115</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Oct;203:281-291</Citation><ArticleIdList><ArticleId IdType="pubmed">27317921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 Nov;22(11):1576-1584</Citation><ArticleIdList><ArticleId IdType="pubmed">27400854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2015 Jul;40(4):250-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25768030</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2010 Jun 11;7:34</Citation><ArticleIdList><ArticleId IdType="pubmed">20540736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Nov;47(11):1694-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23896207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2012 Sep;37(5):333-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22498078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Apr 1;67(2-3):269-75</Citation><ArticleIdList><ArticleId IdType="pubmed">14984887</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2012 Jan;45(1):37-47</Citation><ArticleIdList><ArticleId IdType="pubmed">21310238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Aug 29;154(5):971-982</Citation><ArticleIdList><ArticleId IdType="pubmed">23993091</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2017 Mar;61:387-388</Citation><ArticleIdList><ArticleId IdType="pubmed">27311765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2008 Oct;107(1):1-19</Citation><ArticleIdList><ArticleId IdType="pubmed">18643793</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:113-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25496759</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 Sep;41(5):1095-104</Citation><ArticleIdList><ArticleId IdType="pubmed">25616505</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2018 Jan;22(1):207-222</Citation><ArticleIdList><ArticleId IdType="pubmed">28782169</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 Sep;132(3):211-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25891376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Aug;15(5):457-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23755739</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2011 Dec;36(13):2650-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21814185</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1992 May;45(1):53-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1410078</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2016 May 31;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">27207915</ArticleId></ArticleIdList></Reference><Reference><Citation>Innate Immun. 2012 Jun;18(3):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">21994254</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 May;46(7):1547-58</Citation><ArticleIdList><ArticleId IdType="pubmed">26947335</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2006 Mar;40(3):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16476148</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Oct 14;9(10):e110024</Citation><ArticleIdList><ArticleId IdType="pubmed">25313834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Aug;12(5):541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20712756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2007 Nov 15;85(15):3347-58</Citation><ArticleIdList><ArticleId IdType="pubmed">17847118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2007 Feb;114(2):261-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16897601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Dec;16(12):1234-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20938433</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 May;42:35-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24509064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Metab. 2011 Dec 7;14(6):724-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22152301</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2017 Jul;44:17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">28531561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Dec;11(8):807-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19922551</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2015 Nov;138(Pt 11):3440-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26373602</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2015;2015:708306</Citation><ArticleIdList><ArticleId IdType="pubmed">26075104</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2016 Sep 01;4(1):95</Citation><ArticleIdList><ArticleId IdType="pubmed">27585976</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2015 Apr-Jun;37(2):121-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26018648</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Apr;72(4):305-15</Citation><ArticleIdList><ArticleId IdType="pubmed">25651064</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2015 Oct 15;765:249-57</Citation><ArticleIdList><ArticleId IdType="pubmed">26321148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Feb 22;32(8):2657-66</Citation><ArticleIdList><ArticleId IdType="pubmed">22357850</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2006 Jan 15;53(2):201-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16206167</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Mar 6;77(5):873-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23473318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Aug 15;182:64-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25973785</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2012 Aug;51(1-2):32-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22800605</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Nov;71(11):1518-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20584522</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Mar 15;193:39-50</Citation><ArticleIdList><ArticleId IdType="pubmed">26766032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Oct 8;378(9799):1306-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21851976</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12411217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 May;17(3):248-56</Citation><ArticleIdList><ArticleId IdType="pubmed">25257942</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):192-200</Citation><ArticleIdList><ArticleId IdType="pubmed">23810479</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 May;17(3):235-47</Citation><ArticleIdList><ArticleId IdType="pubmed">25346322</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2014 May 22;8:117</Citation><ArticleIdList><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2011 Oct 25;11(11):775-87</Citation><ArticleIdList><ArticleId IdType="pubmed">22025055</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Mar;133(3):214-20</Citation><ArticleIdList><ArticleId IdType="pubmed">26513535</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2017 Jan 24;7(1):e1011</Citation><ArticleIdList><ArticleId IdType="pubmed">28117843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1994 Oct;14(5):330-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7806688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2010 Jul 15;1:e56</Citation><ArticleIdList><ArticleId IdType="pubmed">21364661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2016 Feb;73:102-107</Citation><ArticleIdList><ArticleId IdType="pubmed">26714201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Aug;15(8):784-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20351717</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2010 Oct 8;7(4):483-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2015 Aug 6;300:141-54</Citation><ArticleIdList><ArticleId IdType="pubmed">25981208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2014 Aug 14;11:140</Citation><ArticleIdList><ArticleId IdType="pubmed">25115727</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2014 Aug 25;5:98</Citation><ArticleIdList><ArticleId IdType="pubmed">25202283</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):111-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22343008</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Mar 1;1(2):186-194</Citation><ArticleIdList><ArticleId IdType="pubmed">27047994</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1996 Sep;67(3):1014-22</Citation><ArticleIdList><ArticleId IdType="pubmed">8752107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceuticals (Basel). 2014 Nov 25;7(12):1028-48</Citation><ArticleIdList><ArticleId IdType="pubmed">25429645</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2010;62(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20453532</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(434):41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17688462</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 1;186(7):4415-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21346235</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2018 Apr;55(4):2967-2978</Citation><ArticleIdList><ArticleId IdType="pubmed">28456938</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 Jun;131(6):458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">25640667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2016 Oct;37(10):3474-85</Citation><ArticleIdList><ArticleId IdType="pubmed">27198848</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2015 Jul;122(7):1019-33</Citation><ArticleIdList><ArticleId IdType="pubmed">25307869</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Dec;206:210-215</Citation><ArticleIdList><ArticleId IdType="pubmed">27475892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Dec;21(12):1696-1709</Citation><ArticleIdList><ArticleId IdType="pubmed">26903267</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21624424</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Aug;134(2):91-103</Citation><ArticleIdList><ArticleId IdType="pubmed">27097559</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Wound Care (New Rochelle). 2012 Feb;1(1):10-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24527272</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscientist. 2015 Apr;21(2):169-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24722525</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2017 Dec;47(16):2753-2766</Citation><ArticleIdList><ArticleId IdType="pubmed">28585513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cell Biol. 2016 Aug;26(8):587-97</Citation><ArticleIdList><ArticleId IdType="pubmed">27004698</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Sep;47(9):1119-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23768870</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Oct 15;64(8):718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18602089</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Oct;150(1):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23911257</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2007 Jan;32(1):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17160506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jan 10;144(1-2):16-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22749156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Dec;151(1-3):12-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24257517</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2016 Jan;64(1):76-89</Citation><ArticleIdList><ArticleId IdType="pubmed">26295445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2014 Oct;1(5):351-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26360999</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Aug;14(5):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">22834460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Sep 15;202:1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27253210</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2015 Apr;138(Pt 4):918-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25688078</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2014 Apr 18;265:147-57</Citation><ArticleIdList><ArticleId IdType="pubmed">24480366</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2016 Mar 15;292:52-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26943959</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2010 Jun 2;167(4):1025-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20226844</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2014 Aug;40:219-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24703991</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2016 Jan;72:22-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26519766</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Feb;67(2):155-66</Citation><ArticleIdList><ArticleId IdType="pubmed">20124115</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18771602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Jan 1;170:95-103</Citation><ArticleIdList><ArticleId IdType="pubmed">25237732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Aug;17(5):507-17</Citation><ArticleIdList><ArticleId IdType="pubmed">25929806</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2008 Dec;8(12):958-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19029990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 May;75(5):e450-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24922497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Jun;17(4):415-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25295837</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2008 Nov 6;60(3):430-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18995817</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2016 Sep;37(9):608-620</Citation><ArticleIdList><ArticleId IdType="pubmed">27443914</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2015 Dec 17;9:476</Citation><ArticleIdList><ArticleId IdType="pubmed">26733805</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2012 Sep 27;221:140-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22800566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Jan 1;189:287-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26454334</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2016 May 16;13(1):110</Citation><ArticleIdList><ArticleId IdType="pubmed">27184631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Feb;209:246-253</Citation><ArticleIdList><ArticleId IdType="pubmed">27936454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 Mar;19(2):74-83</Citation><ArticleIdList><ArticleId IdType="pubmed">28444949</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Dec 15;110(13):4319-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17848619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Apr 5;146(2):286-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22858217</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jul 1;74(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>